

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

FEDERAL TRADE COMMISSION

I N D E X

OPENING REMARKS	PAGE
CHAIRMAN LEIBOWITZ	3
KEYNOTE ADDRESS	PAGE
SCOTT STERN	13
JAN PAPPALARDO	141
DAVID BALAN	306
PANELS/PAPER SESSIONS	PAGE
Panel Session One	30
Paper Session One	70
Paper Session Two	171
Paper Session Three	232

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

FEDERAL TRADE COMMISSION

FEDERAL TRADE COMMISSION/)	
NORTHWESTERN UNIVERSITY)	
SECOND ANNUAL:)	Matter No.
MICROECONOMICS CONFERENCE)	PO85800
)	
-----)	

THURSDAY, NOVEMBER 19, 2009

Conference Center
Federal Trade Commission
601 New Jersey Avenue, N.W.
Washington, D.C. 20580

The above-entitled hearing was held, pursuant to notice, at 9:00 a.m.

1 P R O C E E D I N G S

2 - - - - -

3 DR. FARRELL: Good morning, everyone. Thank you
4 for coming. Welcome to the Federal Trade Commission and
5 the Second Annual, I think that makes it a tradition,
6 FTC/Northwestern Microeconomics Conference.

7 I'm told the Chairman will be arriving any
8 minute to give -- and here he is, Chairman Leibowitz.

9 CHAIRMAN LEIBOWITZ: I thought I had really bad
10 timing. Were you introducing me, Joe?

11 DR. FARRELL: I was just introducing you so it's
12 perfect. This is Jon Leibowitz, Chairman of the Federal
13 Trade Commission.

14 CHAIRMAN LEIBOWITZ: I work for Joe, as everyone
15 here at the FTC knows, and thank you all so much for
16 coming. I've noticed that when we pair with
17 universities to do our conferences, the food is much
18 better. We inherently have hot coffee as opposed to
19 cold coffee.

20 So anyway, thank you all. Thank you all so much
21 for coming and welcome to the Second Annual FTC and
22 Northwestern Microeconomics Conference, which brings
23 together cutting edge academic economic research with
24 real world policy problems, and that's very much in line
25 with the Commission's mission of protecting American

1 consumers.

2 The conference began last year when my
3 colleague, Bill Kovacic, who was then Chairman, and is
4 now a Commissioner, and was the brain child of your
5 predecessor, former Bureau of Economics director,
6 Michael Baye, who teaches at Indiana, wanted to do
7 something focused around the Big Ten. I know it's early
8 in the morning, but that was a joke. We hope this is
9 going to become a regular and important part of the
10 FTC's fall schedule.

11 We're grateful to Northwestern University and
12 the Searle Center on Law, Regulation and Economic
13 Growth, as well as the Center For Study of Industrial
14 Organization for cosponsoring the conference.

15 I'm delighted to note that Northwestern and the
16 Searle Center will also be hosting our third workshop on
17 the horizontal merger guidelines. That's in Chicago on
18 December 10. I'm going to try to make it because if
19 there's one thing I love about Chicago, it's being there
20 in December. It can only be topped of course by being
21 there in January.

22 For those of you who are here from other
23 institutions, and I'm sure there are some of you, just a
24 few words about us. As you know, the FTC is an
25 independent agency that enforces antitrust law,

1 alongside the Department of Justice, and also enforces
2 Federal consumer protection law.

3 As Joe Farrell, our fabulous Director of the
4 Bureau of Economics likes to say, these missions
5 reinforce each other. Competition is sharper and better
6 aimed when consumers are making well informed decisions
7 and free choices, and consumer protection works best of
8 course when consumers have real alternatives. We think
9 of our consumer protection and our competition missions
10 as both trying to make the marketplace work better.

11 The Bureau of Economics is home to even more
12 Ph.D. microeconomists, including our visiting scholars,
13 we have about 75, which is more than our colleagues,
14 friends, neighbors at the Antitrust Division have. That
15 may make BE, as we call it, our Bureau of Economics, the
16 biggest institutional center for microeconomics in the
17 world, and of course we're bigger today by virtue of all
18 of you coming.

19 I want to thank a number of people who have
20 helped to put this together. We have a really
21 distinguished scientific committee again this year, and
22 if you're here this morning and I mention your name,
23 please stand up or at least raise your hand, including
24 Professor Kyle Bagwell from Stanford University. Thank
25 you.

1 Professor Marianne Bertrand from Chicago's Booth
2 School of Business. Not here yet.

3 Professor Aviv Nevo from Northwestern? Coming
4 here soon I'm sure.

5 And Scott Stern from MIT Sloane School of
6 Business. Thank you, Scott, so much.

7 I understand all four of you -- or the two of
8 you here and the two of you who are not here yet --
9 worked very, very hard in creating this fantastic
10 program. I also want to thank Joe for putting this
11 conference together, and from the bureau as well, where
12 are Chris and Paul, Chris Adams and Paul Rothstein?
13 Thank you for organizing the conference and other bureau
14 staff members, including Viola Chen, Loren Smith, Maria
15 Villaflor, Alethea Fields and Laura Kmitch for their
16 hard work.

17 Let me highlight just a few topics of great
18 interest, I think for all of us at the conference and
19 for the Commission. This morning we have a very timely
20 panel discussion on mortgage delinquencies and loan
21 modifications. We have now brought more than two dozen
22 foreclosure rescue scams and mortgage modification
23 cases.

24 We have brought literally more than two dozen,
25 it will be two dozen by next week, cases on mortgage

1 modification and foreclosure rescue scams alone this
2 year. We're also in the process of writing two major
3 rules in this area and we've been given, for purposes of
4 doing that, APA rulemaking authority, which makes it
5 much easier for us to write rules. It is sort of a
6 medieval form of rulemaking, and we got this authority
7 in the Omnibus Appropriations Act earlier in the year.

8 I'm sure you've heard the old saying that laws
9 are sort of like sausages. You don't want to know what
10 goes into it, but it comes out okay usually. I would
11 say that's probably, at least with respect to our new
12 jurisdiction for rulemaking in the Omnibus Act,
13 certainly that's the way we can think about it, and it
14 hopefully will do a good thing for consumers. We think
15 it will.

16 We have paper presentations this morning also
17 looking at the interaction between competition and
18 innovation. In the afternoon we have presentations
19 looking at the relationship between advertising and
20 consumer choice, which is, I'm sure you know, a question
21 or an issue of perennial interest to the Commission.

22 Tomorrow morning, we have papers on some very
23 interesting topics, including online privacy, which is
24 also very timely, and discrimination in the nation's
25 peer-to-peer lending market. We also have a panel

1 discussing the very important topic of innovation
2 policy, and somewhere in between it, I think you guys
3 have dinner at Johnny's Half Shell, which is a wonderful
4 restaurant nearby.

5 So welcome again, and enjoy the program. We
6 appreciate all of you coming. We think it will be
7 incredibly useful going forward. We hope again to do
8 this annually. And thank you so much. I will return it
9 back to you, Joe.

10 (Applause.)

11 DR. FARRELL: Thank you, Chairman. A couple of
12 logistical things. The rest rooms are across the
13 hallway. It is possible, but you have to be careful, to
14 get to the restroom and back without going through
15 security.

16 Speaking of security, the security briefing is
17 as follows: If you go outside the building or get lost
18 on your way to the restroom without an FTC badge, you
19 have to go through the security check again. That's why
20 you want to be careful.

21 If there's a fire, or for any other reason an
22 evacuation of the building, please leave the building in
23 an orderly fashion. I'm not quite sure what that is,
24 but you can probably interpret it.

25 Once outside the building, you're supposed to go

1 across the street and to the right, or maybe just to the
2 right. It's a little ambiguous, but anyway, go away
3 from the fire and try to meet up somewhere off to the
4 right.

5 In the event that it's safer to remain inside,
6 you will not be asked to leave the building. And if you
7 spot suspicious activity, I think that means not taking
8 account of colinearity, please alert security.

9 We're running a little bit late, that's my
10 fault. I wasn't quite sure what the timing of the
11 Chairman's arrival was going to be, so let me just make
12 some very brief remarks, and I hope we can catch up
13 without too much trouble.

14 It's amazing to me, and yet the calendar assures
15 me, that I've been here at the FTC for almost six months
16 now. The time has whizzed by. There's way too much
17 going on and I try my best to think about what I'm
18 doing, but that's a challenge. I encountered this
19 phenomena for the first time, this is my third time in
20 Washington, for the first time when I went to the
21 Federal Communications Commission in 1996.

22 At that time, foolishly, indeed insanely, I was
23 also trying to edit the Journal of Industrial Economics,
24 JIE, and one thing that made me realize was it's stupid
25 to try to do too many things at once, but a deeper thing

1 it made me realize is you know how in macro they teach
2 you or they used to teach you that you're not going to
3 find any markets with rationing both on the supply side
4 and on the demand side -- well, that's false.

5 So as JIE editor, I kept receiving these
6 articles that obviously talented economists had put
7 immense amounts of thought and work and energy and
8 intellect into, and they were about questions that
9 nobody cared about the answer to.

10 So that was disturbing, and it was even more
11 disturbing in the contemporaneous presence of the fact
12 that there at the FCC, and in fact throughout
13 Washington, there were important and urgent questions of
14 how to do microeconomic analysis or this or that policy
15 question that were languishing or being decided wrongly
16 because nobody was putting the energy, the intellect,
17 the time, and the thought into figuring them out.

18 So that's what the entrepreneurship community
19 calls a profit opportunity. I tried to take that profit
20 opportunity, not in the form of money but in the form of
21 trying to make things work better, and so at JIE, we
22 tried to encourage people to write and submit papers
23 that were a little closer to real world policy or just
24 real world industrial organization questions. And it
25 didn't necessarily reflect quite the obsessive attention

1 to model building that's traditional in the academic
2 journal world these days.

3 I can't say that we had as much success as we
4 hoped for, but at least we tried, so this conference I
5 think is also along those lines in the sense that it's
6 trying, as the Chairman mentioned, to bring together the
7 academic community and the Washington policy economics
8 community for mutual pleasure and profit.

9 So this happens in a number of ways. I think
10 journals are slowly but surely, at least some of them,
11 getting better about the kind of work that they
12 encourage and reward. We have, especially at the
13 Federal Trade Commission, part of whose statutory
14 mandate it is, a healthy program of research by staff
15 economists, and you will hear about some of that over
16 the course of the next two days.

17 And of course we have, what I think is in the
18 rest of the world regarded with envy, a tradition of
19 academic economists coming to Washington, both for
20 periods of months or years and also frequently for hours
21 and days. And all of those things I think help us to
22 bridge the gap that we're talking about.

23 So enough of that. Let me turn to introducing
24 our first speaker who is Scott Stern. Scott is a
25 professor of management and strategy at the Kellogg

1 School. That's at Northwestern for those of you who
2 don't know. Scott is currently visiting professor at
3 the Sloan School, which is at MIT.

4 Among his many activities, Scott is co-organizer
5 of the NBER Innovation and Policy on the Economy Working
6 Group, which puts out a nice annual volume, and a senior
7 fellow of the Searle Center on Law, Regulation and
8 Economic Growth. That's back at Northwestern.

9 Scott also tries to make the journals work as
10 well as they can be made to work. He's an associate
11 editor of Management Science and of the aforementioned
12 Journal of Industrial Economics and the International
13 Journal of Industrial Organization and serves on the
14 board of management of the International Schumpeter
15 Society, so Scott obviously has not learned a lesson
16 about not trying to do too many things at once.

17 In addition, he has served on the editorial
18 boards of the Antitrust Law Journal and the Journal of
19 Business and Economic Statistics.

20 In 2005, Scott was awarded the first Ewing
21 Marion Kauffman Prize Medal for distinguished research
22 in entrepreneurship. His work explores how innovation,
23 that is the production and distribution of ideas,
24 differs from more traditional economic goods and the
25 implications for business and public policy. Often

1 focusing on life science industries, this research is at
2 the intersection between IO and the economics of
3 technical change.

4 Among Scott's recent studies have been work
5 examining the determinants of R&D productivity, the role
6 of incentives and organizational design on the process
7 of innovation, and the drivers of commercialization
8 strategy for technology epidemiologies.

9 I've known Scott for quite awhile. He's always
10 fun to listen to and always provocative, so I look
11 forward to hearing what he has to say.

12 DR. STERN: The first thing that I'm going to
13 say is that there's going to be some sort of -- thank
14 you, Joe, and I'm hoping we can avoid the reverb. I
15 speak loud enough that if anyone is going to induce it,
16 it's going to be me, so I'm a bit worried early in the
17 morning people kind of having the fingernails on the
18 chalkboard sound, as it's always wonderful.

19 What do I want to talk about? This is
20 actually I want to call it a paper, but it's not really.
21 It's a set of slides that my coauthor, Joshua Gans and I
22 are trying to make into a paper. I'm going to give you
23 some flavor of it, but it's really drawing out some of
24 the implications of a body of research that we've done
25 for really thinking about the antitrust and innovation

1 policy implications.

2 I should mention that Josh is traditionally at
3 the University of Melbourne at the Melbourne Business
4 School, but is actually going to be visiting in the U.S.
5 for all of calendar year 2010, which is academic year
6 2010 in Australia because they have different seasons,
7 and anyone who wants to have him come give a seminar or
8 whatever, he's going to be in the U.S. and a little
9 easier to get ahold of so you can avoid seeing me give
10 these talks.

11 Basically what I want to talk about today is
12 essentially one piece of positive economics, which
13 really is an area that I've worked on quite a bit, which
14 is: How do formal intellectual property rights, most
15 notably patents, impact cooperative commercialization,
16 particularly between technology entrepreneurs, start-up
17 innovators and dominant incumbent firms?

18 And then I want to do a bit of speculating about
19 the normative analysis; namely, what are the antitrust
20 policy implications of that? And then essentially what
21 I'm going to try to do there is actually draw a bit on
22 recent models, most notably the very nice work of Segal
23 and Whinston that essentially introduces a nice dynamic
24 framework for thinking of innovation and
25 commercialization.

1 So some facts. There are a bunch of sectors as
2 were mentioned. I know a little bit, but I don't know
3 much, but I know a little bit about life sciences. One
4 thing you see is that the dominant way these new biotech
5 drugs actually get into the market is not by some
6 start-up innovator outside of MIT attracting capital and
7 then doing all the regulatory trials themselves and then
8 marketing and pricing the drug. But is instead by
9 basically remaining mostly a research boutique,
10 occasionally trying to do one or two things downstream,
11 and ultimately, for a variety of reasons under different
12 conditions, achieving some cooperative agreement,
13 usually with a dominant incumbent player in the relevant
14 therapeutic market.

15 So Bristol Myers now, after many iterations,
16 continues to be the dominant marketing firm that's
17 choosing pricing in most cancer markets, even though the
18 innovation in cancer markets is coming from many other
19 locations.

20 To be clear, that pattern of cooperative
21 commercialization between tech entrepreneurs and these
22 dominant firms is really not constrained to
23 biopharmaceuticals. Indeed, if you look over time, how
24 do venture capitalists actually make money to the extent
25 that they do? This is not going to be a great year for

1 them this year, but to the extent that they make any
2 money, what do they do?

3 It turns out there's really been a sea change
4 over the last 20 years, one that has not received that
5 much policy attention, and that is where the usual way
6 that firms made money was through IPOs. That was the
7 exit strategy, it is now the case that more than 75
8 percent of value and more than 80 percent of exit
9 transactions of venture capitalists are essentially
10 through acquisition. And the model form of those
11 acquisitions is by dominant downstream players in the
12 market. Think of companies like YouTube and Google.

13 Indeed, there are some companies, and we write
14 about these and teach them in business school with great
15 aplomb, essentially a company such as Cisco, that's all
16 they do. They advertise themselves quite explicitly as
17 not really being in the research business but being in
18 the research buying business. And then they kind of let
19 a thousand flowers bloom and essentially over many
20 generations of the technology, Cisco maintains a
21 dominant position in the downstream market and relies on
22 different innovators over time for upstream innovation.

23 Now, the question is: Where is that coming
24 from? What are the institutions that have led to this
25 sea change? And Josh and I have investigated in a

1 number of ways, along with some other coauthors and
2 other groups have also looked at this, what I call the
3 commercialization hypothesis. That is that effective
4 intellectual property protection; the rise in the use
5 and the sophistication around patenting has promoted
6 trade in the market for ideas, this upstream innovation
7 market. And that's enhanced cooperative
8 commercialization patterns between start-up innovators
9 and the people that can most efficiently get those
10 products into the market, namely these downstream
11 dominant firms. The welfare consequences of that of
12 course are ambiguous.

13 Just to kind of round out some evidence around
14 this, Ashish Arora and his colleagues down at Duke have
15 provided broad based evidence across many different
16 sectors that just show a tight correlation, really a
17 correlation in the data between all sorts of patenting
18 activity and all sorts of licensing receipt activity.
19 They've cooked that up as sort of saying, it seems like
20 these patents are facilitating the market for
21 technology.

22 Josh and I have gone a little bit deeper into
23 that in two very brief studies I'll talk about. One was
24 a paper that we did a few years ago with David Hsu in
25 the RAND, where we surveyed a whole bunch of

1 entrepreneurs and figured out how they ended up making
2 money from their innovation, which you might think is
3 kind of an obvious thing to do, but not a lot of people
4 have done that, so that was good for us.

5 Basically it turns out that if you can get a
6 patent and if there's relatively reasonable size
7 barriers to entry in the industry, you end up with a
8 very high rate of cooperative commercialization. So
9 relative to the rate when there are no patents in the
10 industry and this low fixed cost where you get a very
11 few innovators, only 14 percent are earning money
12 through cooperative commercialization or more than 50
13 percent are earning money through partnering in the
14 patent high entry cost situation.

15 So then you might say, there's something about
16 patents that is pretty closely aligned with this
17 strategy, but is it really the patent system per se? Is
18 it patent policy that matters?

19 In a very recent study that we published in
20 Management Science, I think we provided some
21 interesting, pretty causal evidence for this. What we
22 did was look at the timing of licensing by a fairly
23 large sample of technology entrepreneurs and we looked
24 at exactly when the licensing occurred.

25 Now remember it takes almost forever to get

1 these patents and it's very random. And so what we
2 looked at was: How does the hazard rate of licensing
3 change after you get your kind of envelope from the
4 Patent Office down the street -- I guess it's across the
5 river, in Boston that means something else -- but how
6 does getting the grant notice from the Patent Office
7 change the hazard rate of licensing?

8 It turns out that a tremendous amount of all
9 licensing occurs essentially within about 12 to 18
10 months after the patent is actually granted, so there's
11 a long delay where there's not a lot of licensing. Then
12 you get the patent. We see this very dramatic rise in
13 licensing rates.

14 So what does that all mean? That's a good
15 question. On the one hand there's a piece of positive
16 economics here. There seems to be this different role
17 for intellectual property such as patents, not simply
18 the usual. It let us enhance the innovation incentives,
19 but it's actually enhancing the ability to contract in
20 the market for ideas, facilitating cooperative
21 commercialization and potentially avoiding product
22 market competition between innovators and dominating
23 firms.

24 Let's be clear. In most of this research, if
25 you read, it is not focused on the antitrust

1 implications. Ashish Arora and his colleagues, and to a
2 certain extent our work, really have this kind of broad
3 sense that, hey, this is a pretty good thing because it
4 is somehow enhancing the division of innovative labor.
5 There are probably some R&D productivity benefits here
6 and there are very few attempts to really draw out the
7 implications of this sea change in commercialization
8 strategy in terms of its antitrust implications.

9 Few attempts are made within the licensing
10 guidelines, though there's relatively little enforcement
11 of the idea, to evaluate a dominant firm, say a Google
12 or a Microsoft that picks up a true start-up innovator,
13 a YouTube or Twitter or something like that. There is
14 very little, usually relatively little evaluation of
15 those mergers in terms of really understanding that
16 maybe YouTube could have been the competitor. So what
17 we're going to try to do here is analyze what are the
18 antitrust implications of the impact of formal IPR on
19 cooperative commercialization.

20 To do that, I'm going to take one little side
21 detour. Do I still have 20 minutes to talk? I'll try
22 to do it in all 18.

23 DR. ROTHSTEIN: You have another ten minutes.

24 DR. STERN: Perfect, thanks. So we're going to
25 take a very short detour into what I think is one of the

1 most interesting papers in this area over the last
2 pretty long while by Segal and Whinston that appeared in
3 the AAR many years ago. Many of you are probably
4 familiar with it in which they undertake an explicit
5 dynamic analysis of the impact of antitrust policy,
6 basically should we allow or disallow certain practices
7 on innovation, incentives and welfare.

8 Essentially their idea is really to model an
9 environment, a kind of a dynamic environment that is a
10 step-by-step environment where ultimately a single firm
11 is the dominant firm at any moment in time. There's a
12 firm competing for the market, but there's an outsider
13 who's doing R&D to leapfrog over the current established
14 firm, and therefore earn some rent and promote this kind
15 of gale of creative destruction.

16 Very nicely the incentives for the outsider to
17 enhance the probability of innovation, called PI, are
18 grounded in the expected nature and duration of product
19 market competition once a breakthrough has been
20 realized. So when I'm a potential entrant, I think,
21 well, if I actually do this, if I'm successful, I'm
22 going to have some competition with the incumbent as I
23 displace him; then I'm going to have a certain length of
24 time in which I earn monopoly profits with my new
25 leading technology and then ultimately I'm going to get

1 displaced. Perhaps I'm going to get displaced, and I'm
2 going to have the duopoly profits during that time.

3 Key insight is that I, as the entrant, am
4 thinking about the fact that if right now I face high
5 barriers to entry, namely, there's all sorts of
6 exclusionary practices against me, I'm not so unhappy
7 about that because I'm going to be able to do that when
8 I'm the innovator, when I'm the established firm I'm in
9 the next period. So incumbent firm actions and
10 antitrust policy is then modeled as a parameter that
11 essentially terms how much of this detouring activity
12 the established firm can take on.

13 Basically what they're able to do is very nicely
14 divide this into an innovation benefit curve. That's
15 the kind of sloppy thing that goes down that looks
16 vaguely like a demand curve and then they have this
17 innovation supply curve. Most importantly, it is upward
18 slopping at every point and then the point is that if
19 the IS curve is upward sloping, essentially the dynamic
20 equilibrium impact of antitrust policy on innovation
21 incentives can be evaluated. Essentially you shift the
22 innovation supply curve when you change the antitrust
23 policy.

24 You just change the returns to innovation, and
25 so if you know how the alpha, the antitrust parameter,

1 shifts around this IB curve, you're going to get your
2 impact on welfare.

3 Key insights. The very practices that are seen
4 as barriers to entry by a traditional antitrust analysis
5 essentially also serve as innovation incentives since
6 the returns to being the monopolist become higher.

7 At the same time, the net impact of allowing
8 such policies can still often be detrimental, so sort of
9 if you cooked up this line, that allows for a pretty
10 permissive antitrust policy because, let's face it, that
11 actually gives an incentive for the market. You
12 actually wanted pretty good antitrust policy because the
13 net effect, even after accounting for the fact it is
14 positive, and part of that is because the entrant faces
15 the costs of the deterring activity upfront while they
16 only realize the benefit way out in the future.

17 Now, I'm going to draw out the implications of
18 that type of model for a world in which we think about
19 the market for ideas. In particular, there are two very
20 important assumptions in the Segal Whinston framework.
21 The first is that the strategic impact of the monopolist
22 only impacts the returns to innovation, but they can't
23 affect the innovative productivity of the potential
24 entrant. They can't shift that innovation supply curve.

25 Moreover, the potential entrant always has

1 access to the incumbent's technology and they can really
2 focus all their efforts on going that next step. So
3 that in some sense implies a background assumption that
4 the established firm, once they're dominant, has to give
5 over a lot of technical information and proprietary
6 knowledge to potential entrants to allow them to
7 innovate.

8 At the same time, once the entrant has developed
9 a breakthrough, the only strategic action available is
10 to enter the product market. In the interest of time,
11 let me just note that both of those assumptions are
12 really almost counterfactual. On the one hand, the one
13 thing established firms can do through their strategic
14 actions is really limit the ability of entrants to even
15 do R&D in their industry.

16 At the heart of the Microsoft case, for example,
17 were lots of claims about the ability of potential
18 innovators to get access to certain code that would
19 allow them to develop competing products. At the same
20 time, if you develop and develop your breakthrough
21 innovation as the entrant, now you know you're going to
22 enter and you face a prospect of competition with the
23 current established firm, you have pretty good
24 incentives to collude, which in the business schools we
25 call cooperative commercialization.

1 So what we're going to do in our last few
2 minutes is say: What's the impact of these alternative
3 policies on allowing or disallowing different types of
4 transactions in the market for ideas? I'm just going to
5 highlight two things that we're looking at, one of which
6 is an extension of a point that Segal and Whinston bring
7 out and one of which is a bit more explicitly novel.

8 The first point is to note that any strategic
9 action by the current incumbent to reduce the R&D
10 productivity of potential entrants turns out to reduce
11 total innovation incentives. To be clear, there are two
12 effects and so this is where we go a little beyond Segal
13 and Whinston. On the one hand, you would be shifting
14 down that innovation supply curve; that's bad. But that
15 very fact also means that there's a higher innovation
16 benefit.

17 The innovation benefit curve is going up so that
18 might actually enhance R&D incentives. It turns out
19 that the net impact when you do an equilibrium analysis
20 turns out to be negative, so anything that reduces the
21 R&D productivity of potential entrants actually has a
22 negative consequence on welfare in one of these kind of
23 cumulative innovation markets.

24 At the same time, the ability of potential
25 entrants to access the technologies of current

1 incumbents is severely limited as an empirical fact.
2 Trade secrecy, proprietary systems, exclusionary
3 standards all serve to reduce the ability of innovators
4 to leapfrog current technologies, and this is
5 particularly true in my evaluation in these markets in
6 which people are competing for the market.

7 The last insight is, and this is just drawing
8 out the logic of it, if you have competing for the
9 market antitrust policies, so kind of the Evans and
10 Schmalensee kind of policies, which might have something
11 to them, and you separately advocate for a
12 strong intellectual property regime, namely giving
13 people tons of patents, that's not going to imply
14 competing for the market where you have serial
15 monopolists, but is basically going to imply the
16 persistence of dominant firms.

17 Schumpeterian analyses emphasize that innovators
18 compete for the market. They often say, oh, we don't
19 really need a lot of antitrust because someone is going
20 to come in and be the next big thing. Many of these
21 same animals actually also are very big on, let's also
22 give everybody patents for everything, but if an
23 enhanced IPR facilitates the market for ideas, a loose
24 antitrust policy includes limited review of mergers or
25 licensing between dominant firms and start-up

1 innovators. The equilibrium prediction is not serial
2 monopolists but serial innovators commercializing with a
3 persistently dominant firm.

4 As some concluding thoughts, I hope that from an
5 empirical perspective, we have some evidence that's been
6 accumulating that formal intellectual property serves to
7 enhance the rate and extent of cooperative
8 commercialization, particularly between these
9 entrepreneurs and established firms. But there's been
10 very little policy analysis of really what's been a sea
11 change in technology entrepreneurship strategy on
12 antitrust policy.

13 And this preliminary analysis suggests that
14 allowing dominant firms to reduce innovator R&D
15 productivity likely reduces welfare and that practices
16 allowing free form licensing between start-up innovators
17 and dominant firms may indeed reduce the competitive
18 pressures associated with technology entrepreneurship.

19 Thanks.

20 (Applause.)

21 DR. FARRELL: Thank you, Scott.

22 DR. SCHNEIDER: Scott, can you point to what
23 changed in the patent system that would cause this
24 five-year change? What would cause a sea change?

25 DR. STERN: So there's a beautiful book by Jafee

1 and Lerner and endless National Academy reports, and
2 they all basically say that there were a few different
3 things that mattered here. The first was that the
4 centralization of the Court of Appeals for the Federal
5 Circuit, which basically then became the Appeals Court
6 for patents in the early 1980s, initiated a process that
7 ultimately probably enhanced the incentives to get a
8 clarity of patent law.

9 There were substantive extensions of patent law,
10 a number of them, particularly over basically living
11 organisms, business practices, things like gene patents,
12 a whole bunch of different areas there. And then
13 finally the other institutional shifts that encourage
14 venture capital, for example, Prudent Man Rules and
15 things like that, the change in Prudent Man Rules
16 allowed for the financing of these technology
17 entrepreneurs.

18 Since they have no other assets but basically
19 what's in their head and some designs, that separately
20 probably kind of concentrated on the patents. And then
21 there's a bunch of hypotheses, more among dominant firms
22 themselves, say in the semiconductor industry, about
23 basically these kinds of arms races in patenting that
24 Byron Hall and others have talked about quite
25 extensively.

1 DR. FARRELL: Apparently you answered all the
2 questions. So what do we have next?

3 DR. ROTHSTEIN: We have the panel on mortgage
4 and foreclosure.

5 DR. FARRELL: Thank you, Scott.

6 (Applause.)

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 PANEL SESSION ONE: Mortgage Delinquency and
2 Modification: Economic Research and Policy

3 PANEL MEMBERS:

4 PAUL ROTHSTEIN, FTC, Panel Chairman

5 PAUL WILLEN, Federal Reserve Bank of Boston

6 RICHARD BROWN, Federal Deposit Insurance Corporation

7 MARK MCARDLE, U.S. Department of Treasury

8 LAURA SULLIVAN, FTC

9

10 DR. ROTHSTEIN: Good morning, everyone. Thanks
11 for coming to the event, and especially for this panel
12 on a very timely topic, a topic that you will see
13 written about in the newspapers regularly: Mortgage
14 delinquency and modification. It's also very timely for
15 the Commission, because as the Chairman said, we're
16 involved in a very broad rulemaking on the loan
17 modification process.

18 So we're going to get right to it. We have Paul
19 Willen to speak first. He's a senior economist and
20 policy advisor in the research department at the Federal
21 Reserve Bank of Boston.

22 We have Richard Brown, who is the chief
23 economist at the FDIC, and he's worked for many years on
24 housing finance issues. If you're wondering what the
25 FDIC has to do with loan modification, he'll tell you

1 about that. It's a bit of a surprise.

2 Mark McArdle is a senior policy analyst at the
3 U.S. Treasury working with the Making Home Affordable
4 Program which deals directly with foreclosure issues.

5 And Laura Sullivan, who is an attorney here at
6 the Federal Trade Commission, in the Bureau of Consumer
7 Protection, and in the Division of Financial Practices.
8 She's working directly on the rulemaking issues and
9 litigation involving scams associated with foreclosure
10 and loan modification.

11 So we have the range of experts here from the
12 academic side who have been writing about mortgages, the
13 decision to default, the decision to foreclose on loans,
14 down to the consumer protection issues that are very
15 much a part this entire process.

16 I will not take up any more time. Thank you.

17 DR. WILLEN: I would like to thank Paul for
18 giving me the chance to talk today, and it looks like
19 I'm presenting a paper. I guess maybe I am, but I'm
20 really telling you about our research on understanding
21 loan renegotiation. So first let me say I'm speaking
22 today as a researcher and as a concerned citizen and not
23 as a representative of Boston Fed or the Federal Reserve
24 System and that's important right now.

25 Let me start by saying, and I may get fired for

1 this, when we first started in 2005 really worrying
2 about the mortgage crisis, the incipient problems in the
3 mortgage industry, the first response of the Federal
4 Reserve in any consumer protection issue is to put
5 together a brochure.

6 So we did, and it's called "Interest Only
7 Mortgage Payments and Payment Option Arms: Are They For
8 You?" The answer was, no, so it could have been a much
9 shorter brochure, but anyway, the thing is once we
10 realized the brochure wasn't going to be enough, we then
11 started thinking about loan renegotiation, so this was a
12 long time ago.

13 The thing about loan renegotiation is that it's
14 very hard to talk about. You know how if someone asks
15 you what a goatee is, it's very hard for people to
16 explain it without touching their chin. It's very
17 difficult to talk about loan renegotiation without at
18 some point saying, it's a win/win proposition, so I
19 actually googled it.

20 I found this example basically of the
21 conventional wisdom on why loan renegotiation is such a
22 good idea, and this is a quote, "the problem is that
23 foreclosure is costly for both the borrower and the
24 lender. The mortgage holder gains only half of what is
25 lost by the homeowners." The solution, according to

1 this author, was that in the old days, when the mortgage
2 was granted by your local bank, there was a simple
3 solution to this tremendous inefficiency, and the bank
4 forgave part of your mortgage.

5 The problem is unfortunately this win/win
6 solution is not possible today. Your mortgage has been
7 sold and repackaged in an asset backed security pool and
8 sold in tranches with different parties. This comes
9 from an article from the Economist's Voice by Luigi
10 Zingales but you can see versions of this quote, this
11 argument all over the place.

12 There are three things we did in our research on
13 this: The first thing was just to go to the data and
14 measure the number of modifications lenders were
15 actually doing and basically how common was it for
16 lenders to forgive part of your mortgage effectively.

17 The answer is -- and the conventional wisdom was
18 that it was not very common, and in fact that's exactly
19 what we found in the data, and this is the number for
20 private label, which are securitized mortgages. These
21 are loans that are not securitized by the GSCs but
22 securitized by someone else.

23 So what we found was that of loans that became
24 seriously delinquent in the year subsequent to the first
25 serious delinquency, less than 3 percent of private

1 label loans received modifications. So that part of the
2 conventional wisdom is right.

3 What turned out to be wrong was that
4 securitization didn't seem to matter much. If we looked
5 at portfolio loans, which were loans that were held in
6 the portfolio of a bank, the difference was miniscule,
7 and in fact it's insignificant statistically. And this
8 is for modifications which lowered borrower's payments,
9 but in fact the results in a sense are even weaker; in
10 other words, securitization seems to matter less when
11 you look at broader definitions of renegotiations.

12 And the broadest possible definition of
13 renegotiation is to look at the cure rate, which is the
14 probability that a seriously delinquent borrower either
15 becomes current or pays off their mortgage. It captures
16 anything that the servicer might do to help the
17 borrower. Even with this broadest definition, the
18 difference between portfolio and private label loans is
19 small. It's significant for all of the loans.

20 But for the sub samples of the data where we
21 think there's less unobserved heterogeneity, that
22 difference actually goes the wrong way; in other words,
23 the portfolio loans are actually less likely to get any
24 form of renegotiation, and it's important because I'll
25 come back to this, we think most of these cures in the

1 data and the difference that we observe are due to self
2 cures.

3 In other words, they have nothing to do with any
4 action taken by the lender to help the borrower and the
5 reason we say that is because basically this is looking
6 at cure rates. This is the hazard of curing after you
7 first become seriously delinquent and what you see is,
8 this is for portfolio loans, most of the cures occur in
9 the first three months. And in fact the difference
10 between private label and portfolio appears entirely in
11 those first three months.

12 So then the question is: Why do we see so few
13 modifications? And of course there's this logic, which
14 is quite compelling, the logic that Luigi laid out. The
15 logic is foreclosure costs lenders a lot. Lenders
16 typically recover less than half the balance on the loan
17 and wouldn't a concession to the borrower cost less?
18 And the answer is not necessarily and the reason is that
19 what people generally do is to compare renegotiating the
20 mortgage with foreclosing on the borrower, but there is
21 a third possibility, which is to do nothing.

22 It's possible that the borrower will cure
23 without assistance before foreclosure occurs and this is
24 what we call self cure risk.

25 This is a timeline of foreclosure in California,

1 and you can see here that from the moment that the
2 borrower defaults, which is 90 days after the borrower
3 has stopped making payments. If everything goes
4 according to plan, I mean, there are no hiccups, the
5 foreclosure sale occurs 235 days later. So this means
6 between the first missed payment, between even serious
7 delinquency and foreclosure sale, typically in
8 California at least, there's going to be a year.

9 And so the perception is that you're making a
10 decision, I immediately foreclose on you and cease the
11 property or I renegotiate, and that's not the decision
12 you're making. The decision is: Do I renegotiate right
13 now or do I wait and see what happens?

14 So what we show in the model, we have a simple
15 model, we find alpha nought to be the probability of
16 default without a modification and alpha one to be the
17 probability of default with a modification, and
18 basically what we show is you can divide up the sample
19 into three groups.

20 There's the difference between the probability
21 of defaulting without a modification, that's your
22 baseline, and then the amount that you reduce that
23 probability, that's the difference between alpha nought
24 and alpha one. And those are the people for whom
25 renegotiation is effective, and that part of the

1 distribution is where renegotiation is effective.

2 The problem is there are two other groups.

3 There is alpha one. That's all the borrowers who are
4 not going to repay either way and there in general we
5 would say it's a bad thing because basically you're
6 delaying the foreclosure. The house prices are going to
7 fall. The property deteriorates. Right now arguably it
8 might not be so bad because house prices are going up.
9 On the left here, we have self cure risk, which is
10 basically all the borrowers who are going to pay back
11 either way.

12 That's re-default risk. This is self cure risk.
13 Zingales' argument really is just focusing on that
14 center column there, and the problem is we really can't
15 tell these people apart. Those are houses, I don't know
16 if you recognize it, and they all look the same, so all
17 the borrowers come in, and they all say they want a
18 modification, and you can't tell which one of these
19 types they are.

20 So what do firms actually do? Rich Brown is
21 here from the FDIC. This slide is actually from an Indy
22 Mac PowerPoint presentation about doing modifications
23 and it basically replicates what we have in the model.
24 Basically there's cure rates. If you don't modify, then
25 you go along the foreclosure track. There's a cure rate

1 over here. That's the possibility the borrower cures
2 without any assistance and then you have re-default over
3 there on the far right, so this is exactly what lenders
4 do or at least what they say they do.

5 The problem was this argument that was not new
6 to the FDIC, to Rich, but it was new to a lot of
7 reporters who had been covering the story since 2007,
8 people who I had been talking to for years. When we
9 wrote this paper, when this got out there, they thought
10 this was news. They had never had heard of self cure
11 risk.

12 The reason is the proponents of renegotiation
13 focused on the costs of foreclosure and the benefits of
14 renegotiation. They rarely discussed the cost of
15 renegotiation. The Congressional Oversight Panel
16 Report, which made a big push for mass loan
17 modifications, did not mention self cure in 187 pages of
18 detailed discussion of the issue.

19 Papers by Allen White, who's a law professor at
20 Valparaiso University, who has gotten a lot of attention
21 for his papers, never mentioned self cure. And then
22 there's this paper the economists paid attention to by
23 Piskorski, Seru, and Vig, again no discussion in there
24 of self cure risk. It never even occurred to them that
25 it was an issue.

1 So the paper says that lenders don't renegotiate
2 a lot of loans, but actually over the last two years, we
3 saw a huge increase in the number of modifications.
4 This is in logs. You'll see why in just a second, but
5 you can see they went from modifying on a monthly basis
6 5/100ths of 1 percent of the loans up by the end to 1
7 percent. There was a huge increase in the frequency of
8 modifications.

9 What it parallels is a huge decline in the self
10 cure rate, so basically as borrowers became less and
11 less likely to fix their own problems, lenders became
12 more and more willing to assist them, which is exactly
13 what the model would say and in a sense exactly what
14 their own documentation says.

15 Let me just conclude. One of the criticisms of
16 our study is that if you put the numbers into that
17 model, you still get most loans being positive NPV. And
18 let me just illustrate that it is very difficult to
19 figure out what the true self cure probability and the
20 true re-default probability of the borrowers we're
21 looking at are, basically because we aren't doing
22 randomized trials.

23 If modification was a medicine, we wouldn't just
24 go to the data and say, let's look at the people who
25 took the medication and the people who didn't in non

1 experimental data. And the way to see this just as an
2 example, one of the things that people point to all the
3 time is evidence for why modifications are good is they
4 point to different modifications. These are
5 modifications that increase the principle balance.

6 This is the re-default rate for those and they
7 compare it with loans in which the lender reduced the
8 interest rate, and what you see here is the re-default
9 probability. There's a huge difference in re-default
10 probabilities between the interest rate reductions and
11 principal increases.

12 What's the problem with this picture? The
13 problem with this picture is it assumes that the
14 borrowers were all the same at the beginning. In fact,
15 in this very picture, I've just imposed the assumption
16 that they were all delinquent at the time, at the
17 beginning. In fact, it's not true. The guys who got
18 principal increases, 85 percent of them were delinquent,
19 so, in fact, the number who are delinquent a year later
20 is actually lower than before they got the
21 modifications.

22 But if you compare that with the people who got
23 interest rate reductions, in fact, less than 20 percent
24 of them were delinquent when they got the modifications.
25 So, in fact, the treatment effect, if you just took

1 these reduced form estimates and you tried to plug them
2 into the model, what you would see is that the
3 probability that the borrower is delinquent a year after
4 getting a modification is higher than it was before.

5 Obviously there's a huge amount of selection
6 going on here. That means you cannot interpret these
7 numbers as estimated. You can't just plug them into the
8 model which is what people have been doing.

9 Here's the slide you've all been waiting for.

10 DR. ROTHSTEIN: We'll go straight to Rich.

11 DR. BROWN: Thanks. Good morning. I have seven
12 minutes this morning to talk to about what FDIC did at
13 Indy Mac Federal Bank to modify mortgages, so I'll give
14 you a little background. The problem as it first hit
15 was with sub prime mortgages in 2007. It was a problem
16 of affordability. These are people with low credit
17 scores, that's what sub prime is, but a lot of these
18 loans were done at 40 and 50 percent ratios of debt
19 service to income on a monthly basis, and they were
20 usually done on a hybrid basis.

21 They would have a two-year introductory rate of
22 like 6 to 8 percent, not that low, but after the
23 two-year period was up, they would ratchet it up, it was
24 based on LIBOR, but it would frequently go to double
25 digits.

1 So the point was these folks could marginally
2 afford these loans during the intro period, but after
3 the reset, they certainly couldn't afford it. What
4 happened was they had prepayment penalties during the
5 first two-year period and after that prepayment penalty
6 was up and the loan ratcheted up to a higher interest
7 rate, they all scattered. They either repaid,
8 refinanced, got another loan or they defaulted on it.

9 So what we found is among the 2004 vintage of
10 sub prime hybrid loans, after four years, more than 95
11 percent had either defaulted or prepaid. Nobody stayed
12 around and paid the full rate for long.

13 What happened in 2007 is the sub prime market
14 went away. You couldn't get a sub prime loan. You
15 couldn't qualify for any loan because your home was
16 declining in value and so the game was up. Instead of
17 pre paying, what were they doing? They were defaulting.

18 So our Chairman, Sheila Bair, advocated in a
19 series of speeches to freeze that introductory rate at
20 the starter rate. Maybe they could afford it if you
21 don't ratchet it up because the game was up in terms of
22 new credit.

23 And that was the beginning of our forays into
24 interest rate modification. We ended up doing a lot
25 more work looking into some of the legalities, what

1 could be done under these pooling and servicing
2 agreements. It's a contractual basis where these
3 servicers control the loan after its securitized, what
4 is legally available, and what we found was that it was
5 legal under most, maybe 90 percent of the pooling and
6 servicing agreements, to do an interest rate
7 modification.

8 You can change the interest rate if you can show
9 that that's raising the net present value of the pool
10 itself. You typically could not do principal reductions
11 on a loan that stays in the pool and so that's a real
12 limitation there and especially in today's world with
13 underwater mortgages.

14 But in any event, we had a chance to put this
15 into practice ourselves when we became conservator in
16 July 2008 at Indy Mac Federal Bank. It was a
17 \$32-billion California thrift. At that time it was the
18 largest failure in the FDIC's history, of course dwarfed
19 since then by the Washington Mutual failure, but we
20 became conservator. We ran Indy Mac from July 2008
21 until early this year when we sold it to OneWest; as
22 part of that, we inherited a \$160 billion mortgage
23 servicing portfolio, about 650,000 loans. They were
24 serviced for Indy Mac, loans that were in their
25 portfolio, as well as under pooling and servicing

1 agreements for third parties.

2 So we wanted to put this modification into
3 practice and we came up with something that was very
4 streamlined, a streamlined interest rate modification
5 that would work not just for the loans that Indy Mac
6 owned, but also for the third-party serviced loans.

7 We knew it would work under the pooling and
8 servicing agreements because it was an interest rate mod
9 and we had a pretty straightforward protocol. Basically
10 to qualify, you had to have a debt service ratio to
11 income ratio of more than 40 percent. It had to be
12 unaffordable and you would reduce that debt service, the
13 monthly payment, down to at first a target debt to
14 service income ratio of 38 percent. We eventually
15 reduced that to 31 percent.

16 We did it in three ways. The first thing that
17 you do is lower the interest rate for five years and the
18 floor was 3 percent. And in 70 percent of the cases,
19 that got you to the target debt service income ratio.
20 If that didn't you get all the way there, the next thing
21 you did is extend the term out to 40 years and that got
22 us there for another 21 percent of the cases.

23 The third tool, the third arrow in the quiver
24 was to forebear principle, not forgive because you can't
25 do that for the service loans, but to forebear principal

1 until the loan was repaid, and that got us there in the
2 rest of the cases, to the 31 percent debt service to
3 income ratio.

4 What we found when we got there, of the 650,000
5 loans, about 10 percent were delinquent when we got
6 there. Of those, we found about 40,000 loans that were
7 candidates for modification. That means that the people
8 were still in the home. It was owner occupied. It
9 wasn't in bankruptcy. It wasn't in litigation and
10 hadn't already been modified.

11 So that was our pool to start from and the
12 benefit of what we were doing is you could get there
13 fast. You could automate the process. You could do the
14 analysis off site. So you could send them a letter, run
15 the numbers and send them a letter, we think your
16 payment could be X, and believe me, the response rates
17 on communicating with delinquent borrowers are very low.
18 We got a better response rate by sending these letters,
19 call us back, we want to reduce your payment to this.

20 Now, of course, it worked for the service loans
21 also, which is a big benefit. You didn't need the
22 permission of second lienholders. That was a big
23 benefit and you could automate the documentation. You
24 could go get tax records if they signed a waiver and you
25 could document the income that you needed to make sure

1 that the numbers actually, in fact, worked. But the
2 critical thing was we had to implement a net present
3 value test, as Paul mentioned.

4 We have a fiduciary responsibility to maximize
5 the returns to our receivership assets. We can't just
6 do mods because we think it's a good thing to do. Same
7 thing under the pooling and servicing agreements, we
8 have a legal obligation to maximize the net present
9 value, so our NPV test is just as Paul said. We analyze
10 two strategies: Either you mod or you don't mod. If
11 you don't modify, you have to take into account the cure
12 rate. We assume 15 percent. You have to take into
13 account foreclosure costs, what the loan to value of the
14 loan is, what the discount rate is going to be.

15 Same thing with modification. You have to
16 assume a re-default rate, how many of them are going to
17 come back to you, and we assumed a 40 percent re-default
18 rate at Indy Mac and we assumed the re-default would
19 happen in three months. It would take six months to
20 sell the property. Home prices would fall at an annual
21 rate of 15 percent. That turned out to be about
22 accurate in California for that period.

23 So we did about 22,000 in all at Indy Mac
24 between August of 2008 and July of this year when the
25 last ones came through. How did we do in terms of

1 experience?

2 Well, for the 2008 vintage modifications, the
3 re-defaults are pretty high. We're looking at a 33
4 percent seriously delinquent rate now on the loans that
5 were modified in 2008. Look what's happened though
6 since 2008. California lost 750,000 jobs. Their
7 unemployment rate went from 7.3 to 12.2 during that
8 period, just about the worst economy you can imagine,
9 but we're still under the 40 percent assumption. I
10 think we may get to 40 percent before that program is
11 done. Most of the re-defaults come early, but they're
12 still building up.

13 For the 2009s, the re-default rate so far is 19
14 percent, but those are a newer vintage, and they're also
15 all at the 31 percent debt to income ratio. They're
16 stronger modifications, so we think those will be more
17 durable.

18 We made a proposal late last year to use part of
19 the TARP money when that came about to provide
20 incentives for servicers to do modifications; in other
21 words, could you pay them to do a thousand dollars
22 upfront to do the work? Could you pay them if the
23 borrower re-defaulted to take some of that loss? And we
24 do loss sharing all the time with our bank acquirers, so
25 we talked to the outgoing Bush Administration about it,

1 talked to the incoming Treasury with the New
2 Administration, and eventually I think that idea of
3 using TARP funds to provide incentives to servicers to
4 do a pretty standard modification protocol is what is
5 going to be described to you in a moment about the HAMP
6 Program.

7 Again I think the benefits -- we showed it can
8 be done. It can be done on a pretty large scale. It's
9 not a silver bullet; it doesn't cure all the problems,
10 but by definition, if our assumptions hold, the math
11 works. It enhances the net present value of those
12 portfolios and if we hit the 40 percent re-default rate,
13 assuming the 15 percent cure rate and all the other
14 assumptions, out of the 22,000 mods we did, we kept an
15 extra 10,000 families in their homes, still paying their
16 mortgage every month and not in foreclosure, not as a
17 distress sell.

18 If you ramp up the numbers with HAMP, I think
19 they've done 650 trial mods so far. Again under the
20 same assumptions, you would be looking at keeping
21 300,000 people in their homes, so it can have
22 macroeconomic impact, but it really gets at the
23 affordability problem.

24 I think now we have an underwater problem, a
25 problem of strategic defaults being underwater. This is

1 not as effective in dealing with that problem, but I
2 would say that the NPV test is actually enhanced for
3 underwater loans. You take such a bath in foreclosure
4 on an underwater home. If you can get people to
5 reaffirm and keep paying, the benefits are all that much
6 greater.

7 So I look forward to the other comments on the
8 HAMP program.

9 DR. ROTHSTEIN: Just a quick question on the
10 Indy Mac. There was no taxpayer money or other subsidy
11 being paid to induce the modifications, was there?

12 DR. BROWN: That's right.

13 DR. ROTHSTEIN: So why weren't these people just
14 doing it anyway, if there was no subsidy? What's your
15 explanation for why the market wasn't just having these
16 modifications occur anyway?

17 DR. BROWN: Well again, when we talked about
18 freezing the interest rate on the sub primes at first,
19 there was a lot of resistance in the servicing community
20 in saying, no, that interest rate mark up is ours, we're
21 going to collect that. And we had to convince them, no,
22 you're not going to collect it, they're all going to
23 default or prepay, you're never going to get that reset
24 payment.

25 Again, I think there's a lot of inertia in the

1 servicing community from their main strategy of
2 collecting the checks and going to the contract to
3 trying to switch strategies in a very adverse housing
4 market. They're not very eager to switch strategies.

5 DR. ROTHSTEIN: So it's just some black box of
6 transactions cost at the moment.

7 DR. BROWN: It's a hard to say.

8 DR. ROTHSTEIN: Here come the subsidies.

9 MR. MCARDLE: Yes, there are tax dollars
10 involved with my program, lots and lots and lots of tax
11 dollars.

12 FDIC was a model as we were designing our
13 program, and we were authorized by ESA, which had two
14 stated goals, including preserving home ownership and
15 protecting home values. It explicitly instructed the
16 Treasury Department to create a modification program in
17 Sections 109 and 110.

18 The model we used started with some FDIC work,
19 but we also agree with the NPV. It was the cornerstone
20 of our model, so we wanted to show what everybody sort
21 of knew, that some of these modifications were in the
22 best interest of all parties, and then we also had
23 incentives through the tax dollars to make sure all
24 people's interests were aligned.

25 We use a similar waterfall. The steps are

1 similar. The borrower comes in. We capitalize all the
2 outstanding debt, escrow advances, any out of pocket
3 servicing expenses, but no late fees. We reduce the
4 interest rate, all as low as 2 percent, and that's the
5 first step in the waterfall.

6 We also have the same target rate payment, 31
7 percent, so to qualify for a program, you have to be
8 paying more than 31 percent for your mortgage, and then
9 our goal is to lower you down to 31 percent. We do it
10 through these steps, reducing the interest rate. Then
11 we can extend the term out to 40 years if necessary, and
12 then finally the last step would be deferring a portion
13 of the principal interest free until the loan is paid
14 off, and that would just be the last step in the thing.

15 You can also forgive principal. That's an
16 option you can do at any point in the waterfall, but by
17 and large, that doesn't happen as often as you can
18 imagine.

19 The other thing is this has created sort of a
20 standardized modification process, and we find a lot of
21 the banks are now actually imitating ours, even for the
22 loans that don't qualify for our program, so this has
23 sort of become the new standard modification.

24 One thing also we do is we have a trial period,
25 so once the borrower qualifies, the NPV's positive, they

1 enter a three-month trial period where they see if these
2 new payments work for them. So that's sort of another
3 way to see how this is going to work out and we mostly
4 have trials at this point. As it was mentioned, we have
5 650,000 trials at the current moment.

6 I wanted to talk a little bit about the
7 incentives and why they're there and how they work. By
8 the way as he mentioned, most pooling agreements do not
9 prohibit modifications if you can show it's in the best
10 financial interest to them, and that's the point of the
11 NPV, but we have actual financial incentives as well.

12 If the loan is above 38 percent, the investor
13 takes most of the eating to get it down to 38, but
14 between 38 and 31, we have a cost share payment that we
15 pay to the investors to lower it down to 31 percent.
16 And there also is a \$1,500 up-front payment for a
17 successful modification, not a trial, once they go final
18 into a permanent modification.

19 For servicers, who you've probably read a lot
20 about, they sometimes have incentives to go either way,
21 there are other incentives. We have a thousand dollars
22 upfront for a successful modification, one that comes
23 from trial to official. There's also a \$500 bonus if
24 it's a loan that isn't yet delinquent because one
25 feature of our program is you can be in imminent

1 default. You can be facing payment shock. You could
2 have lost your job. You can still qualify for this
3 program without going 60 days delinquent.

4 And so there's an extra bonus, but obviously
5 that's something new. We had to sort of sweeten the pot
6 for that, and also there's pay for success for servers,
7 sort of an incentive to keep this borrower going
8 onwards. For three years they can get up to a thousand
9 dollars accruing monthly and paid annually.

10 Now, the borrowers also get a success payment,
11 so they can get up to a thousand dollars a year, which
12 is paid towards their principal balance to help lower
13 it, if they remain current for that year, so it's their
14 incentive to keep this modification going and making it
15 sustainable.

16 So it's sort of a balance. I mean, there's a
17 lot of extra work with this program, with the servicers.
18 The investors obviously have to take a sacrifice, so do
19 all parties, we try to re-distribute the pain a little
20 bit. How much time do I have left?

21 DR. ROTHSTEIN: Take another three minutes, or
22 not. It's up to you.

23 MR. MCARDLE: One of the denial reasons that can
24 happen in our program is the pooling agreement still
25 prohibits the modification. We don't abrogate those

1 contracts, so if there's an outright ban, they are not
2 obligated to take the modification.

3 They are obligated to approach the pooling
4 agreement and try to seek an exception and we're also
5 tracking data, so everyone knows about the Berkeley
6 study. We'll have a pretty big pool of data about
7 exactly which investors prohibit modifications and under
8 what circumstances and we're collecting that now.

9 I guess those are my major points, but I'll
10 leave the rest for questions.

11 DR. ROTHSTEIN: The only thing you didn't say
12 was it's 50 billion.

13 MR. MCARDLE: Yes, we have \$50 billion to help,
14 so there's a lot of taxpayer subsidies involved here, I
15 should mention that.

16 DR. ROTHSTEIN: An additional 25 --

17 MR. MCARDLE: 25 goes to the GSCs for their
18 program, which is HARP.

19 DR. ROTHSTEIN: So a total of?

20 MR. MCARDLE: 75 billion. A lot of the HARP
21 money, the 25 billion is for refinancing, and I should
22 also say that our program, it's not the solution for
23 everything. We targeted mostly to sub prime borrowers
24 with higher rates, and that's the population that was
25 originally focused on.

1 Unemployed borrowers with no income, our program
2 doesn't work so well for as the COP report rightly
3 pointed out. Also there are some types of loans that
4 are just impossible to modify and can change into a sort
5 of a standard amortizing project. If you have a pay
6 option ARM where you're paying only a tiny bit of the
7 payment each month, it's very hard to restructure those
8 loans into something sustainable, which is our goal.

9 Our goal is two things: To get people in these
10 modifications, but also to keep them there, and we have
11 made some progress. I'll cite the COP report that said
12 on average our interest rates have dropped from over 7
13 percent to 2 percent for the trials we've made.

14 The front end ratios have dropped from 47
15 percent to 31 percent, so they were paying on average --
16 actually that's the median, 47 percent for their debt
17 ratio, and there were drops to 31 percent. And their
18 average payment dropped by a third, so from \$1,500
19 dropped \$600 each month, so that's the one thing they
20 cited, that we have created affordable payments for
21 these borrowers and giving them a chance to maintain
22 their homes.

23 This program is targeted toward the borrower who
24 wants to stay in their home. This is a long-term
25 commitment on both parts, so it's not targeted to

1 underwater mortgages; it's not primarily designed to
2 address that. It's primarily designed to keep the
3 borrower who wants to stay there and make a commitment
4 to their home.

5 And I should also mention one more feature about
6 our program, so the rate goes down to 2 percent, and
7 after the five-year program ends, it goes up, but it
8 goes up only to market rate. So you had a 9 percent sub
9 prime loan, your loan is now a permanently fixed rate
10 mortgage at whatever the market rate is at the time of
11 the official modification, and it goes up only 1 percent
12 a year after the five-year period, so you have a chance
13 to adjust to the new rate, and then it's capped.

14 So this is a long-term sustainable product,
15 especially if you had a higher interest rate loan to
16 come in.

17 DR. ROTHSTEIN: A lot of these modifications
18 that are being drawn under HAMP though will certainly be
19 for people whose loans are underwater?

20 MR. MCARDLE: Yes, and there's nothing about the
21 program that discourages it. It's just when you're
22 deeply underwater, your incentives change. There might
23 be a point where you decide this isn't working for you.

24 DR. ROTHSTEIN: Right, but this is an important
25 point in Paul's work though, which is that economists

1 might tend to say, well, if you're underwater at all,
2 there's some strong incentive to walk away, but the data
3 say that that's not what people do.

4 MR. MCARDLE: No.

5 DR. ROTHSTEIN: There are some other reasons you
6 might expect some of these underwater people to stay in
7 their homes when you really look at the accounting.

8 MR. MCARDLE: There are a lot of people
9 underwater who are staying put.

10 DR. ROTHSTEIN: That's right.

11 MS. SULLIVAN: Good morning, everyone. It's
12 very nice to be here today to talk to you about the
13 consumer protection angle.

14 As you can probably anticipate, much of the
15 perspective we come at this issue of dealing with a
16 secondary market that has a -- a fairly robust secondary
17 market that has developed in response to the
18 introduction of government programs as well as the
19 mortgage crisis itself.

20 From the consumer's perspective, there's been an
21 increased awareness of the ability to potentially modify
22 the loan. Consumers are facing difficulty in making
23 their payments and it's been introduced into the public
24 consciousness that there may be an ability to approach
25 your lender and to obtain a loan modification. And that

1 has created some issues, from the consumer protection
2 standpoint.

3 We've seen a secondary market of companies that
4 offer services to deal with the lender on behalf of the
5 consumer. Here is a general timeline.

6 The government programs have been introduced and
7 we have seen a corresponding increased awareness in
8 consumers about the ability to seek relief. First in
9 August 2008 there was the Hope For Homeowners Program,
10 and that was primarily a refinancing program. I think
11 it only had marginal success and very few, if any,
12 borrowers derived benefit from that.

13 In October 2008, in California, in one of the
14 hot spots of activity for the foreclosure crisis, the
15 California AD reached a multi state predatory lending
16 settlement with Countrywide, which as you can imagine, a
17 large number of the sub prime loans and the pay option
18 ARMs and ARMs generally were Countrywide loans, now
19 acquired by Bank of America. Basically as part of
20 settling their predatory lending case, Countrywide
21 agreed to modify certain qualifying loans.

22 Finally, more recently in March 2008, as we're
23 all aware, the Making Home Affordable Program was
24 announced. And we've seen an uptake in activity
25 corresponding with this timeline.

1 This is a very basic graph, but essentially from
2 a consumer protection standpoint the ideal line of
3 communication is you have your incentive programs,
4 Making Home Affordable and others, the lender, the
5 servicer and then the home owner. We would like to
6 encourage communication along this line.

7 There are also nonprofit borrower assistance
8 programs free of charge available to consumers to
9 facilitate communications with the lender, but the
10 problem area that we've seen is this for profit mortgage
11 assistance and they are diverting consumers away from
12 these programs. They're paying money that they would
13 otherwise not need to pay and more importantly and what
14 our law enforcement addresses is the promises that these
15 companies are making often have no basis. They're
16 making guarantees to consumers essentially that they can
17 obtain a loan modification and stay in their homes and
18 that's not always the case.

19 We've brought many law enforcement actions which
20 indicate how important a problem this is. We've brought
21 22 cases since early 2008. It's a larger number of
22 cases than normal and there will be more by the end of
23 the year.

24 In April 2009, we sent warning letters to 70
25 companies that were advertising mortgage loan

1 modification services. We've also engaged in consumer
2 education; we are in the midst of a rulemaking process
3 and we've partnered with Treasury, HUD, the states and
4 other agencies to figure out the best way to address
5 this problem.

6 As far as our law enforcement cases, the trend
7 that we've seen is initially these intermediary
8 companies were marketing short-term, high cost loans to
9 homeowners facing foreclosure. The loans were supposed
10 to be a bridge to allow homeowners to get through a
11 tough spot. Later in that year, companies began making
12 promises that they would be able to obtain mortgage loan
13 workouts for consumers that would prevent foreclosure.

14 And this is the standard model. They would
15 require up-front payment of large fees. This trend has
16 continued in 2009. We've brought 17 cases just this
17 year. For-profit mortgage loan modification and other
18 mortgage assistance services have simply exploded.

19 Most of them ask large advanced fees and they
20 make guarantees that they'll be able to obtain a
21 mortgage loan modification that will reduce the amount
22 of the monthly payment for consumers. Another trend
23 that we're disturbed by is that attorney participation
24 to circumvent some state laws has increased greatly.
25 And many of our law enforcement actions involve

1 attorneys.

2 Some of the techniques that relate to the Making
3 Home Affordable Program and other programs that are
4 available to consumers are we've found that many of
5 these companies are masquerading as being affiliated
6 with the government or are, in fact, the servicers or
7 lenders or even in some case nonprofit housing
8 counseling services.

9 Another issue with these for-profit mortgage
10 assistance counseling services is they tie up the home
11 owners for several months. They will often represent
12 that it will be several months before they'll receive an
13 answer from the lender or servicers, so consumers are
14 held in abeyance, and this is problematic because they
15 should be going directly to their lenders and taking
16 steps to address their situation.

17 Another unfortunate technique that is used is
18 they're specifically advising homeowners to stop making
19 mortgage payments. They represent to homeowners that
20 this will make it more likely that at the end of the day
21 they'll obtain a mortgage loan modification. They also
22 tell consumers to stop talking to their lenders and
23 interacting with their lenders, and as you can imagine,
24 this escalates to problems for consumers.

25 Another tactic that they use is they tout

1 special skills and connections in the mortgage industry
2 to negotiate mortgage loan modifications. This is to
3 get around the fact that there are many services that
4 are available free of charge, and consumers can
5 negotiate with their lender directly.

6 DR. ROTHSTEIN: Is that it?

7 MS. SULLIVAN: I would just like to talk or to
8 touch upon the rulemaking. We're engaged in it, and
9 there's not much that I can say, but through a rule, we
10 would like to address the problem globally, and as
11 you've seen, some of the issues arise from the type of
12 representations and whether there's certain information
13 that should be disclosed to consumers that would correct
14 the possibility that they would be deceived by these
15 types of for profit service companies.

16 One of the issues under consideration is whether
17 there would be a need to address the collection of fees
18 in advance of performing services. As I indicated,
19 deception is pervasive. Based on our law enforcement,
20 we've seen a large number of companies that are making
21 outright deceptive claims about the services.

22 And once the consumer agrees to purchase the
23 services and pays the upfront fees, again they are tied
24 up for a certain period of time, so the question arise
25 whether we need to prohibit the collection of advanced

1 fees until the consumer actually receives the result
2 that they're expecting. That's one of the issues under
3 consideration.

4 DR. ROTHSTEIN: Thank you. Thank you very much.
5 So what we've had is we've gone from a completely
6 unstructured kind of negotiation, traditionally you go
7 in and you miss some payments and maybe you ask the
8 lender or services if they can do something for you.

9 If you noticed on Paul's charts, one of the
10 things that they might do for you is increase the
11 principal. They wouldn't reduce the principal. You
12 would miss payments, the missed payments would be added
13 to the principal, and then you would have a higher new
14 payment. This is forbearance. If you could make those
15 payments, you were fine, and if not, you lose your home,
16 and that was the end of the story.

17 Now we have this much more structured
18 negotiation, going from the FDIC's development of its
19 product which is called the Standard Waterfall in the
20 literature, to the adoption of it by the Treasury. What
21 the Treasury is adding are a number of financial
22 incentives into that negotiation process.

23 Regarding unintended consequences, one of the
24 major ones is whenever consumers are directly approached
25 by a policy that might be able to help them, scam

1 artists come along and say, let us be your guide on this
2 journey to get your benefit. It seems to always happen,
3 and it certainly has happened in the loan modification
4 process.

5 We've got just a couple minutes. I had some
6 questions, but why don't we see if anyone in the
7 audience wants to ask a question.

8 Yes?

9 DR. LEWIS: My name is Greg Lewis. I guess my
10 question is about the use of incentives. That seemed an
11 interesting twist on the program. I first wanted to
12 know why we thought it was important to add incentives
13 to the mix, and second, the trial periods that came
14 along with that, is that sort of a screening device? I
15 don't want to handout bonuses, I want to first screen
16 someone first.

17 MR. MCARDLE: Yeah, the second part is right.
18 No incentives are paid until after the trial, so the
19 trial period is a way to wean out those who are probably
20 going to fail, not just fail but just not be able
21 to make the payment, even the new payment.

22 And as to the first part, servicers get paid
23 regardless. They get paid even if the home goes to
24 foreclosure. So you had to change that incentive
25 structure somewhat to make this worthwhile for them and

1 also give them an investment in making sure that the
2 borrower succeeds.

3 The investor obviously is taking a hit and needs
4 an investment, obviously a subsidy as well. And
5 finally, we wanted to really incentivize the borrower to
6 perform well. It's not like this is cash that goes to
7 him. It goes toward his unpaid principal balance, which
8 might actually get larger, depending where he ends in
9 the waterfall.

10 So it creates a long-term incentive for him, at
11 least for five years, to make those payments regularly,
12 to stay on this program, to have a successful,
13 sustainable modification.

14 DR. BROWN: If I can just add: Our original
15 idea to use with the HAMP money to essentially tilt the
16 NPV test in favor of modification was based on the idea
17 that there are externalities. There are macroeconomic
18 consequences. The fundamental source of uncertainty in
19 our economy was falling home prices, distressed sales.
20 If we could just take a chunk out of that, we could
21 actually have some social benefits. That was the
22 original public policy rationale for tilting the NPV
23 test.

24 MR. MCARDLE: Especially the inventors
25 incentives go right into the NPV model and tilt it, make

1 it more likely that a modification is going to occur.
2 We even have a special set of incentives for our areas
3 that are suffering severe price declines called home
4 price protection; if a property is located someplace
5 where the price is dropping rapidly, the investor is
6 going to say, cut my losses, I want out now. This gives
7 them some added incentive to make a modification in
8 those areas.

9 DR. ROTHSTEIN: All right. Yes? Joe?

10 DR. FARRELL: Joe Farrell with the Bureau of
11 Economics. So it seems as if there should be pretty
12 strong incentives to really negotiate if the lender has
13 reason to believe that the alternative is default or
14 certainly if it's going down the path towards
15 foreclosure which is no fun for anyone.

16 But I would guess that a lot of resistance to
17 renegotiation might come from the fact that it's still
18 true, I take it, that most loans don't go into default.
19 So the inframarginal, non defaulters are in some sense a
20 disincentive to renegotiation for those loans that are
21 in trouble.

22 A natural way to try to address this would be to
23 try to predict which loans are at high risk and which
24 loans are not at high risk of going into default. Paul
25 mentioned in passing earlier that being underwater is

1 perhaps surprisingly not a very good predictor. What
2 are the good predictors and how good or mediocre are
3 they?

4 DR. WILLEN: Let me take this one. The negative
5 equity thing is widely misinterpreted and misunderstood,
6 even by some very distinguished economists. Negative
7 equity is, in theory, a necessary condition for default.
8 Nobody defaults when they have positive equity.

9 I don't need the microphone. I'm really loud,
10 you may have noticed and literally, not just
11 figuratively.

12 So the negative equity is a necessary condition.
13 Very few people default when they have positive equity,
14 because they can sell the house. It's a dominant
15 strategy to sell the house rather than to go into
16 foreclosure because you can sell it profitably.

17 So having negative equity is necessary. The
18 problem is that what has been wildly misinterpreted is
19 that it's not sufficient. So nobody who has positive
20 equity defaults and most people who have negative equity
21 don't default either, so the problem is that we have a
22 lot of things that can tell us which group is more
23 likely to default. But it's the famous I know half of
24 the money is spent in advertising and is wasted.

25 I know 20 percent of the borrowers in a given

1 pool are going to default. I just don't know which 20
2 percent, and if I give assistance and I offer assistance
3 to those borrowers, all hundred percent of them are
4 going to come forward. That's the problem, and that has
5 bedeviled loan modification all along right now.

6 People say, well, we know from that the
7 probability of self cure after 90 days is very small.
8 The problem is once you announce that, all right, I'm
9 going to wait until 90 days before I modify loans, then
10 you get the scam -- they're not scam artists. They come
11 along and they say, miss three payments and you'll
12 qualify for a modification.

13 DR. BROWN: Yet there are two conditions. One
14 for the Indy Mac program was you need to be 60 days past
15 due, but also you had to have a debt service to income
16 ratio of at least 40 percent, so it was based on ability
17 to pay. It's much easier to document than willingness
18 to repay, so that's another strength of the program.

19 DR. WILLEN: Let me just say one last thing.
20 The problem is there is no scientific evidence. The
21 difference between a 20 percent debt to income ratio and
22 a 15 percent debt to income ratio, when you model this,
23 has a tiny, tiny impact on default hazards. Just to
24 give an example of this, in the automated underwriting
25 programs that Fannie Mae and Freddie Mac use, the models

1 said 90 percent debt to income was okay, and so they
2 just put in an arbitrary rule that they wouldn't approve
3 a loan above 50 percent.

4 DR. ROTHSTEIN: Thank you very much. We do need
5 to end. Maybe we'll start again in ten minutes instead
6 of fifteen, and we'll get back a little closer to
7 schedule. Thank you very much, everyone.

8 (Appause.)

9 (Whereupon, a brief recess was taken.)

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 PAPER SESSION ONE: Competition and Innovation

2 SCOTT STERN, Northwestern University-Kellogg, Chairman

3 CHRISTOS GENAKOS, University of Cambridge, "Leveraging

4 Monopoly Power by Limiting Inter-Operability: Theory

5 and Evidence from Computer Markets," Presenter

6 PAI-LING YIN, Massachusetts Institute of Technology

7 Sloan, Discussant

8 JACOB GRAMLICH, Georgetown University, "Gas Prices, Fuel

9 Efficiency, and Endogenous Product Choice in the U.S.

10 Automobile Industry," Presenter

11 MATTHEW CHESNES, FTC, Discussant

12 JOHANNES VAN BIESEBROECK, Katholieke Universiteit

13 Leuven, "Market Structure and Innovation: A Dynamic

14 Analysis of the Global Automobile Industry," Presenter

15 ADAM COPELAND, Federal Reserve Bank of New York,

16 Discussant

17

18 DR. STERN: Okay. So we are delighted to start

19 with our first paper session, which is kind of rough and

20 ready titled "Competition and Innovation," though I

21 think the topics here are pretty broad. What we're

22 going to do is start off with a paper by Christos

23 Genakos from Cambridge and a variety of distinguished

24 other coauthors, and what did we say, how long do they

25 get, 20 minutes? Okay, 20 minutes, done, and then

1 there's going to be time for a discussant.

2 DR. GENAKOS: Thank you very much. This is
3 ongoing work, as you can see, and it's still a work in
4 progress, so comments are more than welcome.

5 So what I'm going to be talking about is
6 leverage but of a different kind. So I'm going to be
7 talking about the basic question of: When will the
8 monopolist extend market power into a complementary
9 market by reducing compatibility? This is going to be
10 very interesting of course in the market that I'm going
11 to be analyzing, which is the software market, but it's
12 also obviously very interesting in many network
13 industries, like the telecommunication industry and so
14 on.

15 This is a big policy issue. The underlying case
16 that I'm going to be talking about resulted in the
17 biggest fine in EU, the biggest fine for a user of
18 monopoly power, of the order of 500 million Euros. But
19 I think it's also interesting from an academic
20 perspective in the sense that foreclosure theory has not
21 been merged with empirics, so what we're going to try to
22 do is to merge a theory of foreclosure together and take
23 this field to the data.

24 Of course you always have to answer the Chicago
25 critic, which is: Is there a problem to begin with? So

1 let me give you the basic idea in a very basic slide.
2 So assume you have two markets. Assume you have the
3 monopoly market. I'm going to be talking about
4 Microsoft in the PC operating system market as the
5 monopoly market and you have also the complementary
6 market that is competitive so my example is going to be
7 the servicer operating system market.

8 So Chicago economists in the early '50s and '60s
9 made the following very basic argument: If you have a
10 monopolist here competing in a complementary market,
11 this monopolist has no incentive whatsoever to try to
12 mess with a competitive market. Why is that? Because
13 he can extract all the surplus through his monopoly
14 market, so he can extract the full surplus by just being
15 a monopolist in its monopoly market.

16 So following this argument, in fact this
17 argument can be made even stronger. So if you have
18 product differentiation here, the monopolist welcomes
19 this product differentiation because it's only going to
20 increase the profits that he's making in this market.

21 So following this argument, there was a lot of
22 literature trying to come up with efficiency reasons for
23 these sort of behavior, foreclosure behavior. On the
24 other hand, much more recently there's a large stream of
25 theoretical research, again let me quote a couple of

1 names, Whinston and Bernheim and Whinston in '98,
2 Farrell and Katz in 2000 and Carlton and Waldman in 2002
3 in very well specified models show that foreclosure
4 indeed can arise as an equilibrium behavior.

5 In other words, if you look at the long run, and
6 if you look at a very simple model, a two-period model,
7 it might be the case that a monopolist is doing
8 something that is unprofitable in the first period, but
9 then is doing that in order to monopolize that market,
10 or to exclude competitors in the second period, and that
11 arises through a dynamic mechanism like learning by
12 doing or like investment and so on.

13 We do something completely different. We
14 propose a foreclosure theory that is based on short run
15 incentives, so we see our approach as complementary to
16 the current literature, the theoretical literature. And
17 the reason why we emphasize the short run incentives is
18 both because we think that there are relevant short run
19 incentives in this market, and also because we want to
20 take our model to the data, so the crux of our model is
21 as follows.

22 The basic Chicago argument assumes that the
23 monopolist can extract everything from the monopoly
24 market. As soon as you have an inability of the
25 monopolist to extract a full surplus because they're

1 heterogeneous consumers and he cannot perfectly price
2 discriminate, for example, all due to arbitrage, due to
3 many reasons, then this leaves surplus on the table.

4 Leaving surplus on the table means that it
5 creates incentives for the monopolist to try to enter,
6 to try to mess with the complementary market in order to
7 link these two products and extract a biggest surplus,
8 so that's the core of what we are doing.

9 Is there a truth or a little bit of truth in the
10 real case? This is an email by Bill Gates that was
11 presented in court, so: "What we're trying to do is to
12 use our server control to do new protocols and lock out
13 Sun and Oracle specifically . . . the symmetry that we
14 have between the client operating system and the server
15 operating system is a huge advantage for us."

16 Obviously this can be just cheap talk, right?
17 But what's amazing is the market outcome. So what you
18 can see here is the Microsoft market in the server
19 operating system, and it started around 20 percent at
20 the beginning of '96, and by 2001, it had risen to
21 something like 60 percent, so a really huge increase in
22 the market share.

23 So what we're going to do in this paper is
24 analyze theoretically and empirically the incentives of
25 the monopolist to leverage a complementary market by

1 degrading interoperability. And we do that in three
2 simple steps. So in the first step we just present the
3 basic mechanism with a simple model.

4 In the second step we make the model a little
5 bit more complicated by adding differentiated products
6 and heterogeneous consumers and then we take this to the
7 data by having a structural model of differentiated
8 goods and complementary markets. Again we do that in
9 order to emphasize the short run incentives. There are
10 always going to be also long run incentives.
11 Particularly in this market, there are very strong
12 longer incentives, but we want to take our model to the
13 data.

14 Why do we care? Well, it's kind of the first
15 attempt to merge the theory with the empirics, so I
16 think it's interesting for public policy but also for
17 research. Also I think inherently the two markets, the
18 PC and the server markets, are very interesting markets
19 because they form the backbone of what we call the new
20 economy, or they are essentially inputs for many other
21 industries.

22 And the results that we get, the kind of
23 incentives that we have, are also relevant for other
24 complementary methods. So Microsoft has been accused of
25 all sorts of things, for these sort of behaviors in

1 other markets like the web based application or PDAs and
2 so on, so forth.

3 Finally I think there is some added value
4 academically in the sense that what we saw empirically
5 is that we have a model, I can sell it as BLP, Berry,
6 Levinsohn and Pakes model, a structural demonstrative
7 model, but for complementary markets, so I think there
8 is some added value to that in the sense that this sort
9 of structure can be used in other industries as well.

10 All right. Let me give you briefly the idea
11 behind the simple model. So the simple model assumes
12 that there's a monopolist. The monopolist is always
13 going to be the PC operating system firm facing two
14 customer segments with different elasticities, so think
15 of the two customer segments as large businesses and
16 small businesses, and we're going to assume that these
17 two different customer segments have different
18 elasticities. So the large businesses are more
19 inelastic in terms of their demand for PCs.

20 We're also going to assume that the large
21 businesses are more likely to buy servers, so they have
22 a more inelastic demand for PCs, but they're also more
23 likely to buy servers.

24 These two components give us that if the
25 monopolist can perfectly price discriminate, then we are

1 back in the Chicago world in the sense that we are back
2 in the real world where there are no incentives to mess
3 up the complementary market. But as soon as
4 this perfect price discrimination argument breaks, due
5 to arbitrage, due to any reason, then the monopolist can
6 restore this price discrimination ability by trying to
7 monopolize the complementary market.

8 So in the simplest case where, for example,
9 Microsoft's quality of the operating system is better
10 than all the rivals, this just restores the price
11 discrimination ability of Microsoft. So the welfare
12 effects of that are not clear apparently.

13 On the other hand, if the rivals are better,
14 then our little model shows that Microsoft can have all
15 the incentives in the world to exclude arbitrarily
16 better rivals, and that has very clear welfare
17 implications. So this is a simple model in the sense
18 that there is not product differentiation, so the more
19 general model has product differentiation and we're
20 going to assume that each buyer decides either on the
21 bundle, which in this market is called a work group, so
22 a server with W PCs, a PC or nothing. And we're going
23 to allow W to be heterogeneous in the population of the
24 world, so we're also going to allow for heterogeneous
25 preference for all the other groups.

1 So let me just give you a sense of the utility
2 that we're using. It looks very complicated, but I
3 think it's very simple. It follows all the recent
4 literature in differentiated goods. So the consumer has
5 a preference for the bundle, J , K denotes the PCs, K
6 denotes the servers.

7 So the consumer "I" has a preference for the
8 bundle, and that is a function of the PC characteristics
9 and some parameters. Of the server characteristics on
10 some parameters, the prices of the two and some
11 unobserved brand specific characteristics, as well as
12 idiosyncratic error, so you buy the bundle of the
13 characteristics. That's the idea.

14 The only different thing is that we are adding
15 this alpha parameter, which you can think of it as a
16 matrix or as just this color that denotes how well the
17 rival server operating systems interoperate with the PC.
18 So for the case of Microsoft, we're going to assume that
19 this color is one, so it's perfect interoperability.
20 For everyone else, it's going to be something less than
21 one.

22 We are interested in the profits for the
23 monopolist, so this is the monopolist of the software.
24 There are some choices that we had to make at this
25 point. Here is the profit margin from the PC, so this

1 is price and this is marginal cost times the quantity of
2 PCs, and this is the margin on the server side.

3 So we do not observe the margins, which is the
4 usual problem in structural IO. What we do observe is
5 prices of PCs and servers, so we're going to infer the
6 margins through our demand estimation. The way we model
7 the monopolist is as if the price of software is just
8 added to the price of hardware. In other words, the
9 software producers and the hardware producers set price
10 simultaneously. If that wasn't the case, we would need
11 to model the strategic interaction.

12 It becomes very complicated we think with no
13 added value because we're going to assume that the
14 software producers and the hardware producers act
15 simultaneously. In that world, we can focus on our
16 monopolist in the software market, so the monopolists
17 are recognizing the joint profits from the PC and the
18 server.

19 The incentive is to degrade, so when you
20 differentiate these profit functions with respect to
21 alpha, which is the interoperability parameters, it
22 comes from a trade off. It is a very basic trade off in
23 the sense that the more market share you shift from the
24 PC side, the higher is going to be your server profits,
25 but on the other hand, you are losing PC sales, so let

1 me make this more clear.

2 So when you take the derivative, you arrive at
3 this basic inequality, so this is the server margin
4 denominator, and this is the PC margin. We call this
5 the relative margin effect and this is the effect on
6 sales of PCs of degrading interoperability and this is
7 the effect on servers by degrading interoperability. So
8 this is the relative outward effect, how much demand
9 changes as you change the interoperability.

10 So the idea behind this is very simple, right?
11 The higher your margin in the server, the more you're
12 going to gain by shifting sales from your competitors to
13 your own server operating system market. On the other
14 hand, by degrading the interoperability of your rivals,
15 some of the consumers that were buying your rival's
16 servers, are not going to buy your PCs anymore. So that
17 costs you because you're going to lose some PC sales.
18 The fewer the PC sales, the smaller is going to be the
19 relative output effect.

20 So our paper is about to test this basic
21 inequality, the inequality that says that you're going
22 to gain more by shifting sales to your servers, and
23 you're going to lose by losing sales from the PC side.

24 This is just repeating what I just said, so the
25 third step is to take this to the data. Because of our

1 structure, we can estimate the relative margin basically
2 by estimating demands elasticities for the PCs and
3 servers. So we formulate the model where it's a
4 structural model differentiated oligoplastic market for
5 complementary robust, and we can estimate the relative
6 output in one goal in a sense through our model.

7 So that's how we do it. Again very quickly, the
8 structure of the model is very similar to the basic BLP
9 model, so this is the mean utility for PCs, and this is
10 the difference, the individual differences from the mean
11 utility for PCs. This is the mean utility for servers,
12 and this is the individual differences from this mean
13 utility, which depends on the characteristics and an
14 unobserved product characteristic as well as the random
15 coefficients.

16 So what is different is that our consumer has a
17 preference for the bundle, so that's what we model here.
18 Consumers choose the highest utility because our theory
19 dictates that these two products are compliments, right?
20 Somebody might say, do you need to impose that? In
21 fact, we're going to estimate two alternative models,
22 one in which what we call strong complementarity where
23 we assume that everybody thinks of PCs and servers as
24 strong compliments, and another that we call frequent
25 complementarity that we allow the data to determine the

1 complementarity or the substitutability. This is in
2 line with recent work by Genakos and Song and
3 Chintagunta.

4 So data that uses PC and ID PC and server data,
5 and we go through the painful process of matching this
6 with the characteristics from all sorts of sources, so
7 we have a relatively large cross-section of PCs and
8 servers. We don't have that much of a time series. We
9 have about 21 quarters.

10 The estimation algorithm looks very much like
11 the BLP algorithm that says given some starting values
12 of non-linear parameters and the calculated brand market
13 shares, do the contractual mapping. Now, the only
14 unique thing is because of the complementarity, we need
15 to compute this mean utility for each product category
16 and then do the same for the other category, conditional
17 on the mean utility of the other's complementarity.
18 Otherwise it's exactly like the BLP estimation
19 algorithm.

20 Results, let me not show you any coefficients.
21 Let me show you the results. We tried to quantify you
22 remember the relative margin and the relative output so
23 this is a plot of the two models for our sample period.
24 What do we observe?

25 First of all, the red line is the relative

1 margin, so the fact that it's positive means that the
2 server margin is higher than the PC margin, which
3 confirms our prior thoughts about this market. Server
4 margins are way larger than PC margins.

5 On the other hand, the relative output is also
6 positive, which means of course there is a real cost of
7 Microsoft degrading the interoperability of everybody
8 else because it loses PC sales. So if you look at the
9 graph, what you see is that at the beginning of the
10 period, there's a clear dominance of the relative output
11 to relative margin.

12 That means Microsoft has no incentives
13 whatsoever to degrade interoperability, but these two
14 lines follow opposite trends. So the relative margin
15 steadily increases and the relative output steadily
16 decreases. By the end of the period, there is the
17 reverse order, so the relative margin is much higher
18 than the relative output, which indicates that Microsoft
19 really had strong incentives to degrade interoperability
20 by the end of the period.

21 What's also very interesting is that the key
22 point of divergence in these two lines is around the
23 beginning of 2000, which coincides with the release of
24 Windows 2000, which we know from the court case, had the
25 most difficulties. Rival server operating systems had

1 the most difficulties connecting this with a PC
2 operating system.

3 This is from our baseline model. We do it in
4 terms of robustness, in terms of the samples of
5 consumers, different assumptions, potential market size,
6 blah, blah, blah.

7 Is this model driven? That is our last
8 question. So we estimate two alternative models, right,
9 so we want to see how model specific is this result, so
10 we estimate both a more restrictive model, where we
11 assume that consumers buy only the bundle or nothing or
12 another one is what we call the frequent
13 complementarity, where it allows the data to estimate
14 the complementarity or the substitutability between the
15 two segments.

16 What we find: This is the result from the
17 strong complementarity case, so the button is almost the
18 same as before in the sense that relative
19 output dominates relative margin. So there are no
20 incentives at the beginning of the period, very clear
21 incentives at the end of the period, and now the 2000
22 event plays an even bigger role.

23 With the frequent complementarity, results are
24 much more mixed. Let me just say, because I'm not
25 showing you these here, that the estimate of the

1 parameter that controls the complementarity is positive,
2 meaning that the data tells us that the two markets are
3 indeed complementarity, so that's a verification of our
4 intuition.

5 On the other hand, the two results are a little
6 bit more mixed at the beginning, but again there's a
7 clear positive outcome at the beginning meaning again
8 that Microsoft had these incentives at the end.

9 So we model these monopolist behavior to try to
10 leverage a complementary market. We have explicit
11 conditions and we test these predictions. That's the
12 whole point of the paper and we think that we find
13 robust evidence that these incentives were there, and
14 they go stronger over time.

15 Thank you very much for your time.

16 DR. STERN: And our discussant is Pai-Ling from
17 MIT.

18 DR. YIN: Thank you. Yes, here I am. So thank
19 you very much for inviting me to discuss this paper. I
20 think it's a really nice paper and it fits in with what
21 I've seen this morning. I found the conference already
22 to be very interesting and relevant to a lot of issues
23 that we have to deal with today. I think this paper
24 fits right in with that in the sense that Christos and
25 his coauthors come up with a very robust and show a very

1 robust incentive for monopoly firms who leverage their
2 power into a complementary product via interoperability
3 degradation.

4 One thing they don't emphasize in this paper,
5 but hopefully they will in future papers, is that
6 there's also part of their theoretical model that shows
7 that if the possibility of this complementarity between
8 the monopoly firm and their complementary market and
9 this ability to degrade it so interoperability is not
10 taken into account, then you might actually overestimate
11 margins on monopoly products. So that might be a more
12 general statement about how we think about defining
13 markets when we're trying to estimate markups.

14 Now, if this was a theoretical paper and it just
15 stopped there, then my discussion would be over because
16 I'm not a theorist, so I would just say you've convinced
17 me of this model and that this result would occur and
18 that would be the end of it. But I really applaud the
19 authors because they go beyond just making a theoretical
20 contribution, and they say, okay, well, does this
21 actually matter in a market that we care about, and I
22 think this really brings us to the fact that this is a
23 very relevant paper.

24 So they estimate in a real life, timely setting
25 the competition between Microsoft and the server market,

1 and I would say that no good deed goes unpunished. And
2 so it's along the empirical implementation that I'm
3 going to give a few comments about where I think they
4 might be able to make some improvements. And more
5 importantly, where us as readers might be able to make
6 some improvements, as well because I think the
7 exposition is so easy to follow in this paper that it's
8 really something I encourage people to read. It
9 actually could be implemented, plus Chris generously
10 answered all my questions before this discussion, and he
11 shared his data before this discussion so he might be
12 willing to also answer any questions that you had after
13 your paper if you want to try to implement the result.

14 One thing I will say right now is along the
15 lines of emphasizing this extra contribution, since they
16 do actually bring the model to the data, you might be
17 able to actually give some estimates about what would be
18 the error we would be making if we didn't take this into
19 account versus you've already got the results where we
20 do take this idea of interoperability degradation into
21 account, so that might be an interesting counterfactual
22 to create.

23 So why did I ask Chris for the extra data?
24 Well, one of the things that I'm always careful about is
25 that when we look at market shares, I always wonder: Is

1 the shift in market shares due to market share stealing
2 or is it due to an increase in market share? And, in
3 fact, for all of my comments, I really am convinced of
4 the result, and I think that the interoperability
5 degradation issue still goes through in this market.

6 I think one of the interesting things that you
7 have to think about is notice that the market share of
8 Microsoft, which is not being shown, but it's the big
9 dark blue at the bottom, it's actually increasing, in
10 part because they're stealing market share from netware,
11 but also in part because clearly there's just an
12 explosion in demand in the server market over this time.

13 So one thing we just want to be careful of is:
14 Is this all just market share being taken away because
15 of diminishing interoperability, or are there also some
16 other factors about demand that might be driving a
17 specific preference for Microsoft? And in that case,
18 maybe there's some flexibility on the parameters that
19 you estimate, not just over heterogeneous consumers over
20 the whole time period, but could you split between the
21 heterogeneity of consumers in the early period versus
22 something about the consumers and their heterogeneity
23 and their preferences that is changing later on in that
24 period that also explains why there's just a huge
25 increase in demand, period, for servers?

1 The second area that I would want to make some
2 comments on is about this interoperability coefficient
3 alpha. This is the key thing that we want to deal with
4 and we want to estimate in this model. Let me say, in
5 full disclosure, that Christos and his authors have
6 actually addressed a lot of the things that I'm going to
7 suggest in this slide. And the problem is it's just
8 really hard to estimate these coefficients in general,
9 and especially given that they have a limited time
10 period.

11 But if you're out there thinking about a
12 different data set, maybe you can take some of these
13 suggestions and think about. If you could do things
14 with a little more flexibility, you might actually get
15 some precise estimates. So just to remind you we're
16 going to specify the coefficients that are actually
17 going to estimate this alpha, this interoperability
18 parameter in the actual paper as a coefficient on RAM
19 and on RAM times Windows.

20 So one of the things is that we're just in the
21 paper going to let random coefficients exist on the RAM
22 variable, and not on RAM and Windows. And I think that
23 may be a little inconsistent because, first of all, our
24 coefficient on both of these is going to be determined
25 by the same underlying variables so it seems strange to

1 allow one to be a random coefficient and one not to be.

2 More importantly, given that these coefficients
3 are so close together because the Windows is just dummy
4 that turns on when the RAM measured for that server is a
5 Microsoft server. It seems like maybe by imposing that
6 restriction that one is a random coefficient and one is
7 not, you're actually forcing the random coefficient to
8 predict less heterogeneity than you would if you allowed
9 random coefficients on both.

10 Again it's hard to allow more than a few random
11 coefficients on this and still get precise estimates,
12 but again thinking about another data set, that would be
13 something you would want to do. Again it's going to
14 effect PC demand, but probably the larger incentive
15 results go through.

16 Something that concerns me a bit more is that in
17 this model, we're going to estimate incentives and
18 alpha, assuming that the alpha, this interoperability
19 effect is constant and not optimally chosen. So the
20 concern I have is that anecdotally, we feel like
21 Microsoft was allowing more interoperability early in
22 the period and then allowing less so later in the
23 period.

24 So what I would like to do is let alpha vary
25 over time, so that the estimates of incentives would

1 change, and I think the result of this would be that you
2 would have a less stark difference in the results graph
3 between the relative margins and the relative outputs.
4 I still don't think this rules out the same result, but
5 I just think that we're going to have maybe less stark
6 results if we allowed that flexibility.

7 Now, as for the alpha not being optimally
8 chosen, I think the authors present some great arguments
9 why we might think that would be true, right? There are
10 a lot of reasons why Microsoft can't choose the optimal
11 level of interoperability because there are a lot of
12 costs in terms of trying to make things less or more
13 interoperable, but what I would say is again in the
14 caveats to the application is that interoperability,
15 they show how it could be more optimal.

16 Interoperability could also be less optimal,
17 right? So there's not a one-sided effect in the sense
18 that I think you're giving a little too much credit to
19 the Microsoft workers if you say that they're able to
20 structure everything to some optimal level. So a more
21 gentle interpretation of what's going on here is even if
22 Microsoft is not explicitly degrading, maybe the
23 monopolist has no incentive to exert extra effort to be
24 more or less interoperable than however they turn out
25 from their software engineering side.

1 And finally a small point is just for the
2 instruments that they use. In this market you have
3 prices falling at the same time that product
4 characteristics are improving over the whole time
5 period. So just if you think about using the same
6 instruments that he does in another data set, if you're
7 implementing their paper, then you just want to check
8 that you have a consistent pattern as opposed to maybe
9 prices rising and then falling with product
10 characteristics improving over time.

11 But otherwise I think it's a really interesting
12 paper, very clear to read. I highly encourage you to
13 look at it, and ask Chris for any help if you need it in
14 implementation. Thanks.

15 DR. STERN: Should we do maybe just one or two
16 questions before we move to the next paper?

17 DR. O'BRIEN: Yes, Dan O'Brien, Bureau of
18 Economics. I just wanted to ask Christos: What can we
19 say about the welfare effects of what I think of as
20 really tying going on in your model? I mean, we have
21 complements, and you made an assumption that you can't
22 completely extract. We know that when you sell
23 complements and you're a firm with market power and you
24 can't completely extract surplus with fixed fees or
25 whatever, that tying is a way to extract more surplus.

1 You mentioned that the price discrimination
2 effects are ambiguous and I'm just wondering if you
3 thought about measuring what the ultimate welfare
4 effects were or if you had any results in that?

5 DR. GENAKOS: Should I answer?

6 DR. STERN: Go ahead.

7 DR. GENAKOS: The quick answer would be we
8 haven't done full-blown welfare calculation, but my
9 comment from the very simple model that we had at the
10 beginning was that if the monopolist has this incentive
11 to exclude arbitrary rivals, there's a clear welfare
12 effect there in terms of the sign.

13 In terms of the magnitude, we haven't done the
14 exercise yet, so this is something to be done, but the
15 incentives are there to exclude an arbitrarily better
16 rival, so that will be my quick comment on that.

17 DR. STERN: Great. To keep ourselves, if not on
18 time at least equally far behind, I think we're going to
19 start with Jacob Gramlich from Georgetown, and we're
20 moving from the industry of the second half of the 20th
21 Century or maybe the 21st Century to the automobiles,
22 which is I guess an industry from the early 20s. Okay.

23 DR. GRAMLICH: But still an industry.

24 DR. STERN: And an important one. We all own a
25 little share. I'm a shareholder in many of these

1 companies now. Okay. So we'll hear a little bit about
2 gas prices, fuel efficiency and endogenous product
3 selection in the U.S. automobiles. I wonder when this
4 project was started.

5 DR. GRAMLICH: When this project was started?
6 You will see that when we get to the counterfactual:
7 That one of the things we will talk about is when gas
8 prices are high, but there are still other implications
9 because there's still a lot going on with fuel
10 efficiency, so thanks for having me.

11 So as Scott pointed out, this paper is about gas
12 prices and their effect on fuel efficiency. The
13 endogenous product selection basically means: How do
14 gas prices affect the choice of fuel efficiency?

15 So the goals of the paper are very simple: One,
16 to model the auto manufacturers' choice of fuel
17 efficiency. And when I say fuel efficiency, I mean
18 miles per gallon. For the rest of this talk, it's
19 expressed a little bit differently in Europe, as you
20 might know, but basically it's an expression of how much
21 fuel a car uses to move some certain amount of distance,
22 okay.

23 So we want to model auto manufacturers' choice
24 of this variable and then use the model to predict the
25 market equilibrium in various counterfactual scenarios.

1 When I say market equilibrium, what I mean is supposedly
2 we have a gas price increase or a gas tax. Would that
3 affect the miles per gallon that we see in the
4 marketplaces?

5 By miles per gallon, I mean both what is offered
6 by firms and what is purchased by consumers. So why do
7 we want to do this? There are sort of general reasons
8 that aren't specific to the auto industry and then there
9 are specific reasons in the auto industry. Generally I
10 think it's fair to say that understanding the
11 determination of product characteristics is an important
12 exercise.

13 So there are a lot of characteristics besides
14 price that we actually care about in a lot of
15 industries, so variety, quality, efficiency, location.
16 I mean, this is not new, but there's not a lot of
17 modeling on how these characteristics are set, so the
18 only reason they're limited endogenous modeling, there
19 are plenty of models where there are characteristics in
20 there, but models where the characteristics are chosen
21 are few.

22 I mean, the literature goes back far. In 1929,
23 I guess was Hotelling, so that is what I'm thinking of as
24 a model of endogenous characteristic determination,
25 right, but already once that model goes to sort of two

1 dimensions of characteristic choice, it's already a very
2 unsatisfying model, both because there's no nice
3 analytic solutions and also because there's multiple
4 equilibrium.

5 So there's an empirical literature, which this
6 is a part of, that is addressing this, and that's to say
7 sometimes the models are more interesting in an
8 empirical setting when they're not in a theoretical
9 setting. And that is because the fact that you have no
10 analytical solution will not be a constraint. There are
11 still going to be some multiple equilibria issues,
12 although less so in this paper, and I'll talk about why.

13 So that's to say the question of product
14 characteristics is a real one, and I would say in
15 particular in the auto industry. So the auto industry
16 itself is just very big and uses a ton of our carbon,
17 did I say a ton of carbon? I shouldn't have said that
18 because I didn't literally mean that. It uses a lot of
19 our carbon, okay? It has a big energy footprint, both
20 in terms of energy usage and pollution, and miles per
21 gallon itself is one way to think of or one way to
22 summarize what is a car's impact on the environment.
23 It's not the only way, but it's a pretty good measure.
24 It's such a good measure that there's a whole set of
25 Federal regulations called the CAFE standards, which

1 actually target this particular product characteristic
2 in this particular industry.

3 And we've heard about this a lot recently
4 because the CAFE standards, which sort of mandate sales
5 weighted fuel efficiency, basically say, if you want to
6 sell cars in this country, you have to sell firm by
7 firm. You have to sell sales weighted fuel efficiency
8 of fill in the blank and that number has been about 27
9 miles per gallon for a long time. Recently their
10 regulations pushed up to 35 miles to the gallon. There
11 are literatures on each, but I'm not going to go into
12 that in a presentation of this amount of time.

13 So let me give you an overview of basically how
14 the model works. So if you sort of know Berry,
15 Levinsohn, Pakes 1995, you can kind of update that into
16 your RAM and then we'll build on that. That's what's
17 going on downstream, so we're going to have a two stage
18 game basically.

19 In the first stage firms are going to choose
20 characteristics of their automobiles knowing that then
21 there's going to be some innovation in the gas price,
22 and we're going to play a down stage Nash Bertrand
23 pricing game over the top of the fixed characteristics.
24 So in the first stage you get to the choose the
25 characteristics and then in the second stage the

1 characteristics become fixed and all you have control of
2 is price.

3 So down here we're in sort of this
4 differentiated products Nash Bertrand pricing game,
5 which is very familiar to the literature. And up here
6 we're adding this characteristic setting game.

7 So the most interesting thing or sort of the
8 summary of this upstage game that I'm adding is that the
9 gas price is stochastic. I'm not going to go any
10 further than that, but there's some element of
11 randomness to gas prices. They move around, and that is
12 going to shift consumers' preferences for fuel
13 efficiency. So if we were paying attention in the
14 summer of 2008, gas prices were very, very high and
15 everyone wanted very fuel efficient cars, no one wanted
16 the gas guzzlers.

17 So at times of high gas price, consumers are
18 very sensitive to fuel efficiency. They want it. At
19 times of low gas price, consumers don't care about fuel
20 efficiency. Think of the late '90s, early 2000s, when
21 the SUV industry was big, a segment of the market was
22 sort of born during these low gas prices. Firms can
23 provide fuel efficiency to consumers, but they can't do
24 it for free, okay.

25 So there is a technology frontier between

1 providing fuel efficiency and then providing other
2 stuff, so a lot of the other things we really like about
3 cars. We like it when they're fast; we like it when
4 they're big; we like it when they're roomy and powerful
5 and all those things are sort of negatively related to
6 fuel efficiency, okay.

7 So basically there's going to be a gas price
8 that's bouncing around. Firms are going to face this
9 technology frontier and they're essentially going to
10 slide along this frontier in response to the gas price,
11 knowing that their profit maximizing fuel efficiencies
12 are going to be higher under high gas price and lower
13 under low. That's all I want to say about that.

14 Let me preview the results. On the modeling
15 side, I do model product selection and that's a way of
16 saying there are some endogenous shifters that will
17 actually shift around what I want to endogenize. We'll
18 talk about that in a second. The other is I'm going to
19 use less restrictive identifying assumptions than what
20 we've tended to use in this industry, so we often assume
21 that unobserved quality is uncorrelated with observed
22 quality. There's a way to relax that, not fully but
23 some here.

24 These two points are a little more general.
25 This third point is just about cars, so you'll care

1 about this third point if you care about cars. Previous
2 empirical demand estimation on cars has not found much
3 consumer sensitivity to fuel efficiency. Even if you go
4 back to BLP in '95, you can look at consumers'
5 willingness to pay for fuel efficiency and it just
6 doesn't look like they're willing to pay.

7 And the reason is because there is actually this
8 exact technology frontier that I just showed in the
9 slide before, so by sort of explicitly accounting for
10 that here, my results would definitely say that firms do
11 care about fuel efficiency and the willingness to pay
12 numbers will show that.

13 Then the counterfactuals, I'm going to use the
14 model and sort of run two counterfactuals. So the
15 counterfactuals, just to say what they do, basically
16 say, plug in some new after tax gas price. So suppose
17 we want to say what would happen in the car market if we
18 had \$4 gas, \$5 gas or \$3 gas. You stick in an after gas
19 price.

20 You let all the firms re optimize, knowing that
21 the consumers will repurchase on top of that, and you
22 have new sales weighted fuel efficiencies. I look at
23 two sort of counterfactuals. One is the summer of 2008
24 because as Scott pointed out, that was really
25 interesting. At the time I thought that's interesting,

1 gas prices are high, where will this market go.

2 So the market didn't necessarily head in the
3 direction it was heading in the summer of 2008 because
4 gas prices didn't stay there, but we can sort of look at
5 the sales patterns that the model would predict for the
6 summer of 2008 and compare that to the actuals, and it's
7 a decent fit. I'm not going to editorialize. I'll show
8 it to you.

9 Then this is sort of the punch line. Recently
10 the new CAFE standards, which you have to keep track of
11 week to week almost or you forget where we are, but
12 essentially we're going to achieve 35 miles per gallon,
13 sales weighted for the entire domestic fleet, by 2016,
14 2020. Anyway, we're going to do that with CAFE
15 standards, so there's just a mandate that we're going to
16 do this with CAFE standard.

17 Some people don't like CAFE standards and would
18 prefer a carbon tax or would prefer for gas prices to
19 simply be higher and have that get us to this elevated
20 fuel efficiency. If you wanted to do it that way and
21 you asked my model, what should we make after tax gas
22 prices to get to us to 35 miles per gallon, okay, the
23 model would say we need \$4.55 gasoline so that's sort of
24 the punch line.

25 DR. STERN: You've got seven minutes.

1 DR. GRAMLICH: That's fine. That's why I put
2 everything that's important upfront, so I'm going to dip
3 into this a little bit, but of course this quickly, you
4 can't dip too far. I think if there's one sort of way
5 to drill into the model and see what's going on, I think
6 this sort of tells you a lot of what's going on.

7 This is the utility specification. These are
8 consumers that care about price, fuel economy, quality,
9 and then our unobserved quality so this is observed
10 quality. This is unobserved quality. These are
11 characteristics related to the nesting structure and
12 then this is a nested logit error. These preferences
13 for fuel economy vary by nest, by subsegment.

14 Now, the thing I want to say is that the
15 trade-off that I showed you before was essentially
16 saying you can deliver consumers fuel economy or you can
17 deliver them quality, but not necessarily both at the
18 same time, so I want to capture both of these terms in
19 the utility function but you need proxies for them.

20 There's a natural one for fuel economy, and
21 that's just dollars per mile. It's an interaction of
22 the gas price itself with fuel efficiency, and this is
23 kind of what delivers you, in that in the summer of 2008
24 when gas prices are high, people are paying a lot more
25 attention to fuel efficiency.

1 Now, this is the thing that seems backwards I
2 think when you first look at it. At least it still
3 seems backwards to me when I first look at it, but I
4 think it actually is consistent with that technology
5 frontier that we showed. If you want some proxy for
6 quality, and I've sort of drilled into this, empirically
7 the best proxy is actually miles per gallon itself,
8 assuming that you've controlled for full economy. This
9 is what sort of the earlier empirical papers missed.

10 They didn't include both controls. They only
11 included one and so it basically didn't pick up the
12 effect. But when you include this interaction with the
13 gas price, you actually do pick up these negative
14 quality trade-offs.

15 The reason I don't use some sort of hedonic
16 quality index based on all of the other characteristics
17 is because even if you do, this piece comes in negative.
18 You can't get the negative and statistically significant
19 sign on miles per gallon to disappear, so I'm just going
20 to take advantage of that and parameterize this
21 technology frontier that way, okay.

22 So I think in the interest of time, I'm going to
23 skip over this. Here's the supply game, so we have sort
24 of a downstream or Nash Bertrand pricing game. Again
25 there's a characteristic setting game earlier. I'm not

1 going to talk about what earlier means. I do a bunch of
2 robustness checks.

3 Here's the business about relaxing the
4 identifying restrictions. Usually we assume that all
5 characteristics are set before these shocks are
6 observed. I'm going to relax that at least for the
7 characteristic of miles per gallon. I think in reality
8 we have always believed that firms know what these are
9 when they choose the characteristics, at least to some
10 extent.

11 So it was never the most plausible assumption
12 but it provides a lot of identifying power. But I think
13 in this context when you're explicitly modeling firms'
14 choices of miles per gallon, it becomes even more
15 egregious to assume that these things are going to pop
16 out and surprise everyone afterwards, so that's relaxed.
17 And that's what I mean about the less restrictive
18 identifying assumption.

19 So profits are maximized. We do GMM. There are
20 some interesting things about how to control for the
21 first order of conditions, and Hanson and Singleton are
22 very useful here. If you think back to
23 optimization environments, but I don't want to go into
24 that.

25 What I want to say is so you can get some

1 estimation results, estimate results in these sort of
2 these logit models don't mean much when you just look at
3 the parameters. If you look at willingness to pay
4 though, you can sort of come up with willingness to pay
5 for fuel efficiency increases in the industry, and it's
6 actually pretty sizeable.

7 The reason this is a chart is because
8 willingness to pay varies with a lot of things. So it
9 varies by the subsegment of the car that you're in, so
10 small, middle, large specialties, SUV. It varies by gas
11 price, so that's sort of what you see, and I don't want
12 to belabor too much of these, but a lot of them are
13 pretty significantly different than zero. These
14 willingnesses to pay are what shape the incentives in
15 the counterfactual to actually scale up your MPG when
16 there are high gas prices.

17 Let's jump over to the counterfactual. Again
18 what the counterfactual does is it essentially maps an
19 after tax gas price into a new equilibrium in the
20 industry. You can sort of think of that in a couple
21 stages, and what I do first is you say: Let's insert an
22 after tax gas price, make fuel efficiency stay where it
23 is, do what consumers do, so that's what the firms
24 haven't had a chance to respond yet.

25 But then a year out or two years out or however

1 long you think it exactly takes for firms to actually
2 adjust these characteristics, the firms will then slide
3 up or down their fuel efficiencies, and we'll have a new
4 equilibrium. So in the summer 2008, you can do the
5 first part of this counterfactual. We got to see what
6 consumers do.

7 We didn't get to see firm responses because they
8 were all thinking, boy, I wish we had higher fuel
9 efficiency in all of our cars, but there's nothing you
10 can do about it once you're in the middle of a model
11 year. The consumers were buying fewer cars overall, but
12 in particular, they were buying fewer utility vehicles
13 and trucks because these are the more gas guzzling types
14 of cars. This is what the model would predict in the
15 summer of 2008.

16 So this gives you a sense that maybe the
17 model has got the general shape, overall level kind of
18 close again. I don't want to editorialize too much on
19 that, but that's what you do. Then this is a chart that
20 has way too many numbers, but I actually did want to put
21 this up just to say this is the type of thing that the
22 model can deliver.

23 It can tell you what happens to quality,
24 quantity, miles per gallon offered and miles per gallon
25 purchased, and again at these sort of various check

1 points, so if you want to think in the short run
2 timeframe where only consumers can respond or in the
3 longer term when firms respond.

4 So that counterfactual that I said, the sort of
5 CAFE equivalent counterfactual, says how high do I have
6 to push up the gas price in order to get a 35 down here,
7 which is the sales weighted fuel efficiency for all
8 vehicles after all firms re optimize and all consumers
9 re optimize? So the punch line is \$4.55 according to
10 this model.

11 So for the multiple equilibria interested folk
12 here, it actually doesn't appear to be a problem here.
13 This is not a proof that they're not a multiple
14 equilibria, but I actually have a suspicion there may
15 not be based on the nested logit but more on that is
16 forthcoming.

17 So in conclusion, I model this characteristic
18 choice. It's an interesting characteristic, at least I
19 think. There are less restrictive identifying
20 assumptions and more realistic fuel efficiency
21 preferences. And then in the counterfactuals, again
22 sort of the punch line is you can use the model to tell
23 you if you want to affect certain fuel efficiencies, how
24 high the after gas tax price has to be.

25 To put this in context, \$4.55 and 35 miles per

1 gallon, those sound sort of astronomical to us as
2 Americans, but in worldwide developed standards the
3 Europeans are laughing. They're not actually that high.

4 So there's one other thing I just want to
5 mention. There's a shadow cost to firms that I've
6 estimated in this model of these CAFE; it's actually
7 pretty high. We should really ask political economy
8 people about why we're doing CAFE versus gas taxes. I
9 think there may be some political reasons more than
10 anything else, but gas taxes would move MPG if that were
11 one of the ways you wanted to do it.

12 That's all I have. Thanks.

13 DR. STERN: Okay. Matthew Chesnes from the FTC
14 will be our discussant.

15 DR. CHESNES: Thanks. Good morning, everyone.
16 I'm Matthew Chesnes from the FTC, and I'll be discussing
17 Jake's paper. First let me just say, it's a very well
18 written paper. It's a timely topic and addresses an
19 important policy question, so let me just start with
20 just a brief overview of what he did. And I'll
21 highlight a couple things which he didn't have quite
22 time to get to.

23 It's a model of the U.S. industry where he
24 allows firms to choose this fuel efficiency which is
25 something that's not generally done in some of these

1 models. They usually assume that the product
2 characteristics are held fixed. He used a unique
3 identifying assumption based on the timing of the model
4 and that's what he was getting into in some of the
5 moments that he was presenting.

6 It's a nice way to do it that allows the firms
7 to have some estimate of what the gas price is going to
8 be and then react and choose the fuel efficiency of
9 their fleet.

10 It's really interesting that he includes MPG in
11 there twice, once modeling the cost savings of MPG, and
12 the other one looking at the sort of negative
13 relationship between efficiency and other quality of
14 these other things that we care about. So he has a
15 little more realistic conclusion about how consumers
16 actually do seem to care about the fuel efficiency of
17 their vehicles. Then he finally gets into an estimate
18 of the cost of complying with CAFE standards.

19 So briefly the results, again he had the shadow
20 cost of complying. Consumers do care about fuel
21 efficiency, and there's sort of an interesting result,
22 and I'll come back to this. It's the utility vehicle
23 owners, the guys that drive the big cars that actually
24 cared the most. They have the highest willingness to
25 pay for increases in efficiency.

1 If you looked at the results, you see that the
2 willingness to pay varies a lot for different car
3 owners. Luxury car owners are not willing to pay for
4 these increases all the way up to \$7,000 for SUV owners.
5 And then there are some robustness checks that he goes
6 through, but I'm going to come back to these in my
7 comments here.

8 So the counterfactuals, again he went through
9 these, but the idea I think is kind of interesting.
10 He's looking at, well, we want to raise fuel efficiency
11 of these vehicles, how are we going to do it? Are we
12 going to increase the gas taxes or just tell them you
13 have to have a fleet at a certain level? And again when
14 you look at some of the results, you see the overall
15 efficiency goes up by 31 percent.

16 But if you look at the individual car classes,
17 you see some really interesting results with some cars.
18 Like for cars actually, the MPG falls because the
19 incentive is if the MPG is going to be that high, the
20 equilibrium will put more weight on those other
21 characteristics of MPG, the quality factors, but for
22 CUVs, the MPG goes up quite a bit, so I think looking at
23 some of the segments is really interesting too, to see
24 at what's the reaction for the different types of
25 vehicles.

1 A couple quick comments. Again very nice paper.
2 There's a little data issue with your MPG. It looks
3 like they're only for base models and the higher trim
4 levels of the cars is not reported. So if higher trim
5 cars have lower MPG in general, then this is going to
6 bias some of these estimates, so it might be good to
7 have some evidence as to whether we should worry about
8 this and how important the biased MPG estimates are.

9 Getting back to this idea of the U.S. versus
10 Europe, what would your model say if we applied it to
11 after tax prices of seven or eight dollars per gallon?
12 Would we get the observed 40 miles per gallon
13 efficiency? There's a paper by Molly Espey that sort of
14 talks about sort of the willingness to pay for
15 efficiency in different countries, so that's probably
16 something to kind of take a look at.

17 You actually mentioned this in the paper, but I
18 think one thing you're not allowing is that the car
19 manufacturers can introduce new products, introduce
20 hybrids and things like that. I understand why you
21 didn't do it, but I think this would be definitely a
22 nice extension.

23 Then the last slide is on the sensitivity of
24 utility vehicle owners. I agree with the story; I think
25 you can back it up with some evidence showing that say

1 in the summer of '08, we see not necessarily a reduction
2 in sales of these vehicles, but maybe people switching
3 from less efficient to more efficient SUVs and CUVs.

4 The gasoline press expectations are something
5 which I think what you do is probably right, but you can
6 maybe convince us by saying what would happen if we used
7 forward prices. What if firms were looking at some sort
8 of estimate of what gas prices are going to be over the
9 next year and used that to choose their efficiency?
10 Maybe it's not going to be matter. Most consumers hold
11 their cars for several years, but this might be a way to
12 kind of convince us that your estimate is the right one.

13 Gasoline price volatility is kind of
14 interesting. Do consumers have more of a preference for
15 efficiency when there's more volatility? Not
16 necessarily that it's higher or lower, but maybe there's
17 just more volatility, so maybe the variance of gasoline
18 prices in addition to DPM on the right-hand side of your
19 demand model might be an interesting exception.

20 Finally one kind of more big picture item that I
21 think is relevant is that there's this paper by Hughes,
22 Knittle and Sperling which essentially says that
23 consumers are pretty insensitive to changes in the gas
24 price. They don't change their driving patterns and
25 things very much, but what you're saying is, well, that

1 may be true, but over the longer term, if we see higher
2 gas prices, there is this sort of more macro effect
3 where consumers are actually changing their purchasing
4 decision and the vehicle fleet is changing.

5 So I think that would be a great motivation for
6 your counterfactuals to say, hey, people do care about
7 this and they're reacting to the gasoline price. So
8 that's it. Great. Thanks very much.

9 DR. STERN: That sounds great. You really did
10 save us a few minutes of time. Sofia?

11 DR. VILLAS-BOAS: Sofia Villas-Boas, UC
12 Berkeley. You took the slide away. On the gas price
13 expectations, a former student from Berkeley, Sawhill,
14 actually does this that, the expectation on prices on
15 car automobile purchases. I think he uses the same data
16 set as UC and Zettlemeyer on vehicle choice.

17 I forget what his punch line was, but it was
18 kind of the same idea.

19 DR. GRAMLICH: Well, that paper that you
20 mentioned, that's a paper that actually shows that when
21 the gas prices go up, even on a tight frequency weekly,
22 consumers fuel efficiency responds. One of the results
23 of the paper that Megan and Chris have is consumers
24 actually are very, very responsive to the gas price, so
25 even though you might think you hold the car for seven

1 years, what's the big deal about the current gas price.

2 It actually really does affect people's
3 patterns, even on almost a weekly basis. I don't know
4 if that's what the graduate student found, but that's
5 what Megan Busse's paper essentially found.

6 DR. VILLA-BOAS: Thanks. My other question is
7 if you can say something about welfare because you have
8 the factials on how you do that.

9 DR. GRAMLICH: To the extent that we add a tax,
10 we're always going to decrease welfare, so again just
11 sort of going to the sign, that's the way it would go.
12 But do you mean sort of comparing welfare of CAFE versus
13 a gas tax or something like that?

14 DR. VILLA-BOAS: You said that you cannot make
15 something very efficient without hurting some other
16 characteristics in terms of the front side, so some of
17 these counterfactuals assume that the other stuff stays
18 fixed. But maybe it's not feasible to make this
19 efficiency, and then still have all those other
20 characteristics.

21 So if you can posit, that relationship to allow
22 the substitution that's going to be done to adverse,
23 that would be probably something that you could do.

24 DR. GRAMLICH: Okay.

25 DR. STERN: You can continue answering.

1 DR. GRAMLICH: One thing to be clear, in the
2 counterfactuals, I do actually have the firms slide
3 along the frontier, so it's not that I improve
4 efficiency but don't make them make the sacrifices.
5 They do make the sacrifice, but you're still right that
6 I haven't calculated out the welfare gains or losses to
7 then compare them to presumably the environment
8 externalities we would be trying to correct with the
9 taxes.

10 DR. STERN: Great. Was there maybe even one
11 more? I think we do one more question if there was
12 great desperation.

13 DR. LEWIS: Gregory Lewis, Harvard. I guess my
14 question was about that first stage game. So it seems
15 like in reality, you have a lot of sunk costs on
16 investments and how they do things or how they produce
17 cost. I wonder what you thought the study could gain
18 was an approximation to and how reasonable it was.

19 DR. GRAMLICH: So I think the characteristics
20 setting game is an approximation to the stage where
21 firms have decided they are going to launch a car like
22 the Toyota Camry. That's a decision they make and then
23 it usually lasts for about seven years or so, but within
24 that timeframe, before they do another re-launch say
25 after seven years, you can look at time series of the

1 characteristics of the Toyota Camry.

2 They're not the same every year. It's not that
3 they launch a car and then only change characteristics
4 once there's a whole new car launch, so they have the
5 ability to trim things sort of up or down. If you talk
6 to people in the industry, they say this: They can sort
7 of swap out materials, make things slightly lighter,
8 they can turn off parts of the engine. I think engine
9 trimmings is probably a big thing.

10 Now, the exact timing of the model is not clear.
11 When do they lock in these decisions? Are they exactly
12 a year before? In my model I have to assume it's either
13 exactly one or two or three because I have to take some
14 snapshot of the gas price. It actually doesn't matter
15 much because gas prices are so serially correlated that
16 essentially the results go through largely unchanged, so
17 I don't know if that answered it, but I think I should
18 step down and talk to you more later.

19 DR. STERN: Johannes, come on up. As Johannes
20 continues our discussion of innovation and market
21 structure and innovation, in the global automobile
22 industry, it seems just as a final comment as he's
23 putting it up that these major model changes really are
24 the place where they make the major fuel efficiency
25 choices.

1 And I know it's outside the specifics of your
2 model, but it's always surprised me that no one has ever
3 exploited that, that these companies make these eight
4 year decisions over a three year period, before they
5 even get to market. That's really where the main design
6 choices are being made, and they could follow those out
7 for the IO implications.

8 With that, Johannes on even more cars.

9 DR. VAN BIESEBROECK: Yes. So exactly what you
10 just said. It's a very good place for this paper, and
11 I'm going to continue this. It's even more to the point
12 that I will be doing something very similar to him, but
13 in a very different way and I do it in a different way
14 because my motivation is very different.

15 The crucial thing that I want to look at is this
16 interrelation between market structure innovation. I
17 will explore a dynamic game and I think here I'm going
18 to go away from the miles per gallon choice because for
19 me the car characteristics are crucially chosen
20 strategically and forward looking.

21 So a couple of people have estimated these
22 dynamic games, and most of the time the type of dynamic
23 parameters we want to do are then defined as sunk cost
24 of entry, switching costs. And what we want to do is
25 estimate the cost of doing R&D because that's not our

1 crucially dynamic parameter.

2 So when I present this in an hour and a half, I
3 never get through my slides, so now I have 20 minutes,
4 which is not an advantage. I'll have to skip an
5 enormous amount. I'll flip through some of these
6 slides. The problem is there are a whole bunch of steps
7 in the paper, none of it terribly complicated, but there
8 are a whole bunch of decisions we had to make, and so
9 it's very hard to leave them out, but when I don't have
10 anything interesting to say about them, I'll just fly
11 by.

12 So basically I guess everybody knows what
13 Schumpeter's argument was, that monopolists are not
14 necessarily so bad for innovation because they have they
15 have the RAMS, they have the incentives. But then on
16 the other hand, the incentive is only there if there's
17 going to be competition for the market. And there are
18 two possible effects of market power and innovation, so
19 that's what I want to look at.

20 How do I want to look at this? So there's an
21 enormous array of reduced form studies, so you see I can
22 even list five different surveys, so these are clearly
23 hundreds of papers, and they all have the same
24 structure. You have a measure of innovation. You have
25 a measure of market power. You address one or the

1 other. You try to draw some inferences.

2 So sometimes useful things come out but because
3 neither of these two things are exogenous, it's very
4 hard to draw strong conclusions. So now there are these
5 three other papers already who have similar objectives
6 as me; they basically treat market power also as an
7 endogenous characteristic.

8 So I will continue with the automotive industry.
9 It's extremely innovative and interesting for me.
10 There's been quite a number of important changes in
11 market structure, not only organically but also through
12 mergers, and I will incorporate that in a moment.

13 So as I mentioned, one of the objectives is to
14 estimate one of these dynamic games because we think
15 it's an important application of this. And then the
16 nice thing we can do, theorists do this always, but when
17 you go to empirics, you have to limit yourself, and so
18 we can be a little more flexible because we're going to
19 be very explicit about the incentives for innovation.

20 So if you don't like the structural approach to
21 modeling, you're not going to like our paper, but if
22 you're willing to be convinced, the nice thing that we
23 can do is we can explicitly give the firm a couple of
24 different incentives to do innovation. The first one is
25 you make your power more attractive, so that was the

1 previous paper as well. Better miles per gallon will
2 change your demand.

3 Another reason why you might want to do
4 innovation is because you will change your decision of
5 your competitors today but also in the future. If I
6 innovate a lot, maybe my competitor will be pushed away
7 or pushed down on their response function and they might
8 innovate less. It can go many different ways, but we
9 will model the strategic effects explicitly.

10 Then a third thing which is more unique to our
11 specific application is there have been a lot of mergers
12 in the industry. We allow a firm to do innovation
13 because when they will be taken over, it will be good
14 for their shareholders because they will get a better
15 price for the firm. So I guess this is building on what
16 Scott was saying and then the middle one was building on
17 Christos' papers, so everything together and we will
18 have to make dozens of assumptions you're not going to
19 like.

20 At the end of the day, pay off is what we can
21 quantify as the effect of those three incentives. And
22 then finally we can also look at how to change the
23 market structure because now for us, we have a model of
24 how all these things are connected. We can have some
25 parameter changing or something else changing in the

1 industry exogenously which has some sequencing effects
2 on market function and innovation, and we can see how
3 everything moves together. So that's what we want to
4 do.

5 So how do we do this? You see from the top,
6 I'll have to talk about the demand side; the supply side
7 is merging and equilibrium. The demand side is
8 interesting so I'm not going to say much about it.

9 The one thing which I will say or I actually
10 have this utility for consumer "i" who buys a vehicle,
11 so for us innovation is the crucial characteristic you
12 want to look at. Innovation leads to knowledge, this
13 omega, and knowledge immediately pushes up the utility a
14 consumer gets from your car, so this is just a shorthand
15 way of saying if you have more knowledge, you can
16 introduce novel product features. You can make your car
17 more attractive. You can do all kind of things that
18 make people want your car more.

19 So this is one crucial characteristic of a
20 vehicle. Then you have to charge a price for your
21 vehicle, and then we have these usual -- Xi because for
22 us we have a dynamic model. We have to take a stand on
23 what happens with all those things over time. So what
24 we will say is prices are chosen strategically during
25 the period, can adjust fully in the period, are chosen

1 by maximizing a differentiated product virtual model,
2 conditioning on all the state variables of the model.

3 Omega is basically the stock of knowledge which
4 a firm can influence by doing innovation, and that will
5 be chosen strategically in a forward looking manner.

6 Then we have the ξ , the unobserved quality of the
7 vehicle that the consumers agree about, and that will
8 follow an ARS process with a fixed effect, but it will
9 evolve exogenously so no one can influence it.

10 Consumers and firms observe it, and it might influence
11 the pricing and innovation decisions but they cannot
12 control this area.

13 There's a whole bunch of things going on, and we
14 map that into this type of reduced form utility
15 function. I don't want to go through it twice, having
16 the model and all the estimates, so I will show some
17 estimates as I go through it. So let me say something
18 about how I'm going to estimate this.

19 We think innovation is truly a strategic global
20 variable, so when these firms decide on this, this is a
21 global choice, and it will effect all the vehicles
22 they're making worldwide. So we basically are
23 collapsing all this rich car data to have firm year
24 observation, so one observation is GM worldwide in a
25 certain year, and so in order to do that, we need to get

1 some innovation measures, and we have the patent data
2 that provides it.

3 We need to get a market share, so the number of
4 cars GM sells, and we also need to have a price. So
5 here what we're doing is we estimate a demand pricing
6 model in the U.S. and in Japan. We get firm dummies
7 basically controlling for all the characteristics, how
8 much is a windshield wiper for a car for a certain firm,
9 and I think of a weighted average of this dummies as
10 basically the price. So because this comes from this
11 hedonic regression because we can't control for all the
12 characteristics in this dynamic model, that's going to
13 limit some functional form choice but that would all
14 happen below the surface.

15 There's the data set we're working with. So
16 then we estimate it. We find that this is basically the
17 coefficient of knowledge in the utility function. It's
18 positive for price. It's negative and we use
19 instruments just like in DOP so at least we have this
20 enormous aggregation at first in all of its reduced
21 form, but at least at first glance these results seem
22 reasonable.

23 So on the supply side, this is what happens. We
24 start out with 23 firms. They observe their individual
25 and industry states so the state is the knowledge stock

1 and the quality that succeed for all firms, plus the
2 size of the market. So there are 47 state variables.

3 You can see this is going to be a nightmare to
4 estimate, but that's what we started from, so that's
5 what firms observe. They make pricing and investment
6 decisions within the period. Profits are realized. All
7 the individual states are updated and then there might
8 be some mergers. I will say exactly what we do with it,
9 but the crucial thing is this is not a model of mergers.
10 This is a model of innovation. First make strategic
11 innovation decisions, mergers might happen and they
12 might take into account that these mergers might happen
13 but they happen exogenously, so if they happen, state
14 variables are further updated.

15 So we have the usual profit function. We have
16 the first order on conditions which will give us
17 marginal costs and then we can relay these marginal
18 costs to other variables in the model. So these are
19 still results from a two state estimate, but now we
20 estimate both the demand and the marginal cost in one
21 joint estimation.

22 So basically we can allow the marginal cost to
23 be a function of the knowledge relative to GM because we
24 normalize everything, and then succeed relative to GM.
25 So what we find in log is that your marginal costs are

1 higher where we have higher knowledge, so this could go
2 either way because more knowledge will lead to more
3 features in the vehicles, and this might be expensive to
4 produce.

5 But on the other hand, this knowledge which
6 further is going to be patents, might be process
7 innovation. And they might lower the knowledge. There
8 has to be positives, so these features dominate the
9 cross innovation, and the second one, this one on is
10 clearly positive for succeed.

11 We do it quadratically, at least here it's
12 negative quadratic term coming in, so this coefficient
13 is squared. This might re-interpret then that if you
14 have lots of patents, there are going to be some more
15 processing patents too and they might lower marginal
16 costs.

17 All right. We have demand. We have marginal
18 cost, so basically from those we can calculate profits
19 in every possible state of the world, which we'll need
20 in our summation. Then there is innovation, so this is
21 here and this is our crucial dynamic parameter, this ξ .
22 What does it cost for a firm to apply to obtain an
23 additional patent?

24 So this is a crucial dynamic parameter we want
25 to estimate and of course we do this by maximizing this

1 dynamic optimization problem where the expected value in
2 the future is taken into account with the entire vector
3 state variables for all the different firms.

4 DR. STERN: I'm sorry, how does your investment
5 affect stock of knowledge?

6 DR. VAN BIESEBROECK: Exactly, only through the
7 Omega. The demand is static and this is sort of dynamic
8 choice comes in. So we have laws of motion, which you
9 already mentioned.

10 So this is basically how the Omega is involved
11 then. Basically what happens is for us, you have some
12 target level of innovation and you need investments to
13 get there, but there's some randomness in the R&D
14 process. So this is still a stochastic evolution of
15 your knowledge in the future because you might want to
16 target five or ten or a hundred new patents, but then at
17 the end of the day you might only have 95. So we
18 estimate those things.

19 Then our mergers, so this is just an example
20 with two firms, and it's quite mechanical because the
21 idea is simple, it just leads to incredible estimation
22 problems so let me just show you. So this is the value
23 function of Firm A when there's two firms in the
24 industry, so all of the states entered. This is the
25 profits, cost of investment.

1 There's a probability that they don't merge and
2 that you just have the expected value of the firm in the
3 future, but there's also a probability PM that a merger
4 takes place. When a merger takes place, A and B merge,
5 their states are updated, and then we can do lots of
6 robustness checks how we update their states.

7 This is one possibility, but then only a
8 fraction of the value of these merged firm will accrue
9 to the shareholders of firm A, and that's this. It's
10 basically the standalone value of A and the sum of the
11 two evaluations, so if do you lots of innovation, this
12 is going to be higher and you get a greater share of the
13 merged firm.

14 So this is in there. The problem is this makes
15 a problem not linear in the dynamic parameters any more
16 as in the original Bajari, Benkard and Levin paper. And
17 so instead of estimating this in one or two hours, as we
18 thought we would be able to do, it takes us two days and
19 then another couple weeks to get standard errors, so
20 these keep going, but you don't have to worry about
21 that.

22 So these were innovations. The estimate is just
23 following the, Bajari, Benkard, Levin paper, if you
24 haven't seen it, I will not be able to explain it in
25 five minutes.

1 There are an enormous amount of assumptions.
2 Every time I present, these people come up with other
3 inconsistencies. It's a little bit lower now because we
4 changed the data set a little bit, so now our estimate
5 is about \$30 million to obtain one patent.

6 When we look for firms who report R&D, we get a
7 mean of just under \$60 million for a patent so at least
8 we're ball park, but it's really, especially our choice
9 for marginal cost is very low, so we have some
10 robustness checks, basically varying things in the model
11 to see what's important.

12 So this is very important, for example, this
13 depreciation rate of patents. We have a patent stock,
14 an economic value of the patent stock, and these
15 patents. The economic value depreciates, and so the
16 assumptions we take, 15 percent, which is taken from the
17 literature, 5 or 25 percent, have enormous effect on
18 this estimate to the consumers.

19 That's the first thing we did. The results we
20 got out of it are sensible now. This is raw data on the
21 horizontal axis. We have a number of firms, we start
22 out with 23 firms in 1982.

23 Then all these mergers happen and there are only
24 13 firms at the end. And what we see is there's a lot
25 more patenting activity. This is a scatter plot.

1 What's the difference? This is industry innovation.
2 This is average firm level innovation, when you move to
3 the left, so forward in time. Then if it gets more
4 concentrated, we see more innovation, but of course we
5 know patenting has been strengthened, as was already
6 mentioned before.

7 So if you control for flexible time trends, it
8 really depends. We might get a U-shape, an inverted
9 U-shape like in the papers. So just from the raw data,
10 it's hard to make a clear case what's going on, but now
11 we have a model, and we can do something more.

12 So this was basically at the industry level, at
13 the firm level, these inverted U shapes seem to be
14 coming out more nicely, but the curvature differs a lot
15 when we look for firm difference in '82 or 2004. So
16 this is the raw data, but now with our model we can take
17 our model from a certain starting point and simulate it
18 forward and see what kind of results come out.

19 So in the other one, the only X variable measure
20 of competition of market structure we had was number of
21 firms. Here we can calculate marginal cost to price
22 ratios. My coauthor was a macroeconomist, and I was
23 telling him, oh, we just want to look at the learner
24 index, but he has to read up on it so he insisted on
25 this measure.

1 The one thing that's crucial to interpret this
2 is as the industry gets more competitive and moves
3 forward, I have to think myself, more competitive means
4 lower prices, so we're referred to the right, mergers
5 happen. We move left and we see this inverted U at
6 altitudes. It's coming through very clearly in the data
7 as we run our model forward.

8 The industry level also comes out very nicely,
9 and this is all we do when we start our model in 1982.
10 If we do the same thing but we start it much later, at a
11 much more concentrated state, then this inverted U is
12 maybe a little impaired in the beginning, but basically
13 we're all on this downward sloping trajectory, so this
14 is the opposite from what Schumpeter says.

15 From our model and this industry, if the
16 industry gets more concentrated, innovation seems to be
17 going down. And then we can go back to our model to
18 really say which parameter our model is causing this.
19 If you shed down some of these values, how does this
20 change or how doesn't it change?

21 So now the one thing we were doing now is we're
22 solving this model exactly because once we solve the
23 model, then we can really change some exogenous
24 parameter and see whether the equilibrium innovation
25 that our model would predict it, but with 46 state

1 variables, that's impossible, so right now we're able to
2 solve it for four firms allowing for one or two mergers,
3 but those results I'm still waiting for myself.

4 So then I want to take out what simulate; we
5 estimate this model and most of the things we get out of
6 this after our enormous amount of assumptions do seem to
7 make sense. And then we can confirm this result from
8 the QG from a couple of years ago that there is this
9 inverted U relationship. Only we are much better able
10 to figure out which part of the model is driving this
11 result and we also find if you start from an initial
12 stage, which is quite concentrated, this inverted
13 U-shape is not there anymore.

14 All right.

15 DR. STERN: Great. And your discussant is Adam
16 Copeland.

17 DR. COPELAND: Let me just say, first of all, I
18 really enjoyed reading the paper. I got a little
19 different version than the one presented here since one
20 of my graphs is a little bit older. And also let me say
21 that these are my own views, not those of the Federal
22 Reserve Bank in New York or the Federal Reserve System.

23 So like I said, I like this paper a lot. I
24 think it has a lot of potential. There's still a bunch
25 of work that needs to be done. It's actually a really

1 old question of economics and a really important one
2 that looks at how the changes in market structure affect
3 innovative activity.

4 You're looking at the global automotive market,
5 and Johannes sort of mentioned this, but in the
6 theoretical camp, there are sort of two schools of
7 thought generally speaking. One is the Schumpeter
8 thing. It says that if you have more and more
9 competition, you'll have less incentives to innovate.

10 The idea is you put these huge fixed costs in to
11 come up with an innovation and the marketplace is really
12 competitive, you can't extract enough to payoff the
13 fixed costs. But there's another school of which has a
14 complete reverse because as markets get more
15 competitive, there are more incentives.

16 The idea there is in competitive markets, you
17 want to differentiate yourself, and that leads you to
18 innovate, and that leads you to innovate so you can
19 differentiate yourself and charge at a higher price.

20 So really it becomes sort of an empirical
21 question about what the relationship is between
22 innovation and market structure. Like Johannes sort of
23 mentioned and has done a bunch of work, but it is
24 unusual, the fact that when firms are making the
25 decision whether or not to innovate they're forward

1 looking, and they're taking into account and they have
2 expectations about how the market structure will evolve.

3 So very importantly here, their innovation
4 decision doesn't affect how the market structure
5 evolves. They're just taking that into account, so if I
6 invest a lot of innovation now, I don't say that's going
7 to make the market structure more competitive or less
8 competitive, I'm just looking forward and saying, okay,
9 there might be some merger downs the road, how does that
10 affect how I innovate or not.

11 Now, the main result is really interesting
12 because when I sort of loosely characterized the
13 theoretical literature, everything was monotone,
14 individuals are either increasing competition or
15 decreasing competition.

16 Where it gets I think a little more complicated
17 is that we have this relationship which is the inverted
18 U-shape relationship, so this is a graph from the older
19 paper, but it has the same sort of humped shaped look
20 that he ended with.

21 So the horizontal axis accounts for price, so
22 .84 means that marginal cost is 84 percent of price. As
23 you go towards the right, you get more competitive, and
24 on the vertical axis, you have how much innovation
25 you're doing. So you can see as you go from left to

1 right, you have this sort of monotone relationship,
2 which is sort of outlined, which is very cool.

3 One thing I think would be sort of neat, just to
4 give you some better intuition about the models, is if
5 you fixed your level of competition at .84 and then just
6 showed how much innovation you would do given different
7 expectations of what the future will be. So if you
8 think it's going to be very competitive in the future,
9 you can innovate more or less conditional on the current
10 level being .84, or just some graph like that might be
11 useful just to flesh out how these forces are working.

12 Then I have some comments. In the interest of
13 time, I'm going to skip the first one and just talk
14 about the merger process, and this is going to be sort
15 of a smaller point. I have a bigger point to make.

16 The smaller point right now is that mergers are
17 completely exogenous and random. So you decide, this
18 will fall from the sky, and I understand why they're
19 doing this, and I thought, well, one way to improve it
20 right now is to say, well, when two firms merge, you
21 have two product lines like Chrysler and Mercedes Benz.
22 They merge, and it becomes one product, with a number of
23 products.

24 And I think as a consequence of that is the
25 profits of the firm before the merger added together are

1 higher than the profits from the firm after it merges,
2 so I guess it's a destruction value added, which is sort
3 of troubling because it means why did they merge in the
4 first place.

5 I thought one way around that might be, one, you
6 keep the number of products the same, so when Daimler
7 and Chrysler merge, they still sell two products, but
8 maybe they have the stock of knowledge that gets a fixed
9 function or some function. So both their products are
10 improved, but you don't reduce the variety, and that
11 actually might make mergers sort of profitable, and
12 maybe it would be more powerful than what we currently
13 have.

14 If it's true that mergers are more profitable,
15 you can actually rate mergers. Right now mergers I
16 think are just completely a uniform of probability, so I
17 think GM and Ford merging had the same probability as GM
18 merging with BMW, which probably isn't true, but if you
19 could say different mergers have different levels of
20 probability. You could assign higher levels of
21 probability to them and that also might be kind of neat.

22 So skip that. Let me end with sort of a big
23 picture point. When I was reading this paper, I kept
24 asking myself this question about, what's going on in
25 the industry as a whole, and as you saw, the picture got

1 very concentrated over time.

2 So I thought it might be nice to have sort of a
3 big picture, and this might be a separate paper. It
4 might be something you draw in a deduction. I don't
5 really know, but I really thought that Sun's argument
6 about endogenous fixed costs was really related to
7 what's going on in the current industry on the global
8 scale.

9 The idea there is that in the Sun models, you
10 have four firms in a market, and they actually control
11 the fixed cost to entry, which would be advertising or
12 R&D. And this demand on that market grows larger and
13 larger and larger.

14 The way these four firms block other firms from
15 entering is that they say, we're going to spend more on
16 R&D and more on advertising to raise the fixed cost, and
17 that deters entry, and I thought this might be the story
18 with automobiles as well.

19 In the beginning of our sample, maybe the market
20 wasn't so global. Rather it was sort of fragmented
21 because of trade barriers or income. Certain parts of
22 the world are just too poor to buy GM cars or whatnot.

23 Then over time, these segmentations disappeared
24 and you can have a truly global market. In reaction,
25 what the firms have done is said, well, what I'm going

1 to do is sort of raise the fixed costs by investing
2 quality in such, and that's going to drive other firms
3 out of business.

4 So that will give you sort of a nice general
5 framework of thinking about how the industry is going.
6 What I really liked about this, and this will probably
7 be a second paper, is now you have innovation market
8 structure being decided at the same time, so when you
9 make your innovation decision, you're actually raising
10 the endogenous fixed cost to entry, and you're affecting
11 market structure in the future. I think that would be a
12 very cool model to sort of estimate something else.

13 So I really like this framework. It's a simple,
14 dynamic story, and it's consistent with what had
15 happened to other industries. He has a whole book that
16 goes into the sugar market, stuff like that, so I
17 thought that would be a sort of tie in point.

18 Okay. Thanks a lot.

19 DR. STERN: Very, very good. Okay. I
20 think that any questions we have are between us and
21 lunch, but ideas are food as well, so do we have one or
22 two questions to sort of finish us off? Over there.

23 DR. BONER: I notice your model has a machinery
24 for looking at welfare. My name is Roger Boner. I'm at
25 the FTC. I know your model has the machinery for

1 examining welfare as it varies with market structure.

2 Did you happen to look at that?

3 DR. VAN BIESEBROECK: So we didn't initially.
4 Some of the slides I skipped had some consumer effects
5 too, but there are two problems there. One is that we
6 don't have an outside good and industry choice matters
7 greatly for welfare, so that's one thing that we don't
8 really trust our results for.

9 The second thing is that the way modeled mergers
10 really matters, so as Adam pointed out, the way we
11 modeled mergers, leads to products that disappear, so
12 choice for consumers goes down, and this has a negative
13 impact on welfare.

14 So for us there are two things: There's this
15 consumer choice, which goes out, but then innovation
16 might go up or down, and it has opposing effects in many
17 situations. So the short answer is we can do it, but we
18 don't trust our model sufficiently yet that I want to
19 show you those results.

20 DR. STERN: I think we should give our
21 presenters and discussants both a hand. Everyone did an
22 excellent job at presenting, stayed within the time
23 well. We started late. That was exogenous, but we
24 ended equally late, so there you go. And really I
25 wanted to thank everyone for excellent papers and

1 discussions.

2 (Applause.)

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 DR. PAPPALARDO: Well, I hope lunch is good
2 because then you will be a happy audience.

3 I'm very pleased to be here today. I was very
4 honored that my colleagues asked me to speak to you a
5 little bit about what we know about consumer protection
6 regulation, and as with all of these things, it's not
7 really until the day before that I really try to focus
8 on what the main message is for the presentation.

9 As I thought about it when I was driving to work
10 yesterday, I think the message I want to leave with you
11 is that we have to move beyond the economics of
12 information, which provides the backbone to most of our
13 analysis of consumer protection, to the economics of
14 consumer comprehension, understanding that just throwing
15 information out there may not mean much if consumers
16 don't understand the information in the way it is
17 intended.

18 The views expressed today are those of the
19 presenter. They are not necessarily shared by the
20 Federal Trade Commission or any individual Commissioner.
21 So I think a big silver lining in the financial crisis
22 is that you read more and more about consumer protection
23 in the newspapers and on television everyday. I think
24 for those of us who have been working in consumer
25 protection for decades, this provides a golden

1 opportunity, an opportunity to get more minds working on
2 consumer protection issues and trying to make sure that
3 we get consumer protection policy right.

4 But with it also comes a responsibility because
5 big change in most regulatory areas, and consumer
6 protection is no exception, comes along once in a
7 generation. So I think it's really important to rather
8 than rush ahead to do things, because doing something
9 seems better than doing nothing, to make sure that what
10 is done is really well thought out and likely to really
11 do more good than evil.

12 What can I contribute to the debate? Well, I've
13 been here, as Paul said, for over two decades. I can't
14 believe it's been over two decades. It seems like just
15 yesterday I was pouring through job openings for
16 economists in graduate school, and I remember clearly
17 staring at the ad for the Federal Trade Commission
18 thinking that it was my first choice job, despite the
19 fact that I really love teaching. And it was a really
20 hard choice to make, I'm really glad that I came to the
21 Federal Trade Commission.

22 I came from the back end of being primarily
23 interested in consumer policy first and economics
24 second. I think most people who work here come from an
25 interest in economics first and then come to consumer

1 policy. I did my graduate program at Cornell University
2 where there used to be a program called The Department
3 of Consumer Economics in Housing.

4 That program no longer exists because people
5 couldn't figure out what it meant to be the Department
6 of Consumer Economics in Housing, and so now it's the
7 Department of Policy Analysis and Management. In
8 graduate school I came to love economics when I was
9 doing my master's thesis. I was doing a study of
10 regulation of home insulation, of all things.

11 And I started out with a minor in public policy
12 working with a wonderful political scientist, but it
13 wasn't until I studied industrial organization that I
14 could see how I could model the problem in my industry
15 in a way that really made sense, pairing away the
16 unimportant facts and getting to the meat of the matter.

17 So I'm a real believer in the helpfulness of
18 microeconomics to try to understand consumer policy
19 problems.

20 Then again my experience may not be very
21 helpful. I stole this lovely cartoon from one of my
22 colleague's doors. "They pretend to know? Yes. Yet
23 they don't know? Correct. And they get paid for this?
24 Paid well, too. Man, I want to be an economist."

25 Where to begin? It's hard to know after 20

1 years here. There's 20 million things I would like to
2 say, but you can only say a few. One thing I would like
3 to say is that the consumer protection group at the FTC
4 is probably the best group of people that study consumer
5 protection anywhere in the world. I've been so pleased
6 to learn by having so many wonderful mentors over the
7 years, people like Jerry Butters, who was my boss for 20
8 years, who understood information in markets better than
9 anybody I know, and is also the kindest person I know;
10 people like Pauline Ippolito, who has really done a lot
11 of pioneering work in the role of information in many
12 markets, particularly regarding health claims in foods.

13 The list could go on. My colleagues are experts
14 in all kinds of information and regulation areas, and
15 even as you look at the papers today, I notice there's a
16 paper on direct to consumer advertising. Well, people
17 probably don't realize that the very first article I
18 believe applying economic analysis of information to
19 direct to consumer advertising for prescription drugs
20 was written by Alison Masson and Paul Rubin, both of
21 whom worked on that while in the Division of Consumer
22 Protection. Alison went on to Pfizer Pharmaceuticals,
23 and actually Pfizer funded much of the research done by
24 Ernie Burton and others to understand DTC advertising,
25 so I can only scratch the surface today of what's been

1 done in this area.

2 I have to pick a few points. "A point in every
3 direction is no point at all," as Harry Nilsson tells us
4 and now we say you can focus on no more than three
5 points in a presentation, so here are the three points.

6 I won't get to the end most likely, so I want to
7 make them clearly now. First, consumer protection
8 policy is often tricky because people are unique.
9 Second, consumer protection policy is unlikely to be
10 effective without a joint mandate to promote
11 competition.

12 Many years ago the American Bar Association did
13 a review of the Federal Trade Commission and examined
14 among other things, the role of economics in consumer
15 protection at the FTC. It included a compendium of
16 articles on the topic written by a lawyer, who basically
17 said that the consumer protection group at the FTC
18 compared favorably to those anywhere and it was largely
19 because consumer protection, as is studied at the FTC,
20 includes an understanding and concern about competition.

21 What often happens with consumer protection is
22 people focus on one side of the market; they focus on
23 consumer behavior. They focus on demand, which is
24 great, but that's only half the story. If you're not
25 also looking at the other side of the market, trying to

1 understand how policies are going to affect firm
2 incentives, you're unlikely to ever end up with
3 solutions that aren't going to do more good than evil.

4 And finally, the third point I would like to
5 make is that information remedies are generally
6 preferred to product restrictions if, and only if,
7 information policies focus on consumer comprehension.

8 The key point of economics in consumer
9 protection is that competition in the free market will
10 usually bring the greatest benefits to consumers.
11 Economics helps identify those areas where intervention
12 may be useful.

13 I love this article that was written by John
14 Vickers. It always seems that when someone has an
15 English accent, even in writing, it always just sounds
16 much more -- it just carries more weight to it. I found
17 this article, and I thought, this is great, here's a guy
18 across the pond who thinks the way I do, that
19 competition and consumer law should be seen as one
20 subject, not two.

21 Competition is pro consumer for the simple
22 reason that rivalry among suppliers to serve customers
23 well is good for customers. In such rivalry, the
24 suppliers who serve customers best will prosper, and
25 those that serve them poorly will not.

1 Competition between sellers is great because it
2 lowers price. Competition on quality improves products.
3 Competition means consumers can go elsewhere if they are
4 not happy with a particular seller and imposes
5 discipline on sellers' behavior. An important consumer
6 protection mission is for government to ensure a
7 competitive marketplace.

8 The power of competition to benefit consumers
9 depends on honest information. Competition can lead to
10 more honest information if competitors have incentives
11 to point out other's lies. Government policies should
12 encourage provision of honest information.

13 Competition is great, but it is not perfect.
14 Asymmetric information can lead to market failures.
15 Sellers with good products may not be able to convince
16 buyers of the good quality. Sellers may try to convince
17 buyers that products are better than they really are.
18 We have fraud, outright lies about worthless products,
19 and we have more fraud cases than you can possibly
20 imagine. We see them everyday, and deceptive claims,
21 not quite a fraud, not quite a lie but stretching the
22 truth about a legitimate product. Government no doubt
23 has a role in stopping fraud and deceptive claims.

24 Now, when you work in consumer protection, what
25 are some of the things that you consider when someone

1 asks you to review an action to see whether or not it's
2 unfair or deceptive under FTC law? The first question
3 is: Exactly what is the problem?

4 Oftentimes policymakers have a solution, and
5 when you ask, what's the problem, they're not clear in
6 their own minds. Well, it's hard to have the right
7 solution unless you understand first what the problem
8 is. Two questions that we often have to ask are: Is it
9 an efficiency problem? Or is it an equity issue?

10 And as economists we have different roles to
11 bring to both of these types of questions. Will the
12 problem persist if government doesn't take action? Is
13 there a governmental failure that's contributing to the
14 problem? Gosh, I hate to say how often that's the case,
15 but often it is the case.

16 We try to estimate how much consumer injury
17 there is from a practice. The final question is: Is
18 there a viable remedy? And for economists, that
19 basically means do you have a remedy that you're pretty
20 sure is going to pass a cost benefit test? Often the
21 devil is in the details because often when you try to
22 sit down and think about possible remedies it's not
23 clear what remedy would be best for consumers.

24 So what sort of consumer protection policy
25 remedies exist? Well, I didn't bring up the obvious one

1 which is to do nothing. The famous political scientist,
2 Thomas Dye, says that public policy is the study of
3 everything that you do as well as what you don't do.
4 Doing nothing is a remedy of no action.

5 Another remedy is to inform consumers, give
6 consumers information with which to make better purchase
7 decisions with the idea that the market will work better
8 as a result. One can also educate consumers. In my
9 Lexicon, education goes one step beyond information.
10 Providing information is giving people the facts.
11 Educating consumers is telling them how to use the
12 facts. Often involved in education is some aspect of a
13 judgment call about what the relatively important facts
14 are or how people might want to make decisions.

15 The newest policy remedy is to nudge consumers.
16 For example, one nudge idea is to change opt-in opt-out
17 rules. This hopefully leads people to better outcomes.
18 The final consumer policy remedy, which I would say is
19 the most restrictive, is to restrict product
20 characteristics. You can just say certain types of
21 products are no good for consumers. And they should be
22 banned from the marketplace.

23 In approaching questions about what types of
24 problems should be remedied with interventions and what
25 interventions would be best, we tend to look at several

1 literatures, and in the consumer protection group, we
2 hang our hat on traditional microeconomics. I often
3 hang my hat on household production. I think in terms
4 of models as like Gronau or Becker where individuals or
5 households have a utility function that would include
6 things like health.

7 And then there is a production function that the
8 household has where people can combine different inputs,
9 their time and other inputs such as doctors or medicine
10 to produce helpful outcomes. The economics of
11 information literature is also important. People are
12 maximizing utility subject to budget constraints.
13 Understanding when it makes sense for people to get more
14 information is important for knowing how different
15 remedies will affect the marketplace.

16 We spend a lot of time looking at the marketing
17 research literature. One of my colleagues, Jim Lacko,
18 is always great at finding articles that I've never seen
19 before. He recently showed an article to me that I had
20 never seen before written by Louis Wilde. It was
21 written in 1980, by Wilde of Wilde and Schwartz. It's
22 called the "Economics of Consumer Information
23 Acquisition," and it was published in the Journal of
24 Business in 1980.

25 And in here what he basically says is that

1 traditional economists have a lot to learn from consumer
2 researchers, that the two need to work together to
3 really put some meat on the economic models, and to put
4 some empirical structures on the consumer behavior
5 models. And I feel like not having read this article, I
6 think he would be very pleased to know that this is
7 really what we've been doing in the Division of Consumer
8 Protection over the past 20 and 30 years.

9 Behavioral economics of course I think is
10 important. I think it's very similar to a lot of the
11 traditional social psychology literature which has been
12 included in marketing research, and of course the law
13 and economics literature is very important too.

14 How do you evaluate consumer issues? The FTC
15 prohibits unfair or deceptive acts or practices. What's
16 unfair? What's deceptive? How do you hang some
17 theoretical structure on these terms to have rational
18 regulation?

19 Well, some cases are easy. Outright fraud
20 provides no benefit to society, so resources permitting,
21 action is warranted. There's no concern about over
22 deterrence, but those aren't the interesting cases.
23 Some cases are hard and they require substantial
24 analysis using all available data and the collection of
25 new data.

1 For example, consider advertising substantiation
2 cases where there is scientific support for a
3 relationship between a product and health, but the
4 support is not complete. Without proper substantiation,
5 you can run afoul of government labeling rules with
6 health claims. However, what you can say on a label
7 about health and what metric you focus on will have an
8 effect on how firms compete, what consumers choose, and
9 what's available to them in the marketplace.

10 Differences among people complicates the
11 analysis. Models of constrained utility maximization
12 recognize that people are different. They have
13 differences in tastes. They have differences in their
14 income or wealth constraints. They have different
15 reactions to time constraints.

16 The great thing about economics I think is that
17 it does understand that people are unique, and it's
18 difficult to say because Joe did this and Jim did that,
19 that somehow one was not solving a constrained utility
20 problem.

21 I love this cartoon from the New Yorker. "I
22 want to read something targeted directly at me." People
23 are unique and people want goods and services that fill
24 their unique circumstances, and so there are benefits to
25 having a marketplace to provide many niches for many

1 people.

2 Now, I was going to focus today almost entirely
3 on financial markets, but I wanted to go back to this
4 point about advertising, and that regulation for
5 advertising and health claims for advertising can be
6 very complicated, and regulators can make mistakes.

7 When I first came to the FTC, I was asked to
8 work on a project with Jack Calfee to look at how to
9 regulate health claims in advertising, and in doing that
10 work, I spent a lot of time reading through old
11 scientific literature and learning about relationships
12 between dietary fat, dietary cholesterol, serum
13 cholesterol and heart disease.

14 And what I was surprised to learn was that
15 scientists knew by the late 1950s that cooking oils that
16 are low in saturated fat and high in polyunsaturated fat
17 would reduce someone's serum cholesterol when
18 substituted calorie for calorie. So Ancel Keys was one
19 of the leaders in the area. His research became the
20 foundation for the 1989 Diet and Health Report that was
21 put out I think by the National Academies.

22 What was surprising to me was that I thought in
23 the '80s that the understanding about the relationship
24 between different types of fats and dietary cholesterol
25 and serum cholesterol and heart disease was something

1 new, but it wasn't. Well, why didn't we know that?

2 So I ended up working with a wonderful
3 colleague, Debra Ringold, who is a specialist in
4 marketing research, and we tried to understand more
5 about the role of advertising in the provision of
6 scientific information about goods in the marketplace.
7 Marketing people draw these boxes, so we drew boxes.
8 You have a discovery. It goes to a professional
9 journal. It goes to the popular press.

10 It eventually gets to consumers if they
11 happen to read the popular press, but none of this sort
12 of information is advertising. People can get
13 information from advertising about the
14 relatively healthful attributes of food products.
15 Regulators can assess what happens in advertising and in
16 labeling.

17 They can say, yes, this claim is okay in
18 advertising or, no, it's not, so we did a content
19 analysis. We looked at advertising for fats and oils
20 from 1950 through the 1980s, and what we saw was very
21 fascinating. As soon as there started to be strong
22 scientific support for the relationship between dietary
23 cholesterol, saturated fat, polyunsaturated fat, serum
24 cholesterol and heart disease, that information appeared
25 in high press articles such as in Readers Digest and

1 similar places, and manufacturers started to put that
2 information in advertising for corn oils.

3 Corn oils, I will have you know because I did a
4 lot of this research, actually have the best profile of
5 any oil that was studied by Keys. It went beyond the
6 typical saturated fat, polyunsaturated fat piece of
7 their regression analysis because there's something in
8 the unsupportable fraction of corn oil that made it
9 particularly good for your serum cholesterol.

10 So people, firms like Mazola, started bringing
11 this information to consumers. We're looking here at a
12 measure of the content of the advertising. We looked at
13 ads with any heart disease claim, so information about
14 heart disease in an advertisement.

15 We looked at two types of advertising. We
16 looked at advertising to professionals, for example, in
17 the Journal of the American Medical Association or the
18 Journal of the American Dietetic Association, and
19 advertising to consumers in popular magazines.

20 So what did we find? We found that as soon as
21 there started being strong evidence, in the period 1955
22 to 1959, the manufacturers tried to bring the
23 information to the consumers in their advertising.
24 Regulators, however, thought that the information was
25 premature. FDA policy made sure that this information

1 was no longer available to consumers.

2 What's interesting is if the information was so
3 bad and didn't have much scientific support, then why
4 would you have that same information going to the
5 professionals? So the fact that it went to the
6 professionals, the dieticians and the doctors who are in
7 the best position to know whether or not the scientific
8 support had merit, but didn't go to consumer suggests
9 that consumers didn't get important information for
10 decades.

11 You see similar patterns, but not quite as clear
12 with dietary cholesterol claims and not quite as clear
13 as with saturated fat claims. What happened was doctors
14 were telling their heart patients to look for products
15 that were low in saturated fat, but you had to have
16 that information from your doctor or another source to
17 know why saturated fat mattered for heart disease.

18 So the point is this: Regulating information is
19 very difficult. Recalling the differences between type
20 one and type two regulatory errors, harming people from
21 allowing information that turns out to be false versus
22 harming people from prohibiting information that turns
23 out to be true, is a balancing act that must be done.
24 It's very difficult to do, but if we're going to have
25 rational consumer protection information policy,

1 appreciation for both type one and type two regulatory
2 error is important.

3 Let me talk about financial products. This is
4 the hot thing in the news and what I've been working on
5 lately. It is particularly difficult to judge consumer
6 choices for financial products. Where is a customer in
7 their life circle, their earning cycle? Where you are
8 in the life cycle is going to determine how much you're
9 willing to spend versus save.

10 When you're looking at housing decisions, how
11 much is a person willing to sacrifice to buy a house in
12 a good school district? Education is tied to housing
13 through school districts, so this is an important
14 consideration for many people. What are expectations
15 about future income? There are so many unobservable
16 factors that affect choice that makes it very difficult
17 to say what's best for someone.

18 The FTC put a conference together back in 2008
19 trying to understand more about the role of consumer
20 information in the mortgage market. We had several
21 sessions where we brought together people. Susan
22 Wachter was there from Penn, Anthony Pennington - Cross,
23 Chris Mayer from Columbia to look at the economic
24 analysis of mortgage product development, market
25 structure and mortgage outcomes. The question in the

1 first session was: How has this market developed? What
2 kinds of products have developed to meet what kinds of
3 needs and why?

4 The second session was economic analysis of
5 consumer information and mortgage choice, trying to
6 understand more about the role of consumer information
7 and the understanding of that information and consumer
8 choices.

9 The third session was a general roundtable on
10 information in the mortgage market crisis. The final
11 session was developing disclosures for real consumers to
12 help prevent deception, delinquency and foreclosures,
13 and where policymakers should go from here.

14 So I want to go back to this discussion earlier
15 about policy remedies, what remedies are available.
16 Research is showing that non prime products are not
17 necessarily inherently flawed. And I think suggesting
18 that product restrictions, regulations that basically
19 say certain types of products cannot, will not exist
20 anymore for consumers with less than prime credit can
21 easily do more harm than good.

22 During the conference, Chris Mayer talked about
23 the rise in mortgage defaults, facts and myths, had many
24 sources and take-aways that he was willing to share with
25 us. His research at the time, this is 2008, showed that

1 defaults appeared to be unrelated to mortgage market
2 innovations, including prepayment penalties, rate resets
3 on short-term ARMs, interest only or option ARMs.

4 The evidence was that unprecedented rise in
5 defaults and foreclosures was primarily due to
6 stagnation in housing prices, perhaps driven by the sub
7 prime collapse and slackened underwriting and poor
8 economic conditions in some locations.

9 His suggestion of where to go at that point in
10 time, again this is 2008, was to encourage the private
11 sector to responsibly replace a trillion in lost
12 mortgage originations. Consumer protection regulation
13 should be carefully constructed to ensure credit is
14 available to risky borrowers who can afford it. Legal
15 changes that would allow cram downs or require
16 negotiations would surely reduce the new supply of
17 credit, possibly extending house price declines.

18 We also had work by Paul Willen exploring
19 whether market participants could have or should have
20 anticipated large increases in foreclosures. We
21 basically concluded that analysts on the whole
22 understood that a fall in prices would have disastrous
23 consequences for the market but assigned a low
24 probability to the event. The subprime market opened up
25 home ownership opportunities, and again he gave us data

1 from his research showing that foreclosure rates
2 basically tracked changes in housing prices.

3 During the conference, I had the opportunity to
4 ask all the panelists, and it was an esteemed group of
5 panelists, the following question: Assume that you are
6 a philosopher king or queen with the power to change one
7 consumer policy to improve the mortgage market; what, if
8 anything, would you change? And on a scale of zero to
9 100, with zero being not at all certain, and a hundred
10 being absolutely certain, how certain are you that
11 benefits of this change would outweigh the costs?

12 One panelist out of the 17 who responded
13 suggested a nudge strategy, a 30 year fixed rate, no
14 fees default mortgage that you would have to opt-out of.
15 Almost everybody suggested an information remedy. One
16 remedy was a federal rule preempting state law that no
17 disclosure could be promulgated without scientific
18 support that consumers make better decisions with the
19 information than without it. Simplify, simplify,
20 simplify as much as possible. People need
21 simplification and mild guidance.

22 Other reforms include improved consumer
23 financial education, improved property and foreclosure
24 records, and developing a recommendation tool to sort
25 alternatives in an order correlated with that consumer's

1 personal utility function. This allows consideration of
2 fitting options and makes costly consideration of not
3 fit.

4 John Lynch of Duke University is working with
5 Susan Woodward on this now, trying to come up with
6 decision tools that would be more useful for consumers.
7 So again, coming back to the point of information
8 remedies, oftentimes it's going to be the best for
9 consumers, assuming that we come up with information
10 remedies that actually work.

11 To go back to this favorite article by John
12 Vickers, because he sounds so eloquent, while no one
13 could doubt the wisdom of banishing quacks practicing as
14 doctors or fraudulent advertising, there eventually
15 comes a point beyond which constraining freedom of
16 contract further brings costs that outweigh benefits.
17 These costs, which consumers ultimately bear and which
18 may be hidden from view, can stem from less choice and
19 competition as well as the cost of regulation itself.

20 Indeed, the best solutions often involve better
21 consumer information rather than less consumer and
22 producer choice. But improving consumer information is
23 often easier said than done, especially information that
24 is of immediate and direct, practical use, for as
25 consumers, we are all boundedly rational, and rationally

1 so.

2 Now I would like to talk a little about research
3 that we did trying to understand the perils and promises
4 of information remedies in the mortgage market. This is
5 work I did with my colleague Jim Lacko. The motivation
6 for the research was that there has been a long history
7 of mortgage disclosure requirements in the United
8 States.

9 The Truth in Lending Act goes back to '68 and is
10 often held up as a great example of consumer protection
11 regulation. The Real Estate Settlement Procedures Act
12 goes back to 1974. Yet there is still concern about the
13 effectiveness of the disclosures required by these laws.
14 We at the FTC see deceptive lending cases all the time,
15 deceptive lending cases in instances where consumers
16 received every required federally mandated disclosure,
17 and that leads one to ask the question: How can people
18 be deceived if they're receiving these disclosures? Is
19 it possible that the disclosures are flawed?

20 Despite concerns about disclosures, it's hard to
21 believe, I know, but when we started looking at the
22 mortgage market -- maybe '94 -- there was no
23 quantitative research on consumer interpretation of
24 mortgage disclosures. Let me say that again. People
25 are buying houses. The federal government is requiring

1 disclosures. It's against the law to not fill out the
2 disclosures.

3 Yet there was no consumer research on how
4 consumers understood or misunderstood the federally
5 required mortgage disclosures. The objective for this
6 study was to see how consumers search for mortgages, how
7 well consumers understand disclosures and whether it's
8 possible to develop better disclosures. It was a two
9 part study. It consisted of a series of qualitative
10 interviews with consumers who were recent mortgage
11 buyers.

12 Let me tell you a story there. It's not so easy
13 to find a sample of recent mortgage buyers. We had
14 contracted with a firm that was going to do this for us,
15 but it turned out that we wanted people who had closed
16 on a mortgage within two, three, four months at most.
17 We couldn't find that data set. We found the data by
18 going to the courthouse in Montgomery County, Maryland,
19 myself and various RAs, and sifting through mortgage
20 records to try to put together a list of recent mortgage
21 customers that could then be sent to the contractor.

22 General observations: In the qualitative
23 research, most respondents began the interview happy
24 with their mortgage experience. These were not a sample
25 of complainers, but they're attitudes deteriorated

1 during the interview as they recalled problems, and they
2 got very nervous as they started looking more and more
3 at the disclosures because they started to realize, I
4 don't know what I bought. Even people who were
5 attorneys didn't know what they had bought.

6 Many were unaware that they had a lack of escrow
7 for taxes and insurance or large balloon payments or
8 adjustable rates or prepayment penalties.
9 Misunderstandings were present among prime and sub prime
10 respondents, both those who had done extensive
11 comparison shopping like you think a good consumer
12 should do, and those who had not done any.

13 Many respondents could not understand their own
14 loan terms. They were confused by fees. Few understood
15 the APR. Many people believed it was the interest rate.
16 I think one person thought it was the highest rate that
17 could be charged. The current disclosures were a
18 problem and things that are required by law proved to be
19 big problems.

20 The amount financed is one of those big boxes in
21 the trial form; that's like a center piece of consumer
22 regulation. Many consumers believed that the amount
23 financed was a loan amount, rather than the loan amount
24 minus any settlement costs you are financing, the
25 pre-paid finance charges. So what does that mean? It's

1 a place to hide deception.

2 If you thought you borrowed a hundred thousand
3 dollars and didn't realize that \$2,000 are going to pay
4 for upfront fees, so really you're borrowing a \$102,000,
5 you look at the Truth in Lending statement, it would say
6 amount financed a hundred thousand dollars. That form
7 would never give you a clue that you were rolling the
8 payment of upfront fees into loan principal. Discount
9 fees, people thought that those were a discount fee that
10 they received rather than the fee to be paid. Well,
11 discount fee, what is that? It's very confusing.

12 We then showed people our disclosure form and in
13 qualitative research, they liked it. Then we did
14 quantitative tests in an experimental setting in 12
15 locations across the country, with 819 recent mortgage
16 customers, half prime, half sub prime.

17 We tested in head-to-head competition the
18 current forms, the title form and the good faith
19 estimate, against a prototype disclosure form developed
20 by FTC staff, primarily my colleague Jim Lacko who's
21 great at putting these forms together, to try to
22 understand whether it's possible to improve consumer
23 recognition of the costs and features of a mortgage
24 loan.

25 We used fixed rate disclosures. The prototype

1 format was a one-page summary of key loan costs and
2 features and two pages of further detail. This is what
3 the prototype looked like.

4 In the testing procedure, respondents were given
5 disclosure forms for two hypothetical loans. Half were
6 given current forms, half were given the prototype
7 forms. They were instructed to examine the forms as
8 they would if they were shopping for a mortgage. They
9 were asked a series of questions about a dozen different
10 loan terms and able to continue examining the forms
11 throughout the questioning, so they either had the old
12 forms or the prototype forms.

13 We tested different loan scenarios. Here's the
14 bottom line: Percentage of questions answered
15 correctly. When you asked objective questions of
16 consumers under these two different information
17 scenarios. In both loans, a simple loan and complex
18 loan, under the current Truth in Lending Act and
19 disclosures used during the time of the studies, 61
20 percent of these questions were answered correctly; for
21 the prototype, 80 percent were answered correctly.

22 That's an increase of 19 percentage points.
23 That's huge and that's based on one prototype written by
24 two economists with some input from various colleagues
25 at the FTC. Think how much better you could do if you

1 put even more research behind it.

2 I know that we're out running out of time so I
3 sort of need to get to the end here. Our bottom line
4 finding was that it's possible to create new disclosures
5 that significantly improves consumer recognitions of the
6 costs in terms of a mortgage, and improved disclosures
7 could provide significant benefits to both prime and sub
8 prime borrowers.

9 What is the impact of ineffective current
10 disclosures? The ineffectiveness of currently required
11 federal disclosures is likely to have contributed to the
12 market crisis. Study results show that the current
13 disclosures are not even effective for plain, vanilla,
14 fixed rate loans. They are likely to have been even
15 worse for more complicated loans, which were popular in
16 recent years.

17 We don't want to imply that all consumers
18 misunderstood their loans or that ineffective
19 disclosures are a primary cause of the current crisis,
20 but results suggest that it's likely that many consumers
21 did not know what they were getting into and that this
22 lack of understanding made the current problems worse.

23 For example, some of the loan terms currently of
24 concern and being addressed by new regulatory
25 restrictions are terms that current disclosures were

1 particularly ineffective for consumer understanding,
2 like prepayment penalties, lack of escrow for taxes and
3 insurance and balloon payments.

4 I wanted to mention one more. There is another
5 study that Jim and I did called "The Effect of Mortgage
6 Broker Compensation Disclosures on Consumers and
7 Competition" where we tested the effect of compensation
8 disclosures. The question here was, what was the impact
9 of how much compensation the loan originator was
10 receiving on consumer understanding of the costs of
11 loans. We found that that disclosure actually caused
12 people to make worse decisions than they would have
13 without the disclosure.

14 So the bottom line is that new mortgage
15 disclosure should not be implemented unless consumer
16 testing demonstrates that they're better than those
17 currently required. You can't rush to do something
18 without really testing it. It's very important and it
19 is true that bad disclosures can really do more harm
20 than no disclosure at all and it's important to
21 recognize.

22 But I don't want the take away message to be
23 that disclosures cannot work. In fact, I still think
24 that they're probably better than many other
25 alternatives that are available. Going back to my final

1 point: Consumer protection policy is often tricky
2 because people are unique.

3 You have to be careful banning a type of
4 prepayment penalty: If you ban prepayment penalty,
5 there is no sub prime lending. A lot of people think
6 the government should ban prepayment penalties. If that
7 happens, that's the end of sub prime lending. If you
8 think that's a good thing, that's good. If you think
9 it's not a good thing, it's not good.

10 There are other things that you can do rather
11 than ban the prepayment penalty. Well the prepayment
12 penalty disclosures that we have had for years stink.
13 They say things like "may, may not" have a prepayment
14 penalty. I kid you not, "may, may not" have a
15 prepayment penalty. Well, nobody can tell what that
16 means. I can't tell what that means.

17 Consumer protection is unlikely to be effective
18 without a joint mandate to promote competition. It's
19 very important when doing consumer policy to think about
20 the firms' side of the market and information remedies
21 are generally better than product restrictions, but
22 untested remedies can do more harm than good. We must
23 move beyond the economics of information to the
24 economics of comprehension.

25 And I think there's great potential for success.

1 The stars are aligned for further consumer research and
2 development. I think the future contribution of
3 economics will depend on defining common ground among
4 microeconomics, behavioral economics and marketing
5 research.

6 I think it's very important as policy debate
7 moves forward for people to really be clear about what
8 we are really assuming in traditional post 1970 models
9 of consumer behavior and what assumptions may or may not
10 be founded based on behavioral economics and marketing
11 research. And where there is the common ground because
12 policymakers, to move forward, really need to understand
13 where the common ground is.

14 Thanks very much.

15 (Applause.)

16

17

18

19

20

21

22

23

24

25

1 PAPER SESSION TWO: Advertising, Information and

2 Consumer Behavior

3 KYLE BAGWELL, Stanford University, Chairman

4 FEDERICO CILIBERTO, University of Virginia, "Push-Me

5 Pull-You: Comparative Advertising in the OTC Analgesics

6 Industry," Presenter

7 PAULINE IPPOLITO, FTC, Discussant

8 BRETT WENDLING, FTC, "The Impact of Drug Advertising on

9 Consumer Choice in Health Care," Presenter

10 JAYANI JAYAWARDHANA, Medical University of South

11 Carolina, Discussant

12 SOFIA VILLAS-BOAS, University of California, Berkeley,

13 "Another Nutritional Label-Experimenting with Grocery

14 Store Shelf Labels and Consumer Choice," Presenter

15 JAYACHANDRAN VARIYAM, U.S. Department of Agriculture,

16 Discussant

17

18 DR. ROTHSTEIN: We'll go right into the

19 session, thank you very much, which will be chaired by

20 Kyle Bagwell. Hi, Kyle.

21 So Kyle Bagwell is here to lead the next

22 session. Kyle is the Donald L. Lucas professor of

23 economics at Stanford University, as you all know. He's

24 written on topics ranging from the general agreement on

25 tariffs and trade, the value of price as a signal of

1 quality, the economics of collusion and the economics of
2 advertising.

3 Kyle is a fellow of the Econometric Society and
4 an editor of numerous journals. He's a former editor of
5 the Rand Journal of Economics, but I will stop there.
6 The full bios are available online at the conference web
7 site, and let him get on with the work of the day.

8 DR. BAGWELL: Thank you, Paul. I want to thank
9 Chris and Paul for organizing this great conference and
10 everyone at the FTC and Northwestern as well.

11 The title of this session is "Advertising
12 Information and Consumer Behavior," and our first
13 speaker I believe is Federico Ciliberto.

14 DR. CILIBERTO: So thank you for having me here.
15 It's a wonderful opportunity to somewhat hopefully help
16 shape some policy, so this is a work with Simon
17 Anderson, Jura Liaukonyte and Regis Renault.

18 So the question that we addressed in this paper
19 is really this: How do firms strategically use self
20 promotion advertising and comparative advertising to
21 push up their own brand perception along while pulling
22 down the brand that consumers have of the rivals?

23 So the way that you want to think about it is
24 that you can have two types of advertising really. One
25 is non comparative advertising, which is only positive

1 promotion. And then you have the other one, which is
2 comparative advertising, which has these two components
3 in it, which is on one hand you are pushing up your own
4 perception, but you're also pulling down the perception
5 of the quality that the other products have.

6 So the main objective in a sense is quite
7 confined. So what we want to do is this: We want to
8 have as simple a model as possible. It's going to be a
9 static model and it's a model of targeting advertising.
10 By targeting we mean that it incorporates this
11 comparative advertising rate. And then what we want to
12 do is we want to figure out how to get to some
13 specifications that we can run on some data, and from
14 this specification, learn something about whether or not
15 the comparative advertising is effective, to what extent
16 it is and how you can compare it to self promotion and
17 other things.

18 In case I don't have time to finish the
19 presentation, we show that higher market shares are
20 associated with the higher self promotion advertising,
21 so bigger firms are going to do self promotion more than
22 smaller firms.

23 My outgoing attack against say Chris' is half as
24 powerful as a self promotion for my own quality, so by
25 spending one dollar of competitive advertising I'm

1 pushing up myself by as much as 50 cents. That's the
2 notion. We show that instead of every dollar which is
3 spent by the competitors or incumbent requires 40 cents
4 to me, so incoming attacks also have an effect.

5 So to some extent what you want to think about
6 of this paper as really trying to ask the question: Is
7 this competitive advertising really as effective or is
8 it just something that the firms do? And it's not
9 really as effective as we expect, so we really want to
10 quantify in a sense that they're wrong.

11 We have a model where we have two endogenous
12 variables. One is comparative advertising, one is self
13 promotion. So we will have first two conditions, one
14 for each variable, and when we look at the comparative
15 advertising conditions, we show that the larger the firm
16 is, the more it has an incentive to attack another firm.
17 And the larger the attacked firm is, the stronger is the
18 incentive to attack so there is this interaction in the
19 size of the firms.

20 The paper has a very long literature review
21 which I'm not going to do. I'll go directly to the
22 content. Hopefully I'll give you the main points of the
23 paper. So think of it as each consumer has an intuitive
24 function. In this intuitive function there is a quality
25 function, which is a function of the self promotion

1 advertising by the self promotion advertising by the
2 firm J, so AJJ will be how much the firm J is spending
3 to self promote itself.

4 And then you have AJK which is how much I'm
5 spending to attack my competitors. This will be for all
6 the competitors that I have, and then I will have H and
7 J which is how much competitors are spending against me.
8 So very, very intuitive, very simple.

9 The demand is the classic demand. I'm not going
10 to spend too much time on it. It's a descriptive model,
11 which is written here as logit. The paper is still
12 ongoing in a sense, and now we're working on the next
13 logit. The results still hold, so let me stay on this
14 simple specification.

15 We have a profit. The profit again is quite
16 simple. We have the classic part, which is the market
17 size times the unit price minus marginal cost times the
18 share. But then here we also have the advertising, so
19 the advertising here is being endogenized in the model,
20 which -- I'm not going to spend too much time -- but
21 this is one important part of this work.

22 You have γ . γ is the marginal cost of
23 the comparative advertising. So basically we are saying
24 that it can be that your art is challenged so there is a
25 chance that you have to drop it. And that increased to

1 the cost, that increases the costs of the comparative
2 advertising so think about it.

3 We have an intuitive function. We have a demand
4 and then we have the profit function. We get to the
5 first condition. We will have two first conditions.
6 One is for the non comparative advertising, one is for
7 the comparative advertising, and they lead to an
8 extremely nice and simple relationship, which I think
9 you will see it as a point of strength.

10 The first one is the no comparative advertising
11 which we use to derive the first prediction, which is
12 firms with larger market shares will use more non
13 comparative advertising, and you really see it in the
14 equation itself. This will remind you, for those who
15 are not familiar with the Doveman Steiner condition, but
16 in a context where we have comparative advertising. So
17 here it is really saying that for the larger firm, there
18 is a larger incentive for self promotion advertising.

19 Then we have the other first condition which is
20 the comparative advertising condition. And again is
21 very, very simple after you work it out. There are some
22 literature creeks but nothing particularly devious.
23 Everything is very transparent.

24 You have this comparative advertising condition,
25 again quite simple. Remember γ is the marginal cost

1 of the comparative advertising. Lambda is what we will
2 show is the suitability parameter between self promotion
3 advertising and comparative advertising so basically
4 this is sort of the cost of doing comparative
5 advertising.

6 Cost, the marginal cost, any cost is affected by
7 not using self promotion advertising, and on the
8 left-hand side, you will see the key relationship, which
9 is the interaction of the share. The larger the share
10 of your comparative advertising, the more likely it is
11 that you attack each other. And then so you can
12 formalize these and get the results, which is that the
13 larger will target more of the competitors and the
14 larger is attacked more, so very, very simple
15 predictions you can derive.

16 So what do we do at this point once we have the
17 model set up? We get to the data. The data is the
18 over-the-counter analgesics market. All of us have
19 probably dealt at some point in our life with this, so
20 we have some nationally advertised brands, which are
21 Tylenol, Advil, Motrin, Aleve, Bayer and Excedrin. And
22 then what we do, we have three data sets.

23 The first one is a pretty classic data set.
24 It's aggregate sales, so what is really new here about
25 this paper is the number 2 and number 3. Number 2 is

1 basically a data set; think of it as a self file where
2 one entry is videos, so you click on that entry and you
3 watch the videos. So for that particular ad, you know
4 how much you will spend per month in a particular year,
5 but then you also watch the video.

6 So what's special here is that you will see the
7 content, so you see what the firm is saying, what the
8 one firm is saying against the other firm. So we called
9 each one of them in the following way: Basically we
10 watched the movie. We watched the video, and we ask,
11 who is the firm who is attacking whom? Say Tylenol is
12 attacking Advil, and so that's going to be a comparative
13 ad.

14 We know how much they're spending and then
15 another entry so far will be a self promotion
16 advertising where Tylenol is just self promoting itself;
17 very, very simple. I mean, this is the data set, and
18 then you want to quote it to be merged with the sale
19 data set, okay. It's simple, but really this is a
20 crucial part of the paper.

21 In order to do good empirical work, we want to
22 identify the source of exogenous variation. There will
23 be two sources of exogenous variation. One is the
24 medical news data, so basically we do a search on
25 Lexis-Nexis for any possible negative shock or positive

1 shock which hit the industry at any point in time in our
2 empirical study. Then we use generic price as an
3 instrument, and I will try, if I have time, to discuss
4 why we believe that that's a good instrument.

5 I'm not going to spend too much time on the
6 sales data, just take my word, and then we can go back
7 if you ask me. What's normal in terms of data is really
8 this attack matrix, so if you really want to think about
9 what is this paper trying to do, this paper is trying to
10 explain what this entry is. So you look at this table,
11 and you say Advil is attacking Aleve by 17.80 billion
12 dollars and say Advil is attacking Tylenol, 160.

13 So Advil is attacking Tylenol much more. It
14 makes sense within the model. Tylenol is a bigger firm,
15 but notice that many of the predictions of the model are
16 really there in this simple table, okay.

17 So again, when you ask yourself, what is this
18 paper trying to do? It's really looking at this table
19 and saying, can I explain this entry within a model of
20 profit maximizing behavior?

21 UNIDENTIFIED SPEAKER: Is this just a
22 cross-section?

23 DR. CILIBERTO: No, no, no. Oh, I see. This is
24 the sum over time, the sum of a time, so I could have
25 for each month a little table, but I didn't do that. I

1 mean, in the estimation that's what I'm using. This is
2 just this is describing the general parameter.

3 Okay. So this is the first data set, and then
4 this one really discusses advertising data. News shock,
5 so the key idea is the following: Again you go to
6 Lexis-Nexis. You have some key words. The key words
7 are say Aleve. You look for any possible shock that hit
8 Aleve, and then you create a table.

9 I always like full transparency, so here is what
10 it is: You find the particular shock. You know the
11 date when this shock happened, and then you want to
12 verify that this shock was relevant from a medical point
13 of view. You don't want to take shocks which don't have
14 any effect.

15 Some of the shocks are measured because they
16 appear on USA TODAY or CNN or this type of media, and
17 some are smaller in the sense that they don't appear on
18 major newspapers, but they still are there.

19 So at this point basically we have seen the
20 model. We have seen the exogenous variation. You need
21 to bring the model to the data. I only have five
22 minutes. Can I take your question later?

23 So now you want to see the regression, so if you
24 want to have some type of structure award, you will have
25 to assume some function on the base quality.

1 We spent how much time on this project, months?
2 And when you look at it you say, oh, it looks
3 complicated, and it's not complicated. So why did we
4 spend so much time? Because we want something simple
5 where we capture the major vision of the model without
6 driving the results. You will see the results are not
7 driven by this.

8 Basically you think of this is a approximation
9 of a quality function. It's quadratic in the outgoing
10 and the incoming. I cannot spend too much time on this.

11 So given that you derive nice ancillary
12 conditions, which basically are written as the self
13 promotional is a function of your shares, a function of
14 how much you're spending in comparative advertising and
15 how much you are being attacked. And the comparative
16 advertising is a function of this product of this share,
17 how much the guy you're attacking is spending in non
18 comparative advertising, how much he's spending in
19 comparative advertising, and how much other people are
20 attacking him.

21 So say, for example, they don't tell you that
22 there was a model. And we started my presentation from
23 here and it was a purely reduced form presentation, no
24 structure or anything, and then you ask yourself: What
25 type of regression do you want to run? And then you ask

1 yourself: Are these reasonable? Is this a reasonable
2 regression? And I think the answer is yes.

3 When you think of self promotion, you think that
4 that self promotion is a function of how much you're
5 spending, for example, in comparative advertising, how
6 much you're being attacked. So if you want to have a
7 miniscule view of this paper, you can also look at this
8 as what we are running.

9 I don't have time for the identification. We
10 spent a long time, a lot of time on the paper there.
11 The way we do this is Talbot regressions because many
12 times the first doesn't do any comparative advertising,
13 and so here are the results. We get the result and the
14 way you want to think of it is we can look at this
15 column, at the fourth column, and the fourth column is
16 where we put all the news shock, and you want to look at
17 this number. It is minus 0.452. This is really the
18 marginal substitution of self promotion and comparative
19 advertising.

20 So this is telling you that for each dollar that
21 you spend on comparative advertising, basically that's
22 worth for you 45 cents of self promotion, okay?

23 Similarly, you look at what you do when someone
24 is attacking you and you have the economy parts, which
25 is this one, and you get 0.637. So this again tells

1 you, first of all, it's in terms of the effect. There
2 is an effect. People will tell you that you do have an
3 effect on your quality, okay, and that's what it
4 measures.

5 We are still in the process of determining
6 exactly what this number means, but this is going to be
7 determining the marginal substitution of incoming attack
8 and self promotion attack. Then there is the next
9 table, which is the comparative advertising. I guess I
10 have two minutes at this point.

11 Here the product of the shares are interacted,
12 but they're in the denominator so in effect the factor
13 2, so you will find that indeed you have this
14 relationship in the data that the bigger one is
15 attacking more and the bigger is attacked more.

16 So essentially all the predictions that I tell
17 you are there in the data, but you also learn something
18 about other relationships such as the self promotion
19 advertising of the attack. So you see that the self
20 promotion attack doesn't seem to change my behavior in
21 terms of how much I'm attacking him.

22 So this was quite long. Let's finish it with
23 the conclusions. There are some limitations which I
24 talked with Pauline about, and she anticipated it. In
25 the paper we are extremely clear about it, but if you

1 notice there is no information here. It's all about
2 persuasion, so she can tell you more, okay.

3 If you think about the literature in
4 advertising, there is a big divide between persuasive
5 advertising and informative advertising, and this
6 empirical work is particularly strong. Empirical work,
7 it's clear. You really have these two directions, so
8 when you think of comparative advertising, you really
9 think of the paper by Goeree as the top way, I think of
10 thinking how you model information advertising.

11 Here we really look at persuasion, and we are
12 emphasizing the advertising. And we are trying to see
13 how firms choose in the context where they can have both
14 self promotion advertising and comparative advertising.

15 People question: Can you do welfare analysis or
16 not? No, because we don't have the demand. In
17 principle, when you want to do the welfare analysis, you
18 really need to have an equilibrium model. The perfect
19 paper will be a paper where you tell the firm that they
20 cannot do any more comparative advertising. This is an
21 old idea; it's not our idea.

22 Is there a prisoner's dilemma here where firms
23 are attacking each other and they don't change the
24 share, which is what we see? We don't see changes in
25 the shares in the data. The only time when the shares

1 were changed in the data is when Alevé was hit by a
2 shock at the end of 2004. But the advertising doesn't
3 seem to change the share. So the question is: Are they
4 attacking each other, spending a lot of money and they
5 don't move much? Modeling that is beyond what this
6 paper is trying to do.

7 That's it.

8 DR. BAGWELL: Thank you very much. Pauline will
9 be our discussant.

10 DR. IPPOLITO: Thank you. Well, just to let you
11 know you're in Washington. I speak for no one who
12 matters.

13 This is a very nice paper, and he does a good
14 job in laying out the model. It's a relatively simple
15 model as these things go these days and it predicts
16 results that are not surprising, which is if you're
17 going to attack someone, you attack someone big because
18 you get more share from them, and if you're a very small
19 firm, you're not likely to attack someone big because
20 others will share in the migration away from that firm.
21 It all comes out of an equilibrium. We get the results.

22 So this is in the tradition of IO people who
23 look at advertising issues. It's all about how much you
24 are spending and how it affects share. The paper adopts
25 the unfortunate labeling from the literature and I wish

1 we could all agree to never use these words again. The
2 unfortunate labeling is that there's informative
3 advertising and there's persuasive advertising.

4 Persuasive advertising in this literature means
5 anything that moves demand, and it comes out of the old
6 literature on hidden persuaders, you know, what
7 advertising was doing was getting people to buy things
8 they really didn't want. So if you think about olive
9 oil telling you that saturated fat causes heart disease
10 and therefore you should choose olive oil because it
11 doesn't have saturated fat, that of course shifts demand
12 for olive oil and it is quite informative in the English
13 sense of the word.

14 So this labeling is really unfortunate and I
15 wish we could all collude to never use it again. What
16 makes it particularly unfortunate though, especially
17 when IO people are already thinking about rivalry and
18 only about rivalry, is it leads you down a path to cause
19 you to say things like the authors did in this paper.

20 In the conclusion they say, this gives us quite
21 a negative view of comparative ads in the sense that
22 there is much wasteful battling just to stay afloat.
23 And so I started thinking about, well, is it really that
24 negative a conclusion? Should we think that this is a
25 waste?

1 So I did a little bit of research on the
2 analgesics market and I'm going to give you a
3 three-minute tutorial, and then you will tell me whether
4 you think this is all a waste or not.

5 So in the analgesic market, there are basically
6 two classes of drugs, acetaminophen, Tylenol, and the
7 NSAIDs, which means nonsteroid something or other and
8 inflammatory drugs. Those are aspirin, ibuprofen and
9 naproxen, so that's everything else; so it's Tylenol
10 against everything else. So acetaminophen, Tylenol, is
11 the major brand, reduces fever and it moderates pain.

12 The NSAIDs do both of those things, and they
13 also reduce inflammation, so if you get a joint injury
14 from exercising too much, it's inflamed, you want to use
15 an NSAID. You don't want to use acetaminophen. If
16 you've just got a plain old headache, you might want to
17 use Tylenol, but that's not the end of the issue. There
18 are also the risks. So what are the risks?

19 Well, for Tylenol, acetaminophen, it can cause
20 serious liver damage, and the tolerance limits between
21 the normal dose and an overdose are really quite small,
22 quite narrow. If you get an overdose of Tylenol, you
23 destroy your liver as in you're on the list for a liver
24 transplant.

25 So it's a very dangerous drug in some

1 circumstances. And if you drink alcohol, it magnifies
2 the effect, so a weekend of the flu and a party, you're
3 on a list for a new liver. So that's an issue.

4 Now, what about NSAIDs? So then you should say
5 take NSAIDs. Well, no, NSAIDs are very hard on the
6 stomach lining. They cause ulcers, and they certainly
7 exacerbate ulcers, so that's a serious risk for certain
8 people. It promotes bleeding. If you're prone to small
9 strokes, as an older person, you don't want to be
10 talking a lot of NSAIDs. A small stroke can become a
11 big stroke.

12 Kidney problems, the NSAIDs cause work on your
13 kidney. If you have kidney disease, you don't want to
14 be taking this category of drugs and it's doing harm to
15 your kidney if you're taking them a lot.

16 Then there are the cardiovascular events. Vioxx
17 was pulled from the market, but most people today think
18 that Vioxx really isn't any different than these other
19 drugs in this category and there is a small chance of a
20 major cardiac event from taking NSAIDs.

21 So this is the two minute version of this drug
22 choice. It's not simple. It depends who you are. It
23 depends what ails you. It depends what else is wrong
24 with you. So it's a category where you see a lot of
25 comparative advertising.

1 I don't know what it means. Could be rivalry,
2 could be wasteful, but it could be informative. And so
3 one of the things I would like to suggest to the author
4 is I would like to know a little bit more about the
5 content of those comparative ads, where they're bringing
6 out these kind of issues. The drugs are better for some
7 things than other things. They have different side
8 effects, depending who you are. You might care more
9 about one or the other. If they are, then I'm not so
10 such it's always full rivalry.

11 In terms of the modeling, the understanding of
12 what's going on in this market, the two issues that I
13 would raise or the one in particular that I have
14 concerns about was they model advertising as having the
15 same effect on all consumers. So advertising for
16 Tylenol has the same effect on everyone. Advertising
17 for aspirin has the same effect on everyone.

18 Given the heterogeneity of consumers and the
19 different effects here, I'm not so sure I'm comfortable
20 with that, though I don't think it would matter for the
21 results they find. And then I have three little
22 requests for things they might consider.

23 First, I think the paper really should have a
24 little bit of a discussion of what's in these
25 competitive ads so we can judge this issue. The other

1 thing is this is data to die for. Nobody has this kind
2 of content data for advertising systematically collected
3 over time. What is in these ads? Really look harder at
4 the information issue relative to this competitive
5 issue.

6 I mean, if you really were going to get serious
7 about trying to test the persuasion wasteful advertising
8 against information in this market, you would want to
9 look at: Did the competitive advertising just add to
10 cost and raise prices? Or did analgesic choices get
11 better over time because of this, or coincident with
12 this advertising? With other kinds of data, you might
13 actually be able to look at that, especially where you
14 have the actual ads.

15 Then one final just tidbit: It's absolutely
16 standard, if you're going to do a content analysis, that
17 you explain who did the coding and how they did the
18 coding. I would really hate to have the marketers say
19 we're sloppy.

20 Thanks.

21 DR. BAGWELL: Thank you, Pauline. We have time
22 for one question? Is there -- an earlier question? I
23 can't remember. Nope. Federico, would you like to
24 respond in any way?

25 DR. CILIBERTO: I'll give a brief response. So

1 the coding was done by a law student and then
2 independently we hired another RA who did the collating,
3 and if you feel that we should say it, we will.

4 To some extent, so I'm very sympathetic to what
5 you're saying in terms of the information. Let me
6 give let's call it a cheap answer, and what I think is a
7 better answer.

8 The cheap answer is again, there are no
9 empirical works which do both. I cannot think of them
10 so either the advertising is put in the demand, and then
11 there is a waving of the hands and they said, oh,
12 advertising is there, we just see how it effects, or
13 it's explicitly said it's persuasive or informative.

14 We didn't want to have the waving, so we would
15 rather took the hit, a lot of hit, and we say it is just
16 persuasive.

17 The other part is you described the industry
18 very well, and I thank you for doing that. My hope when
19 we're using the news shocks is that what you're
20 saying about the liver, we caught it now. In other
21 words, what we hope is that by including the news shocks
22 as the exogenous variation, we are in some way lowering
23 the fact that we are not having information. So we hope
24 that somewhat this information directly put on the
25 inside addresses what you're saying.

1 DR. BAGWELL: Thank you very much.

2 Our next talk is by Brett Wendling.

3 DR. WENDLING: So my colleague, Dan Hosken, and
4 I are looking at how drug advertising directed to ad
5 consumers affects their propensity to visit physicians
6 for check up visits. We call our paper "Informing The
7 Uninformed."

8 So advertising in drug markets is fairly
9 controversial. The proponents of advertising for drug
10 markets suggest that advertising can be informative in
11 the sense that if Lipitor advertises their drug, then
12 consumers become aware of the fact that cholesterol
13 conditions are important medical conditions, that they
14 might have a high cholesterol problem, and that there's
15 a treatment available for that condition in the
16 advertisement.

17 Moreover, these proponents argue that these
18 advertisements directed at consumers might be aimed at
19 the least informed consumer, namely the patients who
20 might know very little or relatively less than
21 physicians about these health conditions.

22 The critics of allowing advertisements to be
23 directed at consumers suggests that the profit motive
24 provides incentives to firms to mislead consumers in the
25 sense that they might omit certain types of information

1 or they might misrepresent other types of information.
2 And there has been some documentation by a recent GAO
3 report that suggests that firms have not complied
4 completely with the regulations for the advertisements.

5 An additional concern of critics of
6 advertisements in drug markets in particular, is that
7 advertisements just raise the cost of drugs without any
8 commensurate benefit. These critics don't believe that
9 there are benefits, and in an environment where drug
10 costs are very large and have been rising over the past
11 decade, the increased drug costs of advertising is a
12 concern.

13 These arguments by these critics have actually
14 gotten some traction, and drug advertising directed at
15 consumers has been banned in certain countries. In the
16 United States, prior to 1997, the FDA regulations in
17 place effectively had banned advertisements direct to
18 the consumers and on television and on the radio.

19 And so there are important policy implications
20 for our decisions of how to treat drug advertising.
21 Specifically, should we ban direct to consumer
22 advertising, and if we should allow it, should we
23 regulate it more?

24 So our study is trying to address more of the
25 first one. We're interested in whether drug advertising

1 could provide some sort of informative benefits to
2 consumers. So what we're going to do is we measure how
3 direct advertising affects a consumer's choice to see a
4 physician for a check-up visit, and we're particularly
5 interested in check-up visits because we believe that
6 check-ups are sort of, by their very nature, an
7 informative medical service.

8 You go to get a check-up because you might be
9 unaware of the conditions that you have and you're
10 hoping that the check-up will resolve uncertainty about
11 the information that you might not have about your
12 condition.

13 We're going to focus on a population of the
14 undiagnosed in our analysis where these people are
15 defined as individuals that do not have any chronic
16 condition. This is a particularly relevant policy
17 segment of the population because this is a group that
18 is not receiving treatment for any type of condition and
19 therefore are likely to be uninformed about their
20 medical condition. And we're going to use the detailed
21 personal level information to be able to control for
22 personal level heterogeneity in their decision to visit
23 the physician.

24 So the relevant recent literature on drug
25 advertisement has basically focused on: How

1 advertisements affect the demand for drugs and/or
2 medical services that are related to the prescription of
3 drugs, an office visit where a prescription occurred.

4 And the basic findings of this literature are
5 that increases in the demand for specific drugs raise
6 the sales of the entire category, so there's sort of a
7 free riding problem for any firm. So if Lipitor spends
8 more money on their drugs, cholesterol drugs go up. All
9 cholesterol drugs go up, but Lipitor sales are not
10 disproportionate to the sales of cholesterol drugs.

11 So this got us to thinking, well, there's sort
12 of the mechanism for how these drug advertisements are
13 working is that individuals see the advertisements, and
14 that inspires them to go to the doctor. And then the
15 doctor prescribes the medication, and if that's the
16 case, then there might be, in addition to this sort of
17 free riding within a category, spillover across
18 conditions where you see a drug advertisement for
19 analgesics and you go to the doctor and you learn about
20 your hypertension problem.

21 So in addition to that, we were interested in
22 seeing if there are sort of differential effects across
23 different consumer groups with respect to drug
24 advertising as Ippolito and Mathios found for food
25 advertising in their grant paper. So the advertising

1 data that we're using in our paper is sort of common in
2 this literature. It's TNS Media information where they
3 report advertising expenditures separately by drug,
4 region, quarter and media type where the media type
5 includes information like the television channel of the
6 spending or the radio channel of the spending.

7 What we observe is that most of the advertising
8 in this data are national campaigns. There's very
9 little regional variation. More than 90 percent of the
10 data is national, so we've just decided to aggregate
11 nationally.

12 However, the advertisements do appear to be
13 targeted at different individuals so there's a
14 significant variation across media channels. For
15 example, advertisements that are targeted at birth
16 control ads or acne medications are disproportionately
17 on MTV, which you might think is a younger demographic,
18 whereas prostate condition ads and allergy medication
19 ads are on the golf channel, which is likely viewed by
20 old men who play golf, I guess.

21 So in order to exploit that variation in data
22 across these groups, what we're going to do is assign
23 the advertising to the individuals in our data, sort of
24 based on the demographic characteristics of individuals.
25 For example, we're going to assign sort of menopausal

1 treatment ads to women age 45, so age is going to play a
2 part as is sex. But we're going to allow for every
3 person, advertisements across all the conditions that
4 are relevant to them to be exposed to all those
5 different types of ads.

6 So what we end up with is advertising that
7 varies along several different dimensions. As I
8 mentioned in the beginning of the talk there was this
9 large increase in advertising over the period 1996 to
10 2004, which is our sample period, so we're going to have
11 that variation over time. And we're going to see
12 variation along age and sex characteristics sort of in
13 the way that I was describing earlier where we're going
14 to assign drugs that are relevant to certain age groups
15 to those groups. It's easier to understand that some of
16 these advertisements are not going to be relative or
17 relevant for the different genders.

18 So the data that we used for the demand for
19 office visits is the medical expenditure panel survey,
20 and this is a nationally representative sample of
21 individuals where it follows each of the individuals for
22 two years. What we do is reconstruct for every
23 individual in the period 1997 to 2004, and we construct
24 the four six-month panels, because we observed them for
25 two years.

1 This has a lot of demographic medical care and
2 health information that's relevant for our study. We
3 have age, sex, income information, insurance status.
4 For medical care, we observe whether you went to the
5 doctor for a physician check-up, so somewhat importantly
6 we directly observe whether an individual chooses not to
7 go to the doctor.

8 So we're following individuals over time rather
9 than physicians so we observe when someone chooses not
10 to respond. And we don't have to instrument for sort of
11 the population of people that are relevant.

12 With regards to the health information, we
13 observe self reported health status activity
14 limitations, which vary over time, in addition to
15 chronic conditions which are measured as international
16 classification of disease codes.

17 So in our empirical model, our dependent
18 variable is going to be an indicator of whether a
19 patient has a check-up during the period. It's going to
20 be a function of the advertising, which again varies by
21 these age and sex characteristics over time for a sample
22 of individuals that don't have a diagnosed medical
23 condition as identified with these ICD-9 codes.

24 For a group of individuals that are over 35, and
25 we choose 35 because most of these conditions that are

1 advertised are sort of these late onset chronic
2 conditions that the earliest days for which they're
3 usually observed in the data is for individuals 35 or
4 older.

5 To write down an equation, the estimating
6 equation that we have is: The probability that a person
7 i visits a physician in period t for a check-up is going
8 to be a function of the person specific direct to
9 consumer advertising expenditures as indicated by the
10 DTC. These demographic characteristics that are
11 changing over time such as the self-reported health
12 status; these activity limitation variables like income,
13 et cetera; a person specific fixed effects because again
14 we have this panel of people over time; and finally some
15 controls for the time, such as year dummies and a
16 seasonal dummy.

17 We estimate the equation separately by race, sex
18 and education, and we do it using a linear probability
19 model and a fixed effects logit model. But in the
20 linear probability model, it allows us to interpret the
21 coefficient as sort of the marginal effect.

22 And what we find is that for both men and women,
23 they respond to advertising, and the effects are
24 economically important and statistically significant for
25 both groups, but there's a fairly differential effect.

1 Women are much more responsive to advertising, so the
2 coefficient on the log of advertising is .147 for women
3 and .05 for men.

4 So women are almost three times more responsive
5 than all men. We also find fairly large differences in
6 across other demographic groups, namely race and
7 education levels.

8 With respect to race, we find that Hispanics are
9 particularly unresponsive to advertising. This is not
10 that surprising to us because most of the advertising in
11 our data set is television advertising, and you might
12 believe that Hispanics are less likely to watch English
13 channel programming than other groups.

14 With respect to education this was sort of
15 surprising for us, the college educated appear to be
16 more responsive to advertising than high school grads or
17 less than high school grads. Although all these
18 differences that we're finding are fairly large and
19 economically important, they're imprecisely estimated.

20 So even though we're finding that these
21 differences exist, we can't make statistical statements
22 that they're different from each other, but the
23 magnitudes look like that they are potentially different
24 from each other.

25 So one of the concerns of trying to identify

1 effect using data that trends so hard with respect to
2 advertising is that you might be worried that you're
3 just sort of picking up this correlation and two
4 measures that are trending together. So you might be
5 worried that, well, advertising is going up over time,
6 and if office visits are going up over time, that's sort
7 of what's identifying your effect.

8 So we've done a number of things to try to
9 address that issue, including putting men's advertising
10 into the women's equation and the women's advertising in
11 the men's equation. And we find that this sort of
12 irrelevant advertising doesn't explain check-up
13 propensity at all. If you didn't like our group
14 measures or how we assigned the groups, if you just
15 aggregate up to all advertisements, you get smaller
16 coefficients and larger standard errors, but the effects
17 are still there.

18 What we believe are the contributions of our
19 paper to the literature are: We're using person level
20 panel data that allows us to control for a rich set of
21 individual characteristics over time. We're focusing on
22 what we think is a particularly policy relevant
23 population, one that is undiagnosed and therefore
24 unlikely to be informed about their conditions, and
25 consequently could benefit from the advertising.

1 Our metric allows for the spillovers across
2 conditions that other papers have not been able to
3 address so far, and we believe that our methodologies
4 also allow us to isolate the sort of informative effect
5 that direct to consumer advertising has. So we don't
6 believe that advertising directly to physicians is going
7 to effect your decision to go visit a doctor for a
8 check-up.

9 So in that respect it's isolating the effect of
10 the consumer advertising, and we also think that
11 check-ups is really sort of an informative metric of
12 medical care. So we're getting this informative aspect
13 of the advertising, and then finally we've tried to do
14 our best to address the identification issues in the
15 paper.

16 So in conclusion we found that direct to
17 consumer advertising appears to increase physician
18 visits for undiagnosed patients. This would imply that
19 if we had restrictions on advertising, it would lessen
20 the likelihood that the population would seek treatment.

21 Moreover, we have found that advertising does
22 appear to have differential effects across different
23 types of demographic groups. These effects can be
24 large. Advertising is effective for women and the
25 highly educated but we can't reject that they're all the

1 same statistically.

2 Thank you.

3 DR. BAGWELL: So our discussant is Jayani
4 Jayawardhana.

5 DR. JAYAWARDHANA: Well, thank you for the
6 invitation to discuss this paper. I really enjoyed
7 reading the paper particularly because this is an area
8 that I'm really interested in.

9 I thought the authors take a good approach in
10 terms of trying to measure the effect of the DTC,
11 especially the informative effects of DTC on check-up
12 visits.

13 So as Brett just presented, the objective of the
14 paper is to measure how DTC advertising effects an
15 undiagnosed individual's decision of getting a check-
16 up.

17 When I think authors said undiagnosed,
18 undiagnosed for chronic conditions specifically is the
19 group that they're looking at, and I think that's a
20 pretty interesting group to look at because that helps
21 recapture the DTC effect, the informative effects of
22 DTC.

23 So they use two different data sets for the
24 analysts. The MEPS data and the DTC advertising data.
25 The MEPS data is a survey of national sampling

1 of civilians in the U.S., and that gives you information
2 about health utilization data as well as demographic
3 information.

4 Authors do limit the data analysis to people who
5 are over 35 years old and also people who do not have a
6 prior diagnosis of a chronic condition, and the
7 advertising data basically come from TNS Media
8 Intelligence. They provide data of the drug level and
9 this is a national expenditure, national dollars for the
10 drug level.

11 The findings of the paper basically say that the
12 DTC advertising does have a positive and significant
13 effect on the probability of a consumer seeking a
14 check-up visit. They also have that the effect of
15 advertising seems to vary by the demographic group.
16 Particularly they find women with Medicaid insurance and
17 also the highly educated tend to be more responsive to
18 DTC advertising and they also find that Hispanics seem
19 to be the least responsive.

20 So moving on to some of the comments I have
21 about the paper. As I said earlier, they do focus on a
22 group of individuals undiagnosed for chronic conditions.
23 I thought that's a good approach particularly to capture
24 the informative effects of DTC on check-up visits. This
25 is a group that the previous research hasn't really

1 looked at in the DTC literature, so I thought that was a
2 good touch.

3 They also look at the DTC effect at the
4 demographic levels and that gives us much more
5 information to understand how different groups are
6 reacting to DTC advertising.

7 I thought it was very good that they're using
8 the demographic specific advertising dollars into the
9 analysis, because most of the time what I have seen in
10 the DTC advertising literature is that using that
11 aggregated data. And at least they're controlling it by
12 the gender and by age, so I thought that was a good
13 idea.

14 So some questions actually or concerns that I
15 had about the analysis: It seemed to me that from the
16 paper, that an individual in the data set who can be
17 present up to two-year period, which is like four time
18 periods in the data, they could have multiple check-up
19 visits in the data. We all have check-ups and there are
20 annual check-ups that we tend to do, especially people
21 with health insurance tend to do annual check-ups more
22 than people who do not have health insurance.

23 So how do you capture the effect of a check-up
24 visit that happens due to an annual visit versus a
25 check-up that happens due to an advertising effect?

1 Another question is how to identify the
2 check-ups due to advertising versus check-ups that
3 happen due to a prior check-up visit. I think you are
4 excluding people who do have a prior chronic diagnosis,
5 but you do not exclude people from the sample who had
6 prior check-up visits.

7 For example, this is a quote I got from the U.S.
8 Preventive Services Task Force recommendation about
9 blood pressure measurement. You're not supposed to be
10 actually diagnosed as a candidate for hypertension
11 unless you have two check-up visits and be confirmed
12 with positive outcome. On the first visit you may be
13 not diagnosed, but your second visit happens as a result
14 of the first visit may not be necessarily as a result of
15 DTC effect.

16 So that is sort of what I mean by how to
17 differentiate those two effects. The third one is my
18 understanding is that you are not excluding people who
19 may have acute conditions, only the chronic conditions
20 from the sample. So for example, I could do to the
21 doctor for fever and usually when I go to the doctor,
22 they do check blood pressure, right?

23 And I can be a borderline case for blood
24 pressure, and the doctor might say, okay, you may have
25 to watch out your health habits and come again in three

1 months or six months later. And we'll check your blood
2 pressure and see whether you will have high blood
3 pressure or not.

4 So my second visit is due to my first visit, not
5 necessarily again due to advertising effect. How do you
6 capture those type of effects or differentiate the visit
7 from those type of effects?

8 Another comment I had is that you do control for
9 advertising dollars by the gender and age, but also your
10 response to DTC advertising depends on your exposure to
11 DTC advertising, so it would have been nice if you could
12 introduce some exposure data into the analysis so you
13 can have much more control. I know it is very difficult
14 to get such data, but just an idea to think about.

15 The other thing about this recommendation is
16 it's publicly available. For the last few days we have
17 been hearing about this whole thing about the
18 recommendations about breast cancer screening,
19 mammograms, and changing how often you should be doing
20 them.

21 The earlier recommendation was about 40 years
22 old, and you should be doing it annually, but now this
23 new recommendation came up with age 50 and maybe doing
24 it every two years. So this public information is
25 available to us about how often you should be doing

1 testing. Similar recommendations are available for
2 cholesterol, hypertension. How does that type of
3 information affect the check-up visits and how is it
4 differentiated from the DTC effect on check-up visit?

5 So regardless, I thought this was a good
6 contribution in addressing an important question that we
7 are all interested in finding out more information about
8 the DTC effect, and I know it's an ongoing research
9 area.

10 Thanks a lot.

11 DR. BAGWELL: Do we have any questions? Yes?

12 DR. VAN BIESEBROECK: Johannes Van Biesebroeck.
13 I don't know what the breakdown is in advertising
14 expenditures between over the counter drugs and
15 prescription drugs because that seems like a dimension
16 where you could get stronger results if you find people
17 also going to the doctor and they get exposed to
18 competition for over the counter drugs. It seems more
19 closely.

20 DR. WENDLING: So we don't have advertisements.
21 Our advertising expenditures are only for prescription
22 drugs so there's no over the counter advertising
23 expenditures in our area, but you raised a good point.
24 I mean, these -- the over the counter medications might
25 be sending people to the doctor as well, but

1 consequently because I don't have the other DTC, I don't
2 know what the breakout is.

3 DR. BAGWELL: One more question in the far back?

4 MR. STIVERS: Andrew Stivers, the FDA. You said
5 that the advertisement is successful at driving
6 check-ups. Have you thought at all about the next step?
7 I could construct a scenario where actually check-ups
8 are bad for consumers because they're getting too many.

9 Do you have data? Have you thought about
10 linking check-ups then to some actual positive outcome
11 for consumers?

12 DR. WENDLING: Actually the original version of
13 this paper started off looking at the check-up visits
14 and then had sort of a second analysis of how productive
15 those visits have become. So are people learning about
16 diagnoses at those medical conditions? So actually the
17 short answer is yes, we've thought about it.

18 And at one point it was included in this -- on
19 this paper, but it ended up being two different models
20 because we're focusing on the undiagnosed. We have
21 statistics; most of the people that become diagnosed
22 with any condition have initiated that with check-up
23 visits.

24 And I would say of the undiagnosed population, a
25 fairly large fraction of those individuals are becoming

1 diagnosed. I want to say like 20 percent of them, but
2 we're trying to formally model that in this second
3 paper.

4 DR. BAGWELL: Thank you. Next up we have Sofia
5 Villas-Boas from Berkeley, and we're still on time.

6 DR. VILLAS-BOAS: You have all the tough names
7 in terms of --

8 DR. BAGWELL: Sorry about that.

9 DR. VILLAS-BOAS: No, it's perfect. So thank
10 you for giving us the opportunity to present this work.
11 This is work with Kristen Kiesel from the state of
12 California like myself.

13 In this paper we're trying to measure whether
14 nutritional information, more specifically changes in
15 nutritional information available to consumers at the
16 point of purchase has any effect on their actual
17 purchase decisions.

18 We use incredible data, store level scanner
19 data. So from those data, we have quantity as well as
20 the price. With these store level data, we will be able
21 to compare changes in stores where this information
22 occurred to changes in stores where this information did
23 not occur that I'm going to try to convince you are
24 comparable stores. But we can also, using this data,
25 try to see, okay, if people buy the preferred choices,

1 if we take those out of the choice set, and with the
2 model try to assess a willingness to pay for having a
3 certain attribute available in terms of a nutritional
4 claim.

5 Then an accompanying piece with two coauthors
6 from Washington State, Jill McClusky and Hayley
7 Chouinard will take advantage of a little bit more micro
8 data that are the granular of the store level data that
9 I'm going to present to you today.

10 We actually have transaction level data. In the
11 meanwhile we pulled these recent data, and so we have
12 the purchase history of people before the actual change
13 occurred. And we can see all kinds of micro level
14 evidence on changes in behavior, and we can see whether
15 old consumers responded or the changes in information
16 led to consumer entry into the category.

17 So this is like the big picture objective in 20
18 minutes. Let's see how much I can squeeze in here. If
19 I can't, then hopefully my discussant will tell me what
20 I should have said.

21 I had 20 minutes so I assassinated the
22 literature review slide. I apologize to everyone in the
23 audience that has worked on this and knows much more
24 than me on this. You're all here and you know who you
25 are, but there is incredible evidence that consumers

1 devote minimum time and effort to processing
2 information, especially typical grocery store set up
3 where a facing is typically a product.

4 So what I asked was: Does including information
5 in an easy to process shelf label format effect consumer
6 approach? Of course the second step of the story as our
7 lunch presenter said is: If it does, then will firms
8 adjust? We don't have that second part of the story.
9 We will have the first. We will change something, and
10 we will see if consumers respond.

11 So the idea is given the changes we do, we kind
12 of posit that that's reducing the cost of comparing
13 available choices on the shelf. Products have
14 nutritional claims panel facts, but you know that not
15 only the font is very small, but maybe you could argue
16 that there's too much information there or even for a
17 certain product. You don't know what the other products
18 available are.

19 So our change will help decrease the cost of
20 comparing products available at the point of purchase,
21 and we will also repeat already available claims in a
22 more salient fashion.

23 So the overall question is: Does this result in
24 healthier product selection decisions? I'm not making
25 any welfare statements here. I'm just asking: Do we

1 see a shift in consumers as a result of our change?

2 Nothing is saying that it's a good or a bad change.

3 So the last bullet was here, I think it still
4 was here when I presented this to the nice large grocery
5 retail chain that did this. I was just saying that they
6 have an incredible opportunity to affect consumers
7 because they're the last thing consumers see when they
8 buy.

9 Just to give you a very quick idea, we got these
10 data for changes in information from five stores. These
11 are the five labels that were displayed under the price
12 tags.

13 So no trans fat claims, for example, are already
14 part of the product box. Either it says zero or the
15 actual manufacturers will say no trans fat in bigger
16 font than anything else on the box. So by displaying
17 that, for example, claim we're not giving any new
18 information. It's just making it under the price stack.
19 Maybe it's easier to see, we don't know. We will see.

20 Most of what you see here is low calorie, but
21 who defines that? That's another question. In terms of
22 our scale, the 25th percent, 5 percent, 10 percent, in
23 terms of some attribute could be considered low, so
24 we're telling consumers among these options, this is a
25 low calorie product. This is a low fat product, and

1 then this is a low fat product and it's according to the
2 FDA nutrient content claim. Who's telling you this or
3 based on what are we claiming on this?

4 Of course you can't see a thing here. This is
5 an example of too much information. The idea here is
6 just for those that are very skeptical and want to see,
7 but didn't pass the check-up on the 20/20 eyesight, the
8 five treated stores compared to the control stores. We
9 have a lot of control stores, so that's the average
10 among certain attributes that are in the row of the
11 controlled stores.

12 This slide just wants to tell you that the
13 treatment control stores are pretty similar with respect
14 to the assortment of products except the treated store 3
15 had a much smaller display of the category where the
16 changes occurred. There was the popcorn category. It
17 had a much smaller product assortment.

18 The treatment and control stores served very
19 similar demographics and are actually pretty
20 representative of the national average. The product
21 category where the changes occurred is not
22 representative of a typical grocery purchase. It could
23 be seen as a treat or something that you probably want
24 if you're going to do some damage. You're going to do
25 the whole damage when you buy popcorn, so take this in

1 terms of what it is that we're going to show you.

2 So we got data from the periods before, during
3 and after these labels were attached to the price tags.
4 That's a photo of a typical treatment episode. We
5 obtained data for the five treatment stores as well as
6 all possible combinations of control stores we could
7 have received. We received 27 of them. We have store
8 level product sales for four years.

9 We can use the time before the treatment to kind
10 of try to see if we can match control stores to the
11 treated in terms of pretreatment, et cetera, and kind of
12 have an idea of having a nicer control. If you don't
13 believe the difference-in-difference strategies, I will
14 show you these old data can help us match these stores
15 better. And then you will probably be convinced that we
16 have a constructed if not a very good control, but a
17 combination of controls, also called a synthetic
18 control. We just can see if we can create based on that
19 pre period a very nice benchmark for what would have
20 happened if we didn't do these label changes.

21 We have demographic information from the census
22 and the nutritional facts were obtained from the
23 product. So the idea is a difference-in-difference, and
24 we have the treatment store in October of 2007.
25 Everybody knows that in October 2007 -- I'm to going

1 make this up -- some DVD was released, "Twilight" maybe;
2 I don't know. So both in the control and the treatment
3 period popcorn sales went up because everybody wanted to
4 watch the movie and they need popcorn, of course.

5 So that's the idea: Can we compare the change
6 in the treatment store and the change in the control and
7 contribute the difference in this difference to our
8 little experiment? So the difference-in-difference is
9 going to be my average treatment effect. I'm going to
10 show you.

11 If we pool the data and we look at this average
12 treatment effect, we would find no average effect over
13 all the labels that were implemented.

14 The different columns have different additional
15 controls and the results are pretty robust. I want to
16 say that some claims are already part of the box. Some
17 of the manufacturers sell on average more than others so
18 it's important to control for those already, and that's
19 what these columns are doing, adding additional
20 controls. So on average nothing happens, but remember
21 we have five different treatment stores, some where low
22 calorie was the focus and others were low fat, et
23 cetera. We can break this effect a little bit more than
24 just the average.

25 And this is what this table that is also very

1 hard to read says. Again remember I was trying to
2 highlight the top row, and I'll point to some rows if
3 you're interested or if there are any questions. The
4 low calorie has a positive although not significant
5 affect. Low fat, negative, becomes significant in the
6 store where we added the source of where it's being
7 based on.

8 Then the combined, where we start adding claims,
9 after claims, the average effect is negative for low fat
10 and low cal, but again that's an average across low fat
11 low cal. And the others are kind of adding all these
12 attributes, so we can break up this effect a little bit
13 more in detail, so the low fat label on average
14 decreases by 27.5 percent. This is the log of quantity
15 on this dummy, and that's what that number means here.

16 The non trans fat label increases on average by
17 23 percent but not in combination with other claims, so
18 when it's alone, it has that effect, but when it's in
19 combination with other claims, it does not have that
20 positive effect. The label that has the most claims has
21 the most information but the effect just basically
22 starts dissipating. It starts getting closer and closer
23 to the actual panel facts.

24 You may want to know what happened to the
25 products that didn't get those positive claims. By the

1 way, you may wonder why low? You can probably guess,
2 right? The retailer did not want to put other stuff
3 also, so one just has to live with what one can live.
4 But you can see what inference or at least based on your
5 field preference what happens.

6 In terms of the pooled effect on average,
7 nothing happens to the unlabeled, untreated products.
8 With the exception of the store where the low fat was
9 there, the ones where they had no low fat goes up by 16
10 percent. So I'm not a very big popcorn eater, but I
11 would assume that low fat means no butter, tastes like
12 cardboard or something, so you could see that as a
13 correlation. So using the store level data just to nail
14 this, increases in quantity due to no trans fat labels.
15 Again that information was already available so the
16 salients at least did have an effect.

17 Decreases in quantity due to low fat labels,
18 especially when -- the point estimate is estimated with
19 the FDA claim. Increase in quality due to low calorie
20 labels. We performed a lot of regressions, and these
21 actually become significant when instead of doing
22 product by product you aggregate all products by month.
23 So no inference on unlabeled products except for the low
24 fat store, and the effect seems to dissipate the more
25 claims are added.

1 What happened to total category sales? They
2 actually decrease so at least it doesn't seem to induce
3 consumption, although we can go into much detail when we
4 use the micro level data just to see if new consumers
5 came in, which we're dying to do so. The results were
6 robust to all kinds of things that you can imagine.
7 Placebos never work for anything.

8 You may be concerned with whether our controls
9 are actually replicating what would have happened in the
10 treated store in the absence of these label treatments.
11 And given that we had that pre period, or at least we
12 have a lot of characteristics of the possible controls
13 at the treated stores, we can try to match or construct
14 a good control for each of these treatments, and that's
15 what I mean by creating this synthetic control method.

16 So we use the best match, best combinations of
17 all these controls that make the nice super
18 counterfactual that we're going to use, and we compare
19 the change in our treatment to the change in the best
20 controlled counterfactual synthetic control store.

21 And then we can see, okay, this difference
22 compared to the synthetic control isn't significantly
23 different from when we compare all possible placebos,
24 meaning a control to the best comparison to that control
25 also will have an effect, and what happens to our store

1 compared to all possible combinations of control stores
2 versus their best matched counterfactual.

3 So what we see here, for example this picture is
4 for the low fat label, and the red is the treatment
5 store. This is the difference in sales relative to its
6 best synthetic control, so if you don't know what that
7 synthetic control is again, it's just the best
8 combination of all 27 out there. And you create this,
9 so this is a difference in sales due to the treatment,
10 and it shows that less 27.5 units were sold per week of
11 these products in these low fat label stores relative to
12 its best counterfactual.

13 And the drop is larger than the distribution of
14 all these random changes when you put controls relative
15 to their best match. The change in their store is
16 larger than the distribution of these random changes.

17 The low trans fat labels, if you mix similar
18 pictures and it's in the paper, show an increase of the
19 treatment relative to this best counterfactual control,
20 and the low cal labels again here in this approach show
21 a significant increase. So this again confirms the
22 results of the definitive specification.

23 Recap: Consumers purchases are affected. On
24 average there's no effect but if we go into these little
25 sub treatments we find effect. And the effect seems

1 consistent with some that it's not just hanging a little
2 piece of blue paper, people. Some claims effect people,
3 some have negative, some have positive, so it looks like
4 some of the information was somewhat incorporated.

5 The disclosure where it was coming from also had
6 an additional effect. More nutrients on the label have
7 smaller impacts than a single claim label. Do consumers
8 make inferences about the content of products that had
9 no label? Generally, no, except to the low fat
10 treatment.

11 How am I on time, two minutes?

12 DR. BAGWELL: Almost done.

13 DR. VILLAS-BOAS: So if I have two minutes, I
14 can still say that this is a reduced form approach.
15 There is evidence consistent with consumers not fully
16 incorporating currently available nutritional
17 information. You can look at the trans fat that, when
18 we repeated, had an effect, so maybe it's new consumers.

19 We will be able to see this very soon when we
20 look at the micro data, but there is evidence that at
21 least some of these treatments that had existing
22 information did have a change.

23 Consumers may have taste preference with respect
24 to certain nutrients. I have an FDA person present so I
25 don't want to emphasize bullet 3 because there is an

1 effect. It's become significant with it. I don't have
2 anything to say about that. I'm just saying we're in
3 Washington so I didn't do it. I know nothing.

4 So just to give you a preview, with the store
5 level data, you can just estimate a demand level for
6 these products. And then from the demand model you will
7 have a coefficient on a label that was added
8 orthogonally to prices, so when we divide that
9 coefficient that's marginal utility by a certain level,
10 by the marginal utility of price, you get a willingness
11 to pay for a certain attribute.

12 If you do this, the no trans fat label has a
13 willingness -- this is the point estimate; there are no
14 standard errors -- to pay 62 cents. And for the low fat
15 labels, a negative willingness to pay so consistent with
16 the definition.

17 From the household level data, just very fast
18 and very preliminarily, we can look at a lot of
19 measures. We try to see, does purchase frequency change
20 pursuant to the treatments? We didn't find an effect.
21 We find that a higher percentage of new consumers
22 respond to the treatment, and the effects seem to
23 dissipate after the treatment period.

24 Again this is very preliminary, and we would
25 like to estimate something more thoroughly with these

1 household level data.

2 Thank you very much, and I will leave the floor
3 to the discussant.

4 DR. BAGWELL: Thank you very much. The
5 discussant is Jayachandran Variyam.

6 DR. VARIYAM: Okay. So, first of all, thank you
7 for inviting me to comment on this very strong
8 experiment. I learned a lot from it. And basically in
9 this line, I will just go down to the bottom point to
10 say that information plays a small role in the whole
11 purchase decisions that people make, but the seemingly
12 minor impact is somewhat puzzling in the medical work.

13 There are many reasons why we don't find the
14 significant effect for information, and this interacting
15 with the consumer period. One could be simply the
16 complexity of information and the processing costs,
17 which was kind of the focus of this paper.

18 Then there is of course the overload of
19 information, a lot of competing claims, the number of
20 products, and in fact nutritional messages are notorious
21 for being conflicting in many ways. There is of course
22 producer strategy, which can shroud a lot of activities
23 which they do if they have a product that they need to
24 kind of keep away from the revealed information.

25 There are behavioral factors, which was

1 mentioned earlier. People may be better informed, but
2 there are self control issues and other cognitive issues
3 when it comes to actually making the decision. Then
4 when you look at the large population, you may not find
5 any effect, but there could be an effect within the
6 smaller populations, diabetics or hypertensive patients
7 for specific nutrients or higher education level.

8 Also when we look at some outcomes, we don't
9 find a net impact but that could be simply because
10 people are using the information to kind of make some
11 trades and adjustments in the purchase. And I think
12 that's kind of what we find here somewhat.

13 So the study objectives were in this case simply
14 to look at processing costs. They tried to use this
15 label so that it reduces the processing cost or
16 acquisition costs because it's a straightforward front
17 display shelf label and that would affect the choice.

18 Then there are some other variations with the
19 index and whether they provide a single piece of
20 information or multiple nutrient information. There is
21 some credibility there with the FDA approval. In the
22 manuscript you say disclaimer. I thought the disclaimer
23 should probably be FDA approved. I don't think it's a
24 disclaimer, a very basic low fat standard based on the
25 FDA standard.

1 Then there is, of course, the question of
2 quality/taste trade-off. From a public health point of
3 view, you provide information expecting a certain
4 behavior. Being healthy is the only kind of
5 consideration involved, but people may have other
6 perceptions for these labels, and that becomes too very
7 clear here. That's why the low fat label kind of
8 misfired and people actually substituted away from it
9 when they saw it.

10 So the design: The way I understood is five
11 treatments, some of them low calorie, low fat with FDA
12 approval and so forth. But one question I had is kind
13 of fundamental was: Why did you focus so much on low
14 fat label? Because I thought it was more of a 1990s
15 issue immediately following all the standards set for
16 making nutrient content claims and health claims.
17 Because more recently and subsequently trade shows that
18 being total fat or being low fat is getting less
19 attention compared with the type of fats and especially
20 more focuses on calories.

21 I'm not expecting to go back but the low fat
22 label has been well researched. So if you looked into
23 the trades a little bit, at least you should look and
24 comment on that.

25 For example, I cite some examples here; low fat

1 labels produced lower anticipated hedonic ratings and
2 high fat labels produced higher hedonic ratings in
3 people who are evaluated eating some kind of soup.

4 Now, what happened after consumption is that
5 soups that were labeled high fat were rated as more
6 pleasant and creamier, surprise, than those labeled low
7 fat, independent of actual fat content. So there is a
8 ton of research showing that people, in fact, if they do
9 consume low fat or low calorie, after some time, that's
10 like a prelude.

11 Then they eat something else, and they eat more
12 of it because they ate less earlier, they got lower
13 calories earlier. So the whole dietary issue is replete
14 with these kind of games people play with themselves and
15 information.

16 And then there's Yeomans economic subject
17 report, where I'm from, looking at new productions.
18 Immediately after the NLEA, when this low fat label and
19 all became standardized, manufactures introduced
20 thousands of low fat products. Then by 1999 the number
21 of product introductions kind of tanked because people
22 were just simply not buying them.

23 But on the plus point, putting that low fat
24 label there kind of provides validation. There's an
25 additional piece that is very neat, and overall for the

1 studies, a very strong experimental set up because they
2 actually went to the stores and randomly assigned stores
3 to treatments.

4 And the stores are within the same price
5 division, so there are no other changes in how they set
6 the prices, and then they actually can do some triple
7 differencing, but then when you come to the actual
8 product, it's microwave popcorn. People make purchases
9 of bundles of goods. You can just think how consumers
10 show up and how much a particular visit of information
11 for a single product really carries over in terms of the
12 decision making.

13 It's kind of a challenge there, and in fact, in
14 the latest section of the paper, I thought you kind of
15 said that our treated product category is characterized
16 by relatively low volume of sales and high fluctuations
17 in sales across weeks.

18 Then perhaps there could have been other
19 products, but again on the strength side, it's an
20 extremely rich data, and you do a lot of robustness
21 checks, so there's less about the findings as opposed to
22 what you could have found in terms of other products.

23 And also one thing is that because of your
24 limitation with your grocery store chain, everything is
25 about low. It is not exactly comparable to the UK

1 traffic signal system because there, there is a red sign
2 saying, if this is not vehicle is recreational, then it
3 says stop. That information is not here, so people have
4 to infer, but they do make inferences. People do make
5 inferences when there is no label, at least in one case.

6 So the main result is overall providing this
7 label, there is no effect, but I thought that it's
8 pretty significant in the sense that all the information
9 from a public health point of view is that people should
10 be using it. It's low in calories, low in fat, no trans
11 fat or a combination of that, so people should have
12 moved towards that whereas it's a wash out, and the
13 reason is because of that low fat substitute.

14 So I thought it's again an interesting result,
15 and it just shows how difficult it is to kind of play
16 with the behavior when you look at these outcomes.

17 Now, when specific treatments are examined, of
18 course as you saw, low fat label reduced sales. I had
19 some questions about whether the treatments were applied
20 in all the stores or each treatment was allocated to one
21 store. It was not clear to me.

22 Also when you do that, when you build down to
23 unusual treatments and do the regressions, is there an
24 imbalance between the controls, just one store, then
25 there's one treatment store and then a whole lot of

1 control stores so I was wondering if there was an
2 imbalance there?

3 And also there is an issue that this is an
4 experimental set up, so I thought the strength of an
5 experiment was you're going with a set design and then
6 you limit your analysis right there. Once you have
7 exhausted your design, running further regressions with
8 the data within that purpose of the experiment, I'm not
9 sure how you are then diluting the strength claimed,
10 that this is a randomly designed experiment.

11 You could have the data and you can run that,
12 but I don't know whether it kind of dilutes the power of
13 the results, so that's something you may want to be
14 cautious about.

15 Of course, sadly the low calorie shelf label did
16 not affect sales at least in some of the initial
17 regressions. When you do some additional analyses, you
18 do see some effects, but by that stage, I'm kind of not
19 confident about that.

20 So that's the nice result. When you actually
21 have the low fat label and the competing product gets no
22 low fat label, the sales of that goes up, so it is clear
23 that, okay, when you see low fat label, you are saying,
24 I don't want that, I'm picking this, and I thought that
25 showed the consumer switch.

1 Just to take away and summarize: I thought it
2 was a very strong experimental study. Consumers use the
3 low fat label in an unexpected way, but it shows the
4 importance of market data in actually evaluating the
5 impact of some of these labels because it may not be as
6 you expect simply from a public health point of view.

7 Then there is some evidence that consumers have
8 attached to some credibility that it's a government
9 approved standard, and that's kind of in line with the
10 expectation. And then of course the other kind of take
11 away is that manufacturer and seller strategies do seem
12 to be working, although it was not the focus of the
13 experiment, but you had some additional data which you
14 could include. It shows that when they had some kind of
15 pink ribbons or when the boxes actually had those health
16 claims, sales actually went up.

17 So that shows they really dominate the effect,
18 at least the way I saw it, so it just goes on to show
19 how difficult it is to kind of play with information and
20 get something back, when all the things are going on
21 simultaneously.

22 So that's my comment. Thank you.

23 DR. BAGWELL: Thank you. I think all of the
24 clocks are in agreement now that we have run late so
25 please join me in thanking the presenters and

1 discussants for a very nice presentation.

2 (Applause.)

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

1 PAPER SESSION THREE: Studies in Empirical Industrial
2 Organization
3 AVIV NEVO, Northwestern University, Chairman
4 GREGORY LEWIS, Harvard University, "Demand Estimation in
5 Auction Platform Markets," Presenter
6 CHRISTOPHER ADAMS, FTC, Discussant
7 YING FAN, Yale University, "Market Structure and Product
8 Quality in the U.S. Daily Newspaper Market," Presenter
9 AMBARISH CHANDRA, University of British Columbia,
10 Discussant
11 MITSUKUNI NISHIDA, Johns Hopkins University, "Estimating
12 a Model of Strategic Network Choice: The
13 Convenience-Store Industry in Okinawa," Presenter
14 PAUL ELLICKSON, University of Rochester, Discussant

15

16 DR. NEVO: Why don't we start our third session
17 in this marathon of sessions that we have today. So,
18 the official title is "Studies in Empirical Industrial
19 Organization." That's the official; maybe the
20 unofficial will be "The Young and the Restless."

21 We have three young, brilliant scholars that are
22 going to give three great papers starting with Greg
23 Lewis.

24 DR. LEWIS: Okay. So I think I'm on. Thanks
25 very much. Yes, so this is the paper. It is "An

1 Estimable Demand System For a Large Auction Platform."

2 Its title might suggest to you that you are not
3 about to hear a very empirical paper. Indeed that's the
4 truth. This is going to be I think maybe the only
5 methodological paper on the program, but I'm going to
6 try motivating it. And I'm going to spend a bunch of
7 time motivating it, considering I have 20 minutes,
8 probably too long motivating it. And then I'm going to
9 rush through all the results, and you're not going to
10 understand anything, but maybe you will read the paper.

11 Auction mechanisms are used to allocate goods in
12 many large and important markets, online marketplaces,
13 EBay, the Chinese equivalent, Taobao.com, and online
14 advertising. You can think of key word advertising in
15 particular, huge revenues for Yahoo, Google and
16 Microsoft, massive, on the order of 5 percent of world
17 GDP.

18 Often auction mechanisms are used, Indian tea
19 auction, used car auctions, offline across the country,
20 the list goes on and on, so it's an important set of
21 markets.

22 Characteristics of these markets: It's often
23 the case that we have repeated auctions, that is to say,
24 we don't have an auction for an object once and then we
25 stop. We often auction objects in sequence. This is

1 true obviously of EBay. If you log-in, you will see a
2 lot of items up for sale, typically in sequence.

3 If you look at online advertising, it's almost
4 more than sequential. It's real time. You can
5 routinely update your budgets and your bids on various
6 key words. Procurement auctions arrive as and when
7 procurement needs happen.

8 The other thing that's important is these
9 bidders are persistent, so people will stick around.
10 They're not going to participate in auction, lose and go
11 away. They're going to lose and try and win a second
12 auction or a third auction, and perhaps they're even
13 going to want to win multiple objects. And these
14 markets are infinite horizon. They're not about to
15 disappear tomorrow. These markets persist.

16 Finally, goods being sold are heterogeneous.
17 And you can think of this in a lot of cases and key
18 words. There are different key words. There are
19 different key words in online marketplaces. If I'm
20 looking for a camera, there are a lot of different
21 cameras to buy, and highway procurement contracts come
22 in many different flavors, whether it's sort of
23 repairing a bridge versus repaving a road, large
24 projects, small projects, et cetera. So there's a huge
25 amount of heterogeneous goods, and people have different

1 preferences over these different goods, and that's not
2 surprising.

3 So given that these markets are large and
4 important, we would like to be able to answer some
5 questions about them, and if we had good models both of
6 theory and empirics, I think we could. So let me give
7 you a few applications. You could ask the question:
8 How much consumer surplus is generated by online auction
9 markets? And this is sort of a useful number to think
10 about in analyzing the value of E-Commerce.

11 A second question would be: How would we define
12 a market when allocation is via auctions? So, usually
13 what we want to do is we want to evaluate which groups
14 of products are close substitutes and provide some sort
15 of a test, whether a monopolist could raise prices by
16 some small increments without losing much demand. If we
17 want to get at this, we would like to have a demand
18 system, but we don't really have demand systems for
19 auction markets.

20 A third one which I've actually been asked about
21 before, and I have to say I don't know the answer, is
22 the question of how a seller should dispose of a block
23 of products.

24 So, for example, this came up in the case of
25 Hertz who wanted to know how to sell their used car

1 fleet, so every year they basically have a set of leased
2 cars, and they need to dispose of them because they're
3 too old to lease out to consumers anymore, so they sold
4 them into large off-line used car markets.

5 One company that runs this type of auction is a
6 company called Mannheim. Another company called Odessa
7 has a platform for this, and they wanted to know whether
8 they should just try selling them in one week or if they
9 wanted to kind of dispose of them very, very slowly,
10 over a timeline.

11 They had storage costs, so it would be nice if
12 they could get rid of them in one week, but they thought
13 these products would compete with each other and drive
14 down prices so they wanted to think about what an
15 optimal policy would look like.

16 Here's another one. How much should a seller
17 propose a new product will sell for? In discrete
18 choice, we have demand systems, and we project
19 evaluations down to characteristics. And that means
20 that we can say something about what we think the value
21 of a new good will be in terms of its characteristics.

22 We don't have that analogy in auctions. It
23 seems like it would be useful, especially since if I
24 want to think about trying to work up to how much people
25 are going to bid on a particular product that I'm

1 auctioning in public procurement. In order to do that I
2 really need to be able to have some measure of the
3 underlying cost of bidders in this particular state of
4 the world in terms of the characteristics of the
5 product.

6 Here's two more that I think are really
7 interesting. I think these are the most interesting,
8 but probably the hardest to address since you can't
9 address them with the current version of our paper, but
10 they're interesting nonetheless.

11 One is: How should a platform optimally set
12 fees? So I gave a talk to EBay a couple days ago, and I
13 told them about this, and they sounded very interested.
14 So you have a two-sided market; you want to set fees for
15 say listing products, but it's difficult to work out
16 what would happen if you changed your fees because
17 they're dynamic changes in participation on both sides
18 of the market.

19 If I raise fees, there are going to be less
20 people listing objects. When less people list objects,
21 fewer people are going to participate in the demand
22 side. That's going to drive further sellers out of the
23 market, et cetera. You would like to know where the new
24 equilibrium is and whether that actually raises revenue
25 in the long run or decreases it, and you can't

1 experiment. Large auction platforms run all kinds of
2 experiments all the time, but this is the case where you
3 can't experiment very easily so you would actually like
4 a structural model.

5 The last example: How do we think about mergers
6 between major suppliers? So to the extent that we think
7 search key words on Yahoo and Microsoft are substitutes,
8 what effects do we think that the merger in the key word
9 market should have? Sort of related questions like,
10 what does 'exert market power' even mean in an auction
11 context? It's not obvious.

12 For most of these things we have very good
13 intuition for fixed priced markets, we just don't have
14 that much intuition for in auctions.

15 Given these already interesting questions, why
16 aren't we answering them already? The answer is we
17 don't have very good models. On the theory side, we
18 have a huge literature on static auction mechanisms, and
19 what we don't have is a lot on dynamic marketplaces or
20 sequential auctions.

21 So sort of the classic model on sequential
22 auctions is the Milgrom and Weber paper in '82 but only
23 published in 2000. It talks about sequential auctions
24 of k homogenous goods to n bidders, and this is actually
25 a very, very elegant model that proved very, very sort

1 of elegant results about Martingale pricing, et cetera.

2 But it's a static model. The entire model can
3 be analyzed by the revenue of Collins theorem. There's
4 nothing dynamic in, and the minute you move to an
5 infinite horizon, you allow dynamic entry and exit, and
6 these result goes away.

7 I should say this has dominated the literature,
8 so everybody has written a whole series of papers on the
9 same theme and gone to the data with this sort of thing,
10 and it's just not right for these kinds of markets.

11 So the first problem is we don't know how to
12 think about multi product systems. We're used to
13 thinking in auctions about there being goods being
14 auctioned, not multiple goods. And secondly, these
15 dynamics matter for accurate measurement, so if I want
16 to measure these things precisely, I can't just take the
17 static model and say, oh, well, it's sort of right and
18 hope that things are going to work out. I'm going to
19 show you that actually it makes quite a big difference.

20 How about the empirics? The empirics it turns
21 out were not well suited, although again empirics are
22 very, very elegant, and we have a lot of elegance in
23 this estimation, structural estimation auction models.

24 It turns out that the way those models work is
25 basically like this. This is my opportunity for an

1 animation, so we have these auctions up at the top of
2 the screen. We have these different kinds of people:
3 football players, restaurants and traffic cops I guess,
4 and construction workers, and these completely different
5 sets of people go to these completely separate auctions,
6 and then they bid on them. This happens over and over
7 again, and this generates a data set for me.

8 Well, the data actually looks like there are
9 different goods being auctioned, X, Y and Z. There's a
10 group of people, some of them go to bidding on auction
11 X, and some of them lose, and they will try and go and
12 bid on auction Y because they kind of like auction Y.
13 Maybe a different group of people go and bid on auction
14 Z. So we have the same people bidding on different
15 goods, and the way they decide to bid depends on what
16 kind of preferences they have.

17 Put it in sort of a slightly less animated way,
18 a structural auction is defined for estimation with
19 cross-sectional data. The auction observations are IID,
20 and essentially there's a different population draw in
21 every auction.

22 Products are identical. Or if they're not
23 identical, because data typically doesn't have identical
24 products, we assume essentially that there's only
25 idiosyncratic differences across people, so some people

1 value all products more, but everybody agrees on the
2 valuations of the underlying characteristics. This is
3 sort of the long approach.

4 But actually the data is generally a panel, so
5 we observe the same bidders participate in multiple
6 auctions, and the pattern of participants reflects
7 preferences which says something about which goods are
8 substitutes. You don't have to think very hard to think
9 about a lot of cases in which it looks like a panel.
10 Procurement -- it looks like a panel. EBay -- it looks
11 like a panel. Oil track auctions -- they look like a
12 panel, et cetera.

13 So one way to show that this multiple product
14 thing is actually important is to think a little bit
15 about substitution, so this is sort of a very, very
16 naive way to think about substitution. I'm going to
17 look at digital camera auctions on EBay. I'm going to
18 look at the first auction that people bid in, and then
19 for the people who bid twice, and a lot of people don't,
20 but for people who go on and bid in a different auction,
21 I ask, what's the second auction they bid in? And I
22 divide them up into little categories and I record their
23 bids.

24 The categories are Canon digital camera; a Kodak
25 digital camera; Silicon Valley Peripherals, which turns

1 out to be the small outfit that makes very high mega
2 pixel cameras but very low quality typically, and they
3 sell quite cheaply. And then other is the last
4 category. It's the residual category. And you ask
5 where do people bid the first time that they bid?
6 That's sort of the rows, and then the second time is the
7 columns.

8 So what you will see is if you look at say the
9 Canon box over there, 62 percent of the time if you bid
10 on an auction between zero and 6 mega pixels, the first
11 time you'll bid again 62 percent of the time on the same
12 kind of camera, so within that product category.

13 So that's what we're looking at, so now we go
14 here. About 10 percent of the time actually these guys
15 go to a slightly better camera. The second time around
16 they try their hand at buying a camera between 6 and 7
17 mega pixels. Sometimes they go to one between 7 and 8
18 mega pixels. What we see they don't do very often is
19 actually step out of the Canon segment completely and go
20 and buy another camera, although if they do, it's likely
21 to be a 0 to 6 mega pixel camera.

22 So this is sort of a very naive kind of data
23 set. It's not clear what it's informative of, except to
24 say that people do substitute across products. So it's
25 not like you consider these as a completely separate

1 marketplace and say, well, the right model is just a
2 homogenous goods model, and I'm going to ignore
3 everything else, because there is a substitution across
4 categories and it turns out to be important.

5 Okay. So what are we going to do in this paper?
6 We're going to develop the stylized model of a large
7 auction market, stylized because we need to make a lot
8 of assumptions to actually make some progress here, and
9 this is sort of the first paper that does this, so we
10 try to simplify our lives a little bit.

11 So the sequential second-price sealed-bid
12 auctions are over an infinite horizon; so there's going
13 to be the sequence of them. There's going to be many
14 persistent buyers who are going to dynamically enter and
15 exit. There's going to be an exogenous supply for
16 simplicity, although it's important to think about
17 endogenizing if you want to do some of the applications
18 I'm thinking about.

19 We have multiple products. Importantly we have
20 unit demand, so you only want to buy a camera or a
21 computer, and this is sort of analogous to the discrete
22 choice literature which we're all familiar with in IO so
23 that's sort of where I'm coming from there, and there
24 are multi-dimensional private valuations.

25 So why is that? Well, you've got five kinds of

1 cameras out there. You should have a valuation for each
2 of those five kinds of camera, so that's where you're
3 getting multi-dimensional private valuations from.
4 We're going to characterize the long-run equilibrium, so
5 we're going to define an equilibrium concept which is
6 appropriate for large anonymous markets with a finite
7 buyer-seller ratio.

8 Most of those things are important, and we'll
9 see why later, and we're going to characterize
10 strategies and show existence of an equilibrium.

11 UNIDENTIFIED SPEAKER: Does the unit demand mean
12 you're thinking more of the things like EBay and less of
13 something like procurement?

14 DR. LEWIS: Yes, for sure. That's why I say
15 stylized. I mean, really this is quite a specialized
16 model, and you should definitely start modifying
17 assumptions. Key words is another one where unit demand
18 doesn't make that much sense.

19 We're going to analyze the resulting demand
20 system. We're going to show demand is no one
21 parametrically identified. We're going to provide non
22 parametric and semi-parametric estimation procedures.
23 We're going to show how you estimate when valuations are
24 projected on to characteristics. In fact, that case is
25 particularly simple.

1 It turns out you can run more or less in many
2 cases, and the reason you can do that is because your
3 observed variable. A bid is a continuous variable and
4 discrete choice. We get this horrible discrete choice.
5 It's actually not a very good dependent variable. This
6 is a really good dependent variable. It actually turns
7 out that OLS actually does fine. We're going to perform
8 Monte Carlo experiments to show this working well in
9 finite samples.

10 This last part I'm not going to talk about
11 today, but I'm just going to tell you that we do it in
12 the paper, and the paper is deliberately abstract.
13 We're trying to walk a fine line between worrying about
14 practical estimation issues, trying to do stuff that you
15 would actually estimate, but at the same time try to
16 keep the theory tractable so we're making a lot of
17 assumptions. I'm going to skip the literature.

18 So road map. I'm going to first tell you about
19 the model. I'm then going to tell you about how bidders
20 behave and what an equilibrium looks like, talk a little
21 bit about identification. I'm going to skip estimation,
22 and I'm going to skip the Monte Carlos, so just the top
23 three is the plan for today.

24 So the model has bidders and payoffs to start
25 with. So what are these bidders? They have private

1 valuations X that are defined over a finite set of J
2 goods. The distribution F has a continuous density, so
3 that F is a distribution of these J vectors of
4 valuations. These guys are going to be risk neutral
5 with unit demand. They only want to buy one good.
6 They're going to discount the future at rate θ .

7 The market is going to operate in discrete time.
8 Every period is going to be an auction, and what's going
9 to happen is that at the end of the auction, the winning
10 bidders exit with certainty. That should be true
11 because of unit demand. If I bought my camera and I've
12 got it, then I don't want to stick around. Losing
13 bidders are going to exit randomly at some rate θ .
14 Losing bidder payoffs are going to be normalized to
15 zero, sort of a dynamic games assumption.

16 Then new bidders are going to enter, and the
17 number of entrants depends on how many entrants there
18 already are in the market. The assumption in the paper
19 is basically set up in such a way that the market cannot
20 explode, so as a lot of people are in the market, then
21 the set of entrants gets smaller. There are going to be
22 fewer entrants, a lot of people.

23 They're going to draw the valuation then from F
24 on entry, so every period we have entry and exit.
25 Winning people exit, losing people exit randomly, new

1 people come in. How many new people is random.

2 Last, we're going to have a seller who posts a
3 new item to be sold M periods in the future, so what am
4 I thinking of here? I'm thinking of EBay. When do I
5 post my auction? I post my auction today to be sold
6 seven days away from now. And that's important because
7 it means that people can think about what's coming up
8 when they decide what to bid today, the same way that
9 they can look at a Sotheby's catalog and look at how
10 much they're going to bid on this item based on what
11 item they're going to be able to potentially purchase in
12 the future.

13 The auctions are going to be second-price
14 sealed-bid auctions. Bidders can either bid in these
15 auctions if they're live at this time, or they can just
16 not participate. Non-participation turns out to be
17 important, and I'm going to overemphasize it in the
18 talk, but actually it makes a difference to some of the
19 results.

20 The bidder information. The bidders have an
21 anonymized history of the game for the last K periods,
22 so they observed everything that happened for the last K
23 periods, but anonymized so it doesn't reflect identity.
24 That again is very similar to a lot of online markets.

25 EBay, for example, anonymizes user's names so

1 that you can't tell. In the paper we don't do it quite
2 this way. We do a slightly different version, but an
3 anonymization assumption is a good assumption.

4 Then together with the foresight of M upcoming
5 auctions, they have a window of T minus K to T plus M
6 that is public. I know everything that happened for the
7 last K periods. I know everything that's upcoming for
8 the next M periods. In addition to this public
9 information, I know my private valuation, so I know my
10 type.

11 So a generic definition of a strategy: A
12 strategy is a map from an information set to my decision
13 as to what to bid. So it's going to be beta. I'm going
14 to assume symmetric strategies. It's not unreasonable
15 given that everybody is asymmetric.

16 So this the where things start to get a little
17 more complicated. So it turns out that you could think
18 about a Bayes-Nash equilibrium of this game, but if you
19 did, you might hurt your head. It certainly hurts my
20 head, so a Bayes-Nash equilibrium requires bidders to
21 form beliefs about the opposing set of types, because
22 that's what ultimately going to determine my payoff.

23 How am I going to do against the set of people
24 I'm playing against who are going to be playing some
25 sort of the strategies? So the relevant object for me

1 to form beliefs about is a high dimensional vector of J
2 vectors, so how many people are there in the market
3 currently? For each of them, they have J vector
4 valuations. I should know that entire vector of
5 vectors, okay?

6 And given an initial requirement on the state of
7 the market and the type draws in every period, I should
8 solve a filtration problem based on the observed history
9 to work up what my current history is over the entire
10 set of opposing times. This is I think implausibly
11 complicated, and so we're going to simplify.

12 Here are the assumptions, and these are sort of
13 the main assumptions in the paper. If you buy them,
14 everything else you get. You get a lot of nice things
15 after these assumptions.

16 Here is assumption one: Bidders condition
17 beliefs on a finite state variable which is coarser than
18 the full history. So the state variable could be the
19 range of transaction prices in the last seven days, the
20 number of upcoming auctions in the next seven days.
21 Basically we don't have very strong restrictions on this
22 at all except that whatever this function is that
23 partitions information sets and states, it partitions
24 them into a finite number of states. And that
25 immediately implies that it can only be based on a

1 finite history, so you're going to get a recurrence
2 property.

3 Then what they're going to do with this
4 information is they're going to believe they are going
5 to face a draw from the long run distribution of types
6 in that state. So who am I facing when I bid? I'm
7 facing a set of people, which is a random draw from the
8 distribution of people in that state.

9 So, for example, if I saw the price in the last
10 ten days being between \$90 and \$110, I would kind of
11 think, okay, so I'm going to face a random draw of
12 people who are going to bid between \$90 and \$110, what
13 should I do? So, that's sort of the rough logic. I
14 think this assumption is almost necessary to do anything
15 useful empirically, so I don't feel very apologetic
16 about it at all.

17 The second one I feel somewhat more apologetic
18 about and I think more arguable. Bidders believe that
19 the state transitions are exogenous and first order
20 Markov, so the first thing that's important here is that
21 bidders treat the states as exogenous. That is to say,
22 I don't believe I can affect the state variable. That's
23 going to be wrong.

24 In fact, for example, say that the state
25 variable was what the range of transaction prices were

1 in the last seven days, and it was \$90 to \$110. If I go
2 and I bid \$60, the state variable tomorrow is almost
3 surely going to be \$60 to \$110 unless someone else does
4 something weird and out of equilibrium.

5 So they're going to be systematically wrong, but
6 in the large market, it's going to be very hard for them
7 to affect the state, and we can make that precise, and
8 we do make that precise in the paper. So, the idea is
9 that this is something that's defensible as an
10 assumption in the large market and probably not so
11 defensible in the small market.

12 Okay. So the formal definition of the
13 equilibrium concept then is a competitive Markov
14 equilibrium with respect to a coarsening function T that
15 partitions information sets into states. And the
16 requirements are that bidders use system metric
17 Markovian strategies to depend only on their own private
18 valuation and the public state variable, that they take
19 these state transitions as exogenous, and they correctly
20 anticipate the transition matrix so they're going to be
21 correct in equilibrium about this, although they're not
22 going to see their endogenized own effect on it.

23 They're going to have correct beliefs about the
24 distribution of opposing types, conditional on state,
25 and they're going to choose strategies that maximize

1 payoffs given these beliefs. So that was a lot of set
2 up. What does it get us? It gets us a really, really
3 neat characterization of equilibrium.

4 So look at the value function for a bidder, and
5 I'm going to explain it because I probably haven't
6 introduced any notation yet, or probably not much, so
7 value V of being in state S given that my private
8 valuation is X , i the maximum of my bid, any bid that I
9 have, of the probability I win.

10 What does that depend on? It depends on just
11 the distribution of the highest competing bid, G . All
12 I really care about is: Is somebody going to be able to
13 beat me if I bid B ? That determines whether I win. It
14 also determines how much I pay, so my payoff is I guess
15 my valuation on that particular object, whether it's
16 being auctioned at X minus the expected payment, which
17 is the highest competing bidder, if that bid is less
18 than B , or I could lose, in which case if I lose and
19 don't exit, I discount my future expected payoff. And
20 that's just the transition matrix times my value
21 function from the future.

22 Take a first order condition, you get the
23 optimal strategy. It looks like that. But in words,
24 which are much more intuitive, it says you should bid
25 your valuation less the discounted continuation value.

1 So what do I do in this market? I say how much
2 am I going to get in the future? I'm going to get on
3 the average a surplus of \$10. How much is it worth to
4 me? It's worth a hundred dollars. What do I bid? 90.
5 Valuation minus continuation value.

6 Why is this intuitive? Well, the argument is
7 that it's like a second-price auction where the winners
8 get the object, and the losers get the continuation
9 value. So I can turn it into a static second-price
10 auction by reformulizing the prices. So what's the
11 reorganization?

12 I say, suppose that you were in a static
13 second-price auction and the prize was value of object
14 minus continuation value if you won and nothing if you
15 lost, what would you do? You would bid the value of the
16 prize. So the value of the prize is value minus
17 continuation value.

18 So this is true. I should point out that this
19 really neat characterization is not true in the
20 Bayes-Nash equilibrium. We're missing winners' effects,
21 for example. There are more subtle things going on.

22 Buried in that expression is the long run, so
23 how do bidders evaluate their continuation values?
24 Well, I need to know something about this G_1
25 distribution, the distribution of highest competing bid

1 times given the state, but I need to know what the
2 equilibrium distribution of that thing is. This is a
3 dynamic marketplace. People are entering, people are
4 exiting. How do I know what that object is? How should
5 I expect people to have beliefs about it?

6 So this is what the second Lemma in the paper
7 does. It shows that given any equilibrium and any
8 initial measure on the type space, the market converges
9 at a geometric rate to a unique invariant measure of the
10 type space. So basically we're going to get to a
11 stationery distribution over types, and that means the
12 long run makes some sense.

13 I'm going to start this market and people are
14 going to play some strategies for awhile, eventually
15 they're going to end up at a point where there's unique
16 and variant measures of the types. And at that point
17 they're going to have very simple and well formed
18 beliefs.

19 The other thing that's interesting about this is
20 that once we get to the long run, the information
21 demands of bidders are not that strong. How should I
22 try to work out who I'm up against so I can look at that
23 object in the data? It's in the history.

24 How often would my bid have won if we were in
25 state S and just look at the data for the last 20

1 periods, 40 periods, 60 periods? Does it look like a
2 hundred would have been a winning bid very often? I can
3 work that out. So at equilibrium, at least this is not
4 unreasonable to think that bidders might be able to
5 think this way.

6 Then finally we prove existence, and existence
7 is easy if there's one product because the type space is
8 totally ordered, and it's hard in general, but we've
9 proven that in the paper.

10 So let's move on to the question of demand.
11 I've got this equilibrium concept of this neat
12 characterization of how people behave, and now I would
13 like to actually estimate demands. So, remember demand
14 is just willingness to pay, so I want the distribution
15 of valuations. And already, there's an interesting
16 question: Which distribution of valuations? Do I want
17 the entry distribution F , so the people who are entering
18 this market? Would I want the steady state distribution
19 of valuations which is different in general, and this is
20 something F^* , right? So random entry and exit means
21 that the state of people in the market in the long run,
22 the steady state is not the same as the set of people
23 who enter.

24 Both of these are identified from panel data.
25 So the data we're going to see is a sequence of bids for

1 each bidder. An observation then is an auction, a
2 product that they were bidding on, a bidder and their
3 bid.

4 We assume the econometrician knows how to
5 classify the public history into states, so the
6 econometrician knows what model these guys have of the
7 world, right? They don't care about the last seven days
8 or whatever, and we assume also the econometrician knows
9 the discount rate or can calibrate it.

10 So I'm going to show identification in the
11 really easiest possible case, which is one product and
12 one state, and the reason I'm going to do that is it
13 just turns out to be easier to follow as an argument.

14 DR. NEVO: We're out of time. Why don't you
15 take a few minutes just to wrap up.

16 DR. LEWIS: I'll finish. I knew this would be a
17 disaster in 20 minutes. Anyway, it's impossible. So
18 anyway, here's how I'll do it. Let me finish with
19 identification, and then I'll stop.

20 So bidders are going to bid according to their
21 bid minus the continuation value. The continuation
22 value can be explicitly written out. I could substitute
23 in the unknown. There was an X in the continuation
24 value I didn't know. I can substitute in bid plus
25 continuation value.

1 An important thing is that when I get this
2 rearranged version of the continuation valuation,
3 everything on the right side of that expression is known
4 in the data. It's stuff you can actually go out and
5 estimate very, very easily.

6 So once you have that, then you know the
7 valuations. If you know the valuations and you know
8 that they've bid their value minus the continuation
9 value, I just would add the continuation value to the
10 bid, and I get back the evaluation.

11 I'm done, and this extends to much more
12 complicated things, and since I'm out of time, I will
13 just say that not only can you do that, you can then go
14 and estimate it. You can go and estimate it with
15 characteristics. You can basically do this in a lot of
16 different ways, and you can get demand for these
17 markets. So that's the summary.

18 DR. NEVO: Thank you. Our discussant is Chris
19 Adams from the FTC.

20 DR. ADAMS: So I'm going to discuss
21 Greg's paper. Thanks for letting me do this. I've been
22 working on this question for awhile now, and I think
23 it's a very interesting one. We have a pretty good idea
24 of how to do demand estimation in markets where prices
25 are set by sellers. We don't have a particularly a good

1 idea how to do demand estimation where prices are set by
2 buyers.

3 So just to summarize what Greg said, he comes up
4 with this equilibrium concept, says that bidders are
5 bidding against his long run distribution of types. He
6 shows that that long run distribution exists. He shows
7 this nice structure on the bids. People bid their value
8 less an option value, and then he shows that we can
9 identify this distribution, this joint distribution of
10 values, which is a thing we're interested in -- demand.
11 We want to know what is your demand for multiple
12 products. And then in the paper he talks about
13 different ways that we could go about doing the
14 estimation.

15 One is we could just observe bids for the same
16 person in a bunch of auctions for different products.
17 Another one is he has this parametric thing, which I
18 didn't really understand, and then the last one is he
19 has a hedonic model which is a little different from a
20 standard one. I didn't quite understand how it's
21 different, but it's a hedonic model.

22 My two suggestions for this are not necessarily
23 an attack or anything on this particular paper. I think
24 Greg and Matt have done a huge effort here. This is
25 putting some foundations on a model or an environment

1 that we don't have a particularly good understanding of
2 how to do the econometrics, and we don't have a great
3 understanding even of what the theory looks like -- what
4 equilibrium concepts would make sense in this type of
5 world.

6 I think both Greg and I would like to go to a
7 world where we have this large market so that the
8 bidders are taking account of the future. They care
9 about the future because they have an option value on
10 the future, but they're in a market like EBay. There
11 are lots and lots of bidders.

12 It's sort of unreasonable to think that they
13 really care about revealing their types and how
14 important is that going to be, but when you write the
15 underlying game, and you write the underlying game that
16 Greg has, that comes up straight away, that it really
17 matters what the types are and what assumptions we
18 should be making about it.

19 It's not necessarily possible for this paper,
20 but one thought is it might be nice if we had put the
21 large in the model instead of in the equilibrium
22 concept. And then wrote down maybe a more standard
23 equilibrium concept and then sort of showed, well, as
24 the number of potential bidders gets large, as the
25 market gets large, that sort of standard equilibrium

1 concept moves to something more like what Greg is
2 suggesting.

3 And that's what I say here. One of the things
4 when I wrote this slide, I thought, well, we could just
5 go to a fairly standard equilibrium concept like we've
6 been using in other parts of demand estimation, so other
7 parts of empirical IO like a Markov type equilibrium
8 concept. What I hadn't realized was that it really
9 hasn't been worked out for these types of imperfect
10 information models, so that's an issue.

11 The other point that I wanted to make which is
12 not at all an attack on this paper, it's just saying you
13 should read my paper. In this paper it's saying, well,
14 we're going to observe all the bids for all the bidders
15 across all the items, and in my paper I look at, well,
16 maybe we can't really do identification like that.
17 Maybe what we could do is we could use auction choice,
18 and if we saw auctions occurring at the same time maybe
19 we could infer what people's valuations were for the
20 product that they didn't choose.

21 So what I have in my head is this choice. I
22 think of these two products as absolutely identical, but
23 there's many people in the world who do not. And I
24 wonder if we just ran hedonics, we could run nice
25 hedonics for bidding, people that bid on Chevys and

1 people that bid on Ford, but I'm not sure that's going
2 to tell us anything about the valuation that people who
3 bid on Fords place on the value of the Chevy, which is a
4 question we're interested in.

5 So the last comment is just I have a paper.
6 Email me. Thank you.

7 DR. NEVO: We have time for maybe one or two
8 questions.

9 Why don't we move on to the next paper and we'll
10 try to catch up, so the next paper is by Ying Fan, who
11 is listed as Yale but is now at Michigan.

12 DR. FAN: Used to be the Yale. Good times.

13 So the title of the paper is "Market Structure
14 and the Product Quality in the U.S. Daily Newspaper
15 Market."

16 So this paper studies the effect of ownership
17 consolidations on the U.S. daily newspaper market. A
18 standard merger analysis typically focuses on the price
19 effects only. In this paper I will take into account
20 both the price effect of ownership consolidation and the
21 effect on ownership consolidation on newspaper
22 characteristics.

23 So two research questions are addressed in this
24 paper. First is: What can we learn? For a specific
25 market, what can we learn from an anti-merger analysis?

1 For example, so here we have a little market
2 with five newspapers. These five newspaper were
3 originally owned by five different publishers, and
4 Knight Ridder, which is actually smaller, acquired
5 McClatchy. And as a result of this acquisition, two
6 newspapers went under one roof, and there are a lot of
7 cross-effects. Now they can be endogenized, so what
8 happened after this ownership consolidation?

9 So specifically what happened to the space of a
10 newspaper devoted to news, which is called news hole in
11 this industry? There is actually a reason, and what
12 happens to the number of staff opinion-section, what
13 happened to the number of reporters, and what happened
14 to the two prices involved in this industry, and
15 advertising rate for advertisers? And also what are the
16 welfare implications? So that's the first research
17 question. What can we learn from this anti-merger
18 analysis of a specific market?

19 The first question tells us what happened
20 depends on the specifics of the market structure, but
21 can we say anything general? So what's the
22 relationship? What's the correlation between the
23 effects of ownership consolidation and the underlying
24 market characteristics? So those are the two questions.

25 So to address the two questions, I set up a

1 model and collect data to estimate the parameters in the
2 model. Based on the estimates, I did two sets of
3 simulations corresponding to the two research questions.
4 And finally I will conclude, if I have time.

5 Since I have only 20 minutes, I'm going to
6 present my model in the graph, which is probably less
7 amusing, so the revenue of a newspaper comes from two
8 parts: selling newspapers to readers, the profit of
9 that part can be negative, and the selling of
10 advertising space to advertisers.

11 So readers care about the price, the
12 subscription price. They care about characteristics of
13 the newspaper, and their decisions determine the demand
14 for newspaper, so I use a multiple discrete choice model
15 to model this part. So that's price, characteristics,
16 and also the demographics of the reader affects the
17 utility that a reader gets from subscribing to a
18 specific newspaper.

19 By the way, i here is a household, J is a
20 newspaper, and T is the year. But since I do not have
21 individual level data, I do not have data on the
22 household level, so I use county demographics to capture
23 the mean part of that effect. And then of course we
24 have unobservable. We have this larger error, and to
25 capture the development of online data, Internet

1 penetration, the online data source, I allow a time
2 trend in the utility from the outside choice. So that's
3 basically the idea of the demand for newspaper.

4 So advertisers care about the price advertisers
5 are charged, which is called advertising rate. They
6 care about circulation of the newspaper and some other
7 characteristic of the newspaper, and their decisions
8 determine the demand for advertising. So facing the two
9 demand sides, there are two demand functions.
10 Newspapers are going to choose newspaper characteristics
11 in the first stage, and the two prices in the second
12 stage, price for readers, price for advertisers.

13 Three characteristics are endogenized, so there
14 are more characteristics considered in the estimation of
15 demand. Three characteristics are endogenized in this
16 paper. First is news hole, the space of a newspaper
17 devoted to news, the second is the staff for opinion
18 section, and the third is the number of reporters for
19 this newspaper as a proxy for how much of the news space
20 is written by its own staff rather than copies from news
21 agencies. So that's basically the idea of the model,
22 and I'm not going into detail.

23 So the model gives me five sets of estimation
24 equations. First is the mean utility equation. It's
25 similar to BLP, except exclusion is needed because it's

1 a multiple-discrete choice model. A household might
2 subscribe to multiple newspapers, but the idea is
3 similar. We can derive a mean utility equation, and
4 then we have advertising line. It's basically the
5 quality of the demands for advertising. There's a
6 separate estimation equation.

7 And then there are three sets of first order
8 conditions, first order condition with respect to
9 advertising rate. We assume that in the data, whatever
10 advertising rate I observe is the optimal choice. And
11 then the first order condition with respect to the
12 subscription price for readers. And the endogenous
13 three characteristics, so there are three first order
14 conditions with respect to the three different
15 characterizations. So that's the estimation equation,
16 and I take that to data.

17 So let me briefly mention the endogeneity
18 problem, because I'm now endogenizing price, PNR,
19 newspaper price and advertising rate and the
20 characteristics so you probably are wondering what are
21 the readers.

22 I am going to choose the graphics, so the idea
23 is the graphics predicts demand, which means it shifts
24 the profit function. Therefore it affects the
25 equilibrium result of the prices and the

1 characteristics.

2 Now, the question is: Okay, you mean that the
3 demographics affect demand. It's included, so it's an
4 excluded instrument. What is the excluded instrument?
5 First let me tell you what they are, and then I'm going
6 to explain them. So one set is demographics of all the
7 counties, and demographics of competitors. Let me
8 explain why the second set can be used and an excluded
9 instrument, and then why the first set is will be
10 obvious.

11 So suppose there are two counties. County one
12 has newspaper A and B, and the County 2 has newspaper B,
13 so the demographics in County 2 are going to affect B's
14 decision. And since A and B are direct competitors,
15 demographics in County 2 are going to affect A's
16 decision in the equilibrium because they are
17 competitors. So that doesn't go into the demand system
18 for A directly, and that's why it can be used as an
19 excluded instrument. So that's one bit about estimation
20 that I would like to mention, and I will skip all the
21 details.

22 Now, let's talk about data. So in terms of
23 quantity, I have county-level circulations for each
24 newspaper on the reader side, annual advertising line on
25 the advertiser side, prices and newspaper subscription

1 price for readers, and display advertising rate for
2 advertisers. So, in fact, there are two kinds of
3 advertisements. You see an advertisement next to a
4 piece of news, and that is called an insert.

5 It's basically something that comes along with
6 the newspaper. When you open your newspaper, they all
7 fall out, but I only have data on these pieces. And
8 when I deal with the product, that's the insert. I
9 don't have data in the more ad hoc way. If we have time
10 I can talk about that.

11 So newspaper characteristics: I have data on
12 number of pages, number of staff or opinion section,
13 number of reporters, and frequency. Even though I'm
14 talking about daily newspapers, but they are newspapers
15 that are delivered, published only five days a week,
16 which are considered daily newspapers as well, that can
17 potentially affect your delivery cost.

18 In terms of demographics, I have the number of
19 households in each county, percentage of population over
20 25 with a high education, with a bachelor degree or
21 higher degree, median income and organization. So
22 that's basically an introduction of what kind of data I
23 have.

24 I'm going to actually skip this slide. If we
25 have time we can come back. This is more like the

1 auxiliary stuff. I estimated the model so that I can
2 talk about the simulation.

3 So as mentioned, I have two research questions
4 in mind. One is: What can we learn from this anti
5 merger analysis for a specific market? Corresponding to
6 that question, as simulated, the result of ownership
7 consolidation of Star Tribune and the Pioneer Press
8 basically is the example showed at the very beginning.
9 And then the second question is: What is the
10 correlation between the effect of ownership
11 consolidation and the underlying market characteristics?

12 To answer something like a correlation, I need a
13 lot of data points, so what I did is I simulated the
14 effect of ownership consolidation. By the way, whenever
15 I say merger that just means I'm lazy. What I really
16 meant was ownership consolidation, not two newspapers
17 become one.

18 So to answer that question, what I did is I
19 stimulated the effect of ownership consolidation for all
20 the duopoly and triopoly markets in the sample, which is
21 the last year of my sample. That gives me some thoughts
22 that I can talk about correlation.

23 So let's talk about the first simulation first.
24 This market involves five newspapers. Star Tribune is
25 the biggest one. That's the home county, and Pioneer

1 Press is the second biggest one. Pioneer Press and Star
2 Tribune are the ones that went under one roof, and so
3 that's the coverage of Pioneer Press, and three other
4 small newspapers are involved in this market. One
5 covers here, here, here, and they are linked through
6 those two big newspapers. So here's the result.

7 What I did is I simulated the effect of
8 ownership consolidation without allowing quality
9 adjustment. Just ignore that, what happened. I show it
10 in Table 6. And then I stimulate the effect of
11 ownership consolidation with quality adjustment, with
12 the adjustment of the three characteristics, so there
13 are five findings. I'm going to mention three here.

14 First is no matter whether we consider quality
15 adjustment or not, prices of the two newspapers that are
16 involved in ownership consolidation go up. So, one
17 explanation of that is you can think about the price.

18 So now the owner of Star Tribune owns both
19 newspapers, okay, and then you can even endogenize as
20 the owner of two newspapers. Now I can even endogenize
21 the cross-effect, and the price cross-effect is positive
22 in the sense that if I increase the price, it's going to
23 benefit the other.

24 So they are strategic compliments, and that
25 explains why this is different and why this number is

1 smaller than this number and this is smaller than this
2 number. It is because once we consider the quality
3 effect and the quality factor actually affects the price
4 effect. Let's see why.

5 So if I talk about the effect of ownership
6 consolidation on the characteristics, what I find is,
7 okay, for this two characteristics, it goes down, so the
8 quality goes down, and let me first explain why -- let
9 me first explain why they go down and then let me
10 explain why these go up.

11 So they go down. The story is very similar as
12 to why the price goes up. If I increase the quality of
13 one product, I'm going to hurt the other. So its cross
14 effect is negative, so they are like strategic
15 substitutes. Now, the question is: This is another
16 characteristic, and why does this go up?

17 So the answer here is this characteristic is
18 different from the other in the sense that it also
19 affects the marginal cost; by the marginal cost, I mean
20 the variable cost of various circulations. So no matter
21 how big the circulation is, it's fixed, but if you
22 produce more news, that means more pages to be printed.
23 That means, for each additional household who subscribes
24 to the newspaper, the printing cost is higher. So this
25 characteristic is systematically different from the

1 other two because it also affects the marginal cost.

2 So now if Star Tribune increased the
3 characteristic in this demand, the quality is higher,
4 but at the same time the marginal cost is higher so it's
5 not necessarily an advantage for Star Tribune and not
6 necessarily an advantage for Pioneer Press. Remember
7 that there is pricing competition in the second period.
8 In this specific case, they actually go up, so that's
9 the second finding.

10 Third is if you compare the first row with the
11 second row, Star Tribune is the bigger newspaper and
12 Pioneer Press is the smaller newspaper, so you can find
13 that in both tables. Second row is bigger than the
14 first row.

15 So in English, that means the adjustment of the
16 smaller newspaper is bigger than the adjustment of the
17 bigger newspaper, so this is related to one estimation
18 result saying that this advertising demand is convex in
19 circulation.

20 So my profit function is kind of convex in
21 circulation. It means if I own two newspapers, I have
22 an incentive to shift circulation from my small guy to
23 my big guy for exactly the same amount of shift. There
24 is a loss here. There is a gain here, but because of
25 convexing, the gain is bigger than the loss, so I have a

1 little incentive to shift circulation from small guy to
2 a big guy.

3 Now I'm going to decrease the quality of the
4 newspapers and increase the prices, but I have this
5 incentive, so I'm going to decrease the quality of this
6 small guy by a bigger amount. So, I can shift the
7 circulation from the small guy to the big guy, and that
8 explains the asymmetry of the adjustment, basically the
9 difference between the yellow row and the green row.

10 So here is the welfare implication. Basically
11 what we find is that reader's surplus goes down: Up the
12 ownership consolidation, and we overestimate producer
13 surplus for 80 percent if we ignore quality adjustment.
14 So for different households in different counties that
15 are involved in this market, the effect of ownership
16 consolidation on their surplus is different. Ramsey
17 here is the home county of Pioneer Press, and that's the
18 one that's affected the most.

19 Let me spend two minutes talking about the
20 second simulation. So the second simulation, what I did
21 was I simulated the duopoly market in the five samples.
22 A star here is what is the effect of this ownership
23 consolidation per household reader surplus if we ignore
24 quality adjustment, and I just talked about the star.

25 A dot here is the same thing, the effect of

1 ownership consolidation on reader surplus when there is
2 quality adjustment. And the lines of assessment
3 basically says what the bias is before you ignore
4 quality adjustment, so that's the duopoly. This is a
5 triopoly market, and the dot and the star and the
6 segment means the same thing.

7 Let me go back. So I think there are three
8 variations that are interesting here. One is: Why are
9 the dots different? Some are here, some are here. Why
10 are the dots different. I sorted it by the dots. The
11 second question is: Why are the lines of the second
12 different? Why are the buyers different across markets?

13 Let me go to this graph, so notice the scale is
14 minus 25 here. The third variation is: Why is the
15 graph for duopoly different from the graph for triopoly?

16 So to answer this three questions, I did some
17 very simple regressions. Let me remind you that
18 basically I'm regressing endogenous variables. I'm
19 really just summarizing data here. So the first
20 regression, I regress basically where the dot is. I
21 regress where the dot is, the average per household
22 readers, this welfare change on a bunch of variables
23 that are supposed to capture the market characteristics.
24 So what I find is how much people care about, so the
25 first one is supposed to capture how much people care

1 about reading newspaper in general.

2 Look at the one stream. Suppose people don't
3 care about reading newspapers. You can change the
4 quantity or the quality on the price all day long.
5 Nobody cares. There's no effect, so obviously that
6 matters.

7 Also, how important is the overlap area to the
8 newspapers matters. We can look at another extreme.
9 Suppose there's no overlap here. Then there's no cross
10 effect to listen on the demand side; there's no
11 cross-effect be endogenized so there shouldn't be an
12 effect.

13 Also, the asymmetry of the two largest
14 newspapers matters. That's related to the convexity
15 star, and it's because the big newspaper that has a
16 bigger impact the welfare, that's why this one matters.
17 And also whether the existence of a competitor means the
18 welfare loss for readers, and this one is supposed to
19 capture how big the impact of it is, how important the
20 existence of this competitor is.

21 So basically this regression explained why the
22 dots are different and why the graph for the duopoly is
23 different from the graph for triopoly, and this was
24 supposed to explain about the lengths of the segment of
25 different cross markets.

1 So again whether there exists competitors
2 matters and whether people care about reading newspapers
3 in general matters, and the price elasticity matters.
4 To explain that, I'll probably need one more minute. So
5 I'm actually going to skip that.

6 So here is the conclusion. Do I have a minute
7 to read the conclusion, or you guys can read it?

8 DR. NEVO: Sure.

9 DR. FAN: So basically the message is quality
10 matters. In a merger analysis we care about the
11 characteristics, and the effect of a merger depends on
12 the underlying market structure as you can see. We see
13 these three variations, and the reader's welfare loss is
14 positively correlated with how much people care about
15 reading newspapers in general, and the overlapping of
16 the newspapers that are involved in the merger in
17 ownership consolidation. And that is correlated with
18 the asymmetry of the newspaper sizes and the number of
19 competitors.

20 And profit function is convex in circulation,
21 which means that a multiple newspaper owner or publisher
22 has an incentive to shift the circulation from its small
23 newspaper to its larger newspaper, but because of the
24 partial overlap, it won't shut down one newspaper.

25 So that's it about the paper.

1 DR. NEVO: Thank you. Our discussant is
2 Ambarish Chandra from UBC.

3 DR. CHANDRA: Okay. So let me summarize really
4 quickly what Ying just said in her paper. The goal of
5 the paper is to calculate the welfare effects of
6 newspaper mergers, and the highlight is that most merger
7 analyses is not just in media markets, and most markets
8 only examine price changes. Maybe that's more or less
9 reasonable in many markets, but in media markets,
10 certainly newspaper markets, it's very important to
11 actually consider quality changes or changes in the
12 actual composition of the product.

13 So that's what this paper does, while it's
14 clearly an important concern. And so also we've been
15 seeing over the last few years and accelerating the last
16 few months some pretty big changes in market structure
17 in media markets. So about 30 years ago, there were
18 about 1,600 daily newspapers in the U.S. but ten years
19 that was 1,200.

20 And actually I'm not sure what the latest
21 numbers are, but there have been shut downs and declines
22 of circulation across the country. We're seeing a lot
23 of one newspaper towns go to becoming zero newspaper
24 towns. We're seeing a lot of larger cities that could
25 actually support two newspapers, now just seeing one

1 newspaper.

2 So the latest example is Seattle where it
3 switched from being a two newspaper town to a monopoly,
4 so there's big changes in market structure across the
5 country.

6 What Ying does not so much look at changes in
7 the number of newspapers, she look more at ownership
8 consolidation, but it's the same issue. It's a great,
9 very timely question. It has very important policy
10 implications, so that's what this paper does.

11 So let mention some literature and then I will
12 highlight a couple of abstractions. So, one of the two
13 most important contributions is that the paper
14 generalizes earlier work, just not in newspaper markets
15 but also in media markets in general, which is that
16 household or families consume only one newspaper, only
17 radio station at a time, which is true of a lot of the
18 work in radio markets as well.

19 Now, that's a very easy assumption to make.
20 I've made that assumption myself in previous work, but
21 it's not realistic, and so one of the biggest
22 contributions of this paper is that it actually lays out
23 this very elegant and realistic framework for how
24 households actually consume more than one newspaper.
25 You can use the same framework for households consuming

1 more than one radio station, more than one TV station,
2 so that's clearly a contribution of the paper.

3 I'm going to skip the concerns, they're pretty
4 minor concerns, so that's one of the biggest
5 contributions.

6 The second one is the fact that the newspaper --
7 the paper endogenizes newspaper quality and allows a
8 merger or ownership consolidation to actually lead to
9 changes in the quality of the composition of the
10 newspaper, and that's exactly what we want to think
11 about. We don't want to just think about price effects.
12 If you think about newspapers, and you look on the
13 circulation side, who cares about prices.

14 Prices are in, some cases, set below marginal
15 cost. We're not really worried about increases in
16 prices on the circulation side when we see
17 consolidation. What we really are worried about
18 are things like reduction in opinion diversity or
19 reduction in topics covered, and that's exactly what
20 Ying looks at in this paper, so that's really important
21 for post-merger simulations. It's really important for
22 welfare analysis.

23 And again it's not just in media markets. In
24 most industries we assume that after mergers,
25 characteristics are fixed, and this paper does not do

1 this. It actually endogenizes quality, and so that's a
2 nice contribution to the literature.

3 So because this paper does so much I think
4 that's new, there's naturally a couple areas in which it
5 abstracts away from some issues. Let me just point
6 those out.

7 Actually both of these abstractions deal with
8 advertising, which is pretty much my own area of
9 interest so maybe that's why they stood out to me but
10 the first abstraction is that readers care only about
11 news, they don't care about advertising. There's a lot
12 of conflicting evidence on this in newspapers, in
13 magazine markets, radio stations, and TV stations.

14 You can imagine in radio and TV, it's very clear
15 that advertising is bad for consumers. They draw fewer
16 ads. In print markets, it's not so clear. Maybe they
17 actually like ads. Maybe classified ads in particular
18 might be valuable.

19 In any case even in newspapers it's not that
20 hard for consumers to just switch over or to skip over
21 the ads. And so it's not that strong an assumption,
22 especially given all that Ying is able to achieve by not
23 dealing with the advertising market on the circulation
24 side, so I wanted to highlight that that's one of the
25 abstractions this paper makes.

1 The second one is that the paper sort of assumes
2 that advertisers have the following behavior which is
3 that if you advertise in multiple media or multiple
4 newspapers, you keep advertising until the marginal
5 profit from doing so is zero.

6 Now, that's exactly right in any kind of
7 theoretical or rational framework. That's what
8 advertisers should do. You should treat advertising as
9 some kind of investment. If the marginal profit from
10 investing in advertising in the newspaper exceeds the
11 cost, you should advertise, and if that means
12 advertising in 20 different newspapers, you should do
13 that.

14 So that's the way we should think about it.
15 That's the rational strategy, but I don't think it's a
16 realistic strategy. I think in reality what advertisers
17 do is they have budgets. I think that's actually that's
18 very much the case not just for large national
19 advertisers but for even for small mom and pop stores.
20 They tend to allocate a certain amount of money and they
21 go to the agent and say, here's how much money we have
22 for advertising, get us the best deal, here is the
23 preferred demographic we want, we want let's say
24 affluent, educated consumers or poor minority consumers,
25 whatever it is.

1 In reality I think advertisers tend to have
2 budgets, and if they have budgets, then actually
3 newspapers will care about the advertising prices at
4 competing newspapers. In reality if they didn't, if
5 they followed the strategy that Ling lays out, which
6 again I may point out is actually rational, it wouldn't
7 matter, but I think in reality does matter.

8 So that's a second concern. Let me just point
9 out that actually the fact that Ling has relaxed a lot
10 of the assumptions on the circulation side by
11 allowing households to buy multiple newspapers actually
12 creates this problem. Now again that relaxing of that
13 assumption is good. That's a big advance, but if you
14 allow households to buy multiple newspapers, then you're
15 actually allowing them to overlap.

16 If households only consume one newspaper, then
17 every newspaper would be a monopolist with respect to
18 its own reader base, so you wouldn't have to worry about
19 prices at rivals when you're setting your own
20 advertising price. But if you actually allow households
21 to buy multiple papers, then there would be reader
22 overlap, and in that case advertisers might find it more
23 or less useful to go to a particular newspaper compared
24 to its rivals.

25 The same would hold true in other media markets

1 as well. So in particular, some media may dominate
2 others in terms of demographics, right? And it's
3 interesting to think about a framework where advertising
4 portfolios are kind of like financial portfolios where
5 they're all different assets or investments that you
6 could make, and depending on what kind of target
7 demographic you have, you might choose which of these
8 assets you want to invest in.

9 So I'm not sure it's something that you can fix.
10 I don't think it's even something you need to fix. It's
11 not the highlight of your paper. You're not concerned
12 about advertising, but it might matter for the welfare
13 calculations, and so I think it might be a good idea to
14 point it out.

15 Other concerns. Let me skip these. They're
16 pretty minor concerns. Let me go to the last slide
17 which is about counterfactual. So I think this is very
18 nice work. It endogenizes quality. It allows post
19 merger or post ownership consolidation quality or
20 composition of newspaper to change. That's exactly the
21 way we want to think about this. It's very nice work.

22 One last concern at this point is there's this
23 paper by Lisa George in 2007 which argues that when you
24 have ownership consolidation, you actually can arguably
25 increase welfare for readers because when one chain owns

1 multiple newspapers, it turns out that those newspapers
2 tend to focus on more topics. They tend to have more
3 variety or more diversity, and the reason is very
4 simple.

5 If you have competing newspapers in the same
6 town, a lot of what they are doing is just duplicating
7 each other's work. They're all focusing on the same
8 thing, which is local politics, local sports, local
9 crime, weather. They're just duplicating each other's
10 work. There's not really any real value added there in
11 most cases.

12 When you allow these newspapers to be owned by
13 the same firm or you shut one newspaper down, you're
14 just eliminating all of these duplicating functions, and
15 you're allowing the monopolist to now diversity, cover a
16 wider range of topics, more topics dining or gardening
17 or traveling or whatever it is.

18 So in some sense readers might be better off by
19 having fewer owners in the market. Now, that's not the
20 last word on the subject, but that's a concern and
21 that's something this paper doesn't address because I
22 think in the paper what you have is you've got ownership
23 consolidation. You have on the demand side that readers
24 value having more reporters.

25 When you've got consolidation, the number of

1 reporters drops, and so you would conclude that
2 therefore reader welfare goes down. But what really
3 matters is the allocation of these reporters for
4 different topics, and if the newspapers are now covering
5 more topics or the same number of topics, then it might
6 be optimal from a welfare point of view to actually have
7 consolidation, to eliminate all of these reporters who
8 are not adding any value because they're covering the
9 same topics.

10 And so that's not something this paper gets at
11 either, so now again, all that will do I think is just
12 put a lower bound on the welfare loss if you were to
13 consider that issue so I'm not sure it would change
14 anything. And again I don't think it's something you
15 necessarily want to address or you want to necessarily
16 address in this paper. There's too much else going on,
17 but it's something you might want to just acknowledge,
18 so the fact that mergers might actually increase
19 efficiency by eliminating those fixed costs okay.

20 That's it.

21 DR. NEVO: Thank you. Any questions? Okay.

22 DR. SCHMIDT: Dave Schmidt, FTC. I was
23 wondering if you allow for any price discrimination
24 geographically in your model? I mean for subscribers,
25 it would be pretty easy to identify neighborhoods where

1 there are significant overlap between the papers, and
2 you can imagine pretty fierce competition, just like
3 there is in overbuilds with capable television, that you
4 get pretty fierce competition when there's overlap.

5 But they needn't necessarily have that fierce
6 competition in the non-overlap areas, and I was just
7 wondering if you thought about extending in that
8 direction? And I was also wondering how that might
9 influence your instruments using the sort of non-overlap
10 county's demographics, how that might affect it.

11 DR. FAN: Price discrimination does exist on
12 both sides. On the reader side and on the advertisement
13 side. On the reader side, I'm not too concerned because
14 in the data I can tell whether there exists a difference
15 between one price and outside price, every newspaper
16 uses that price, very few newspapers use that price
17 discrimination.

18 What I'm actually more concerned with but I
19 didn't go over in my presentation because of the time
20 constraints is advertisers, that there's all kinds of
21 price discrimination, frequency discount, whether you
22 want advertisement on page A or page Q. It's totally
23 different.

24 And the data I have is the highest possible rate
25 you would pay. If you go to a newspaper for the first

1 time, say I want to publish a little advertisement of
2 one column each, that's a price charge, so that's part
3 actually is where I'm concerned but that's the only data
4 I have.

5 So on the reader side I'm not that concerned.

6 DR. NEVO: Any other questions? Let's move on
7 to our last paper. It's Mitsukuni Nishida. I hope I
8 didn't butcher that too badly.

9 DR. NISHIDA: Is there a pointer here? Thank
10 you for having me here, and let me start with
11 motivation, so in wide range of industries, we observe
12 multi-store firms being store locations. The examples
13 include Family Mart, Lawson, and convenience store
14 industries in Japan, where I studied, or in the U.S. we
15 see Wal-Mart, Target.

16 And the two major features for those multi-store
17 firms is locations. The first one is the headquarters
18 of those firms tried to internalize a trade-off due to
19 clustering its own stores, and let me be clear by what I
20 mean by this trade-off.

21 So suppose we have nine contiguous cells in one
22 region, and headquarters designs a number of stores for
23 each cell. If you increase the number of stores in one
24 particular cell, like in market or cell one, then you
25 might expect that the sales at the store might be

1 decreasing as the number of stores you put increases.

2 At the same time on the cost side, you might be
3 able to save costs of delivery of the cost of
4 advertising by co-locating, and the trade-off can occur
5 within a cell or across cells. I call each cell a
6 market, although it's kind of confusing because demand
7 and cost are not isolated so that's the terminology that
8 I'm going to use for the rest of my talk.

9 The second feature is that when I talk to the
10 industry people, often they recognize that rival chain's
11 decision of where to locate the store. The first
12 question in this paper is to understand the observed
13 network choice, so namely if we see the observed store
14 network choice, what can we learn about the underlying
15 primitives that would generate the store networks.

16 And especially I'm interested in if we can
17 explain the store networks as the outcomes of the game.
18 And this relates to the second research question I'm
19 asking, which is: After we know about the parameters
20 and distribution shock, can we predict new store
21 networks after two chains or two stores merge?

22 This is related in motivation in the sense that
23 in a typical merger evaluation, the regression also
24 seems to focus on changing price, so this is an actual
25 case in Staples/Office Depot merger, firms that sell

1 stationery goods, and the FTC challenged this proposed
2 merger because they predict prices too high.

3 But I think what missing in this argument is
4 what would happen to the store configuration after the
5 merger, but I think it can be very important if the
6 change in store network changes the total profits of the
7 firm side. And for the consumer side, if there's a
8 change in number of stores, and if there's a travel cost
9 to reach to convenience stores or the retail stores,
10 then it might affect consumer's welfare.

11 So what I want to do in this paper is I want to
12 propose a new framework to estimate a game in which two
13 model firms choose a store network. So, if you think
14 about the industry in two stages, in the first stage,
15 after the merger they choose a location, and then in the
16 second stage, they set the price. So this paper does
17 not look at the second stage; it's more focused on the
18 first stage, which is consolidation.

19 So before I talk about the detail of my model,
20 let me just mention the potential difficulties when you
21 deal with this chain entry game. So suppose we have 16
22 contiguous cells and we can construct each model store
23 firm's decision as choosing a vector with dimension 16.

24 So if you think about Family Mart's decision of
25 how many stores to put in and you allow up to four

1 stores, then you have five choices for each cell. So
2 the total number of model store networks is five to the
3 16. And if you think about your competitor's decision,
4 the number of possible outcomes of the game is you have
5 to multiply this number with the same number. So even
6 in a small number of markets, it can easily become
7 intractable to solve for the profit maximizing vector or
8 to find the equilibrium of the game.

9 There's a paper in 2008 that studies K-Mart and
10 Wal-Mart's choice of store locations, and what I'm
11 adding in this paper is now a firm is allowed to decide
12 not only where to locate, not only whether to enter or
13 not enter in a particular market or cell, now they can
14 decide how many stores to enter in each of those cells.

15 By doing this the benefit is that by having
16 multiple stores in the same market, we can actually
17 think about a trade off of clustering within the market.
18 And by construction, if you only have one choice, you
19 don't have this trade-off, which is I think the
20 fundamental feature of such industries.

21 So basically this is the conceptual change that
22 I'm making to the literature and there are two
23 methodological improvements that I'm making.

24 The first one is: We have seen that solving for
25 the equilibrium can be difficult as a two dimensional

1 problem, so I use algorithms theory to reduce the burden
2 of solving for the Nash equilibrium, so this is the
3 first one.

4 And the second thing is I integrate the chain
5 entry model with post-entry outcome, mainly revenue in
6 my paper, and I'm correcting for the selection of
7 entrants. I will talk about in detail in later slides.

8 I applied this methodology to convenience stores
9 in Okinawa. Okinawa is an island. This is a nice data
10 set that in the sense that in this industry, we observe
11 informal pricing across stores within the same chain,
12 not only in Okinawa but at the national level. So that
13 for this industry we can construct the decision of what
14 would happen to the change in price after merger. I
15 also studied the deregulation question, which if I have
16 some time left, I will touch upon.

17 Let me briefly mention empirical questions. The
18 first one is the trade-off that I mentioned, the
19 trade-off of cross link, which is cost savings and
20 business stealing effect tends to be a very important
21 consideration for a chain. And that predicts as a
22 second finding which is after a merger, the acquirer
23 tends to increase the number of stores in city centers
24 in which the population density is very high, but they
25 reduce the number of stores in suburbs, which is

1 seemingly puzzling because what we expect from the
2 intuition is after merger, they reduce the number of
3 stores and possibly increase the price. So I'll talk
4 about why that happens in my project.

5 Okay. Let me briefly mention that in studying
6 entry models, traditional players have the assumption
7 that markets are independent both in terms of demand and
8 cost.

9 So the recent trend of literature that tried to
10 relax this assumption. And also my work is related to
11 literature that tried to integrate the entry model with
12 post-entry outcomes, and yes, let me go to the model.

13 We have two players, Family Mart and Lawson.
14 The biggest guy is Family Mart in Okinawa, and the
15 setting is complete information while simultaneously
16 moving. Each chain chose a vector of NI, and each
17 strategic profile NI, and each element is the number of
18 stores for each cell for a market.

19 Now, so their objective function is total
20 profits for chain i , which is a summation of market or
21 profit function. And over every market, and in this
22 framework, the Nash equilibrium is defined as a pair of
23 store networks that have responses.

24 So let me briefly mention the profit function at
25 the market level. Although this looks complicated, it's

1 actually simple. The profit is just revenue minus
2 costs. And then the expendable revenue is comprised of
3 the business, three types of business stealing effect.
4 This revenue deduction is coming from my own other chain
5 stores or my rival chain stores or the local stores. So
6 this part is store level sales, and this business
7 stealing effect can occur within a market or it can come
8 from adjacent markets, so same thing for all types. And
9 I have revenue shock.

10 So the cost equation is in the same manner, so
11 this part is the store-level cost of chain i in market
12 M , and I have two types of cost savings. The cost
13 savings can come from the same market, the presence of
14 own-stores, own-chain stores in the same market or the
15 presence of own-chain stores in adjacent markets.

16 And I have other variables, other terms that can
17 affect my cost, such as distance to distribution center
18 from my market, or if the market is in a zoned area.
19 And I have cost shocks.

20 So let me explain the motivation for the multi
21 store model that I have. I think one of the biggest
22 features of the model, so suppose you observed very
23 dense cells in terms of number of stores, the binary
24 choice model would model cells with no more than two
25 stores, so we are going to model the yellow markets.

1 And in my case, since I allow multiple stores in the
2 same cell, clearly the first thing to mention is the
3 better data coverage, but more fundamentally.

4 So I mentioned that by having multiple stores,
5 now we can look at the trade-off between stores of the
6 same chain within the same cell, okay, and the third
7 thing, which might be of practical importance which is
8 that by monitoring the old market, we can endogenize the
9 types of model store firms in all markets, and then we
10 can answer the question of what would happen to the
11 store network if two chains merged.

12 So this is the actual data set in Okinawa, so
13 the blue points are the sea, and this is part of Okinawa
14 island, and you can see many markets with more than one
15 store for each chain, okay.

16 But you might say, okay, why don't we just sweep
17 the market. Well, whether we have finer definition of
18 grids so that we can deal with the binary choice model,
19 so then we'll talk about the restrictions that will be
20 required for me to use competition algorithms, and it
21 turns out that you need to impose a strict restriction
22 for the binary choice model, and let me go to the hard
23 idea with competition change.

24 So I have two algorithms. One is to search for
25 the profit maximizing optimal choice an given my rival's

1 choice, and the second one is solving for the Nash
2 equilibrium.

3 Let me start with the second one, so I am not
4 going into the detail of the supermodular game, but let
5 me emphasize that it turns out that the chain-empty game
6 that I have described is familiar when the path is a
7 business stealing effect across cells, if it's smaller
8 than the cost savings cost across markets or cells.

9 So notice that there's no restriction for the
10 trade-off of cross-string within a cell, although I
11 should mention that although it's not on the slide, the
12 business stealing effect from my rival needs to be
13 negative to make it a supermodular game. The next thing
14 about the assumption game and you can actually use round
15 roving algorithms to compute for the Nash equilibrium.

16 So this step, I'm not going into the detail, but
17 this step is like my response. So the issue here is
18 that how do we compute the best response with the
19 dimension of the choice set? And we go to the next
20 algorithm. Go back to the first algorithm, which is to
21 use Tarski fixed point. They are recommended.

22 So suppose you are upgrading your choice set by
23 not only moving the choice of every market but you just
24 focus on the one particular cell, and you update for
25 each market.

1 So this is a function V , and if this function V
2 is increasing, then we know that the profit maximizing
3 store network choice has a lower one and an upper one.
4 So in this example, suppose we have only two markets and
5 the brute force way of finding the profit maximum store
6 network choice is trying 25 choices, but if after
7 computing and narrowing down by each starting from the
8 zero and zero and four and four and if you drive the
9 upper bound and lower bound, then you can actually
10 compete only for four points, that would dramatically
11 reduce the competition.

12 So I'm going to skip to data. In summation, I
13 use a method of stimulation, simulated moments, because
14 the model is not in closed form in the parameters.

15 So okay. So I construct a moment condition for
16 number of stores, and I do the same thing for the
17 revenue. And so I avoid the selection problem by
18 simulation, namely I construct other cost equations
19 which are the revenue and also construct the number of
20 stores, and I stack up those two conditions and estimate
21 at once.

22 Typically the literature uses two steps in which
23 they first estimate selection and then they plug in the
24 estimated parameters or the barriers into outcome
25 estimation, so I do it in one step.

1 I have no time to talk about the details of the
2 estimation, but let me emphasize that if you have my own
3 chain stores in the same market, it means that your
4 revenue decreased by 20 percent of the total sales,
5 which is quite large. But you can see that if you have
6 additional stores in adjacent markets, of the same
7 chain, it does not affect your remedy margin, so demand
8 is much more localized in this one grid.

9 For the cost equation, the key parameters is
10 fortunately not statistically significant for this
11 specification, but let's take this as if we know that
12 this is true and what happens for the after merger.

13 So the way we calculate this counterfactual is
14 that suppose all the demographics and the local chain
15 stores are exogenous, and I use the same summation
16 models that were used for the estimation, and so for the
17 monopolized choice, profit maximizing choice, and right
18 down here is the population, a number of people living,
19 so you can see that this is a city center.

20 Then you can see that in city centers, they're
21 going to increase the number of stores, but in most
22 suburbs or other areas, they reduce the number of
23 stores. And let me explain how I got this result; so
24 suppose this is a city. Suppose this is the city
25 center, and I used to have rivals in four markets but

1 after the merger, they became my chain stores, so I can
2 enjoy the cost savings from more markets so that can
3 affect the business stealing effect by adding more
4 stores in the same market, in the marketplace.

5 Now, that happens only in city centers because
6 if you go to rural markets, I don't have stores in
7 adjacent markets at all in the first place. So this I'm
8 going to skip the regulation, deregulation results.

9 So let me conclude. This paper, proposed a
10 modeling framework for estimation in which two chains
11 choose store networks. Let me just add that we can
12 think of this model to study other instruments such as
13 ATM locations or instead of choosing location in the
14 geographical space, we can think of choosing items in
15 product characteristic space, so this is related to
16 product bringing decision problems and the differences.

17 The nice thing about this I think is that
18 instead of the monopolist choosing optimally their line,
19 we can have a competitor in the model, and I'm currently
20 working on two extensions. The current framework only
21 works for the case in which the number of players cannot
22 exceed two, so this is clearly a strong restriction to
23 make, so that's what I'm working on.

24 Thank you.

25 DR. NEVO: Thank you. Paul Ellickson is our

1 last discussant.

2 DR. ELLICKSON: This is like an economic
3 marathon, some of the people have already fallen down
4 and been dragged off the course, but the wind is at our
5 backs. So I will try not to take too much time.

6 Okay. So these views only express my own
7 opinions and not those of the Ellickson family or other
8 economists with last names that are Norwegian.

9 So this is a paper about understanding how
10 chains or more generally network entities compete, and I
11 personally think that's important. I'm interested in
12 that stuff myself, and it goes beyond just retail
13 chains. It also goes to how you think about starting to
14 endogenize the product characteristics of multi-product
15 firms, a step we've talked about a little bit already
16 today.

17 The trouble is that both modeling and estimating
18 these types of problems is very, very difficult, because
19 firms are essentially making high dimensional choices
20 knowing that rivals do the same. And so even if you
21 think about a problem like Pam Jia's where you have
22 Wal-Mart and K-Mart essentially making enter and don't
23 enter decisions in like 2000 counties, you quickly get
24 to choice sets and potential outcomes or physical
25 outcomes sets that have more elements than the numbers

1 of atoms in the universe.

2 And that means from a practical standpoint, what
3 I'll call full solution methods, which are essentially
4 solving for an equilibrium, and then predicting outcomes
5 of that equilibrium and then matching those predictions
6 to data, are essentially not going to be even feasible
7 if you try to do an exhaustive search that iterates over
8 all the possibilities because that will converge about
9 the same time that the sun burns out, and it won't allow
10 you to get published or get tenure.

11 So there are two basic options that you can
12 follow. One is the one that's being followed here,
13 which is to stick with the full solution approach and
14 then figure out a clever way to narrow the search in
15 some way, and that's going to be sort of this idea that
16 was introduced by Jia, and I'll talk a little bit about
17 how that works. And the other option is to work with
18 inequalities and essentially just estimate off the best
19 response functions of the first order conditions, either
20 by turning it into a game of incomplete information
21 using a two step estimator or going with a moments
22 inequalities approach. And I have a paper that looks at
23 Wal-Mart and K-Mart and Target from that angle, and if
24 you're interested, you can look that up online.

25 So let me just tell you about what the

1 contributions of this paper are. I have to tell you a
2 little bit about what it's building on, and so it's
3 building on this paper by Pam Jia, who was in
4 *Econometrica* in 2008. And Pam basically introduced this
5 sort of lattice approach where she said, look, if I can
6 show that you a game is supermodular, then I know it's
7 going to have a greatest and least element, so I'm going
8 to use Tarski's theorem, which is going to allow me to
9 start with an initial pre algorithm that is essentially
10 going to bound the set of things that can happen between
11 an upper and a lower bound.

12 I'm oversimplifying things a little bit, but
13 that's going to be a fairly quick exercise and, then you
14 do brute force in between those bounds to search for the
15 actual fixed point that characterizes the equilibrium.

16 So unfortunately, there are pretty strong
17 restrictions that you need to be able to get a
18 supermodular game. In Pam's case it means assuming that
19 the spillovers, meaning the net effect of both business
20 stealing and density economies, have to be positive, so
21 you can't test whether they are density economies. You
22 can just characterize how big they are.

23 The other big restriction is that you can only
24 have two firms, so in some sense you can think of this
25 as you need all these cross-partial derivatives to be

1 positive. In congestive models that's not going to
2 happen because another firm coming in is going to
3 negatively impact your profit, but there's a trick. You
4 can multiply their action by minus one, but it turns out
5 that trick only kind of works if you have two firms.

6 So for this reason, Jia focused on this Wal-Mart
7 K-Mart example, and she only included sort of Bresnahan
8 and Reesy small rural one horse town markets where these
9 guys have at most one outlet per firm, so that meant
10 there were going to be no cities in the model. And that
11 obviously introduces some selection problems and
12 endogeneity problems and you might think also sorts of
13 things that distorts the economic implications since you
14 think these firms are probably taking what happens in
15 cities into account in a pretty big way.

16 So what this paper does is it relaxes
17 assumptions in a way that allows you to have multiple
18 outlets per market, and that's obviously going to
19 greatly expand the applicability of this approach
20 because it's going to mean you can apply it in cities
21 where firms are throwing more than one dart at a time.

22 You're still going to have to allow or force the
23 spillovers across markets to be positive, but maybe
24 that's not so bad because that are more in this sort of
25 density spillover effect.

1 And apparently he's working on relaxing
2 assumption two, the only two firms at a time stuff,
3 which would be really big because then you could take
4 this beyond just duopolies to other oligopic situations.

5 The other cool thing that he's going to do is
6 provide a mechanism for incorporating some post-entry
7 revenue information, so more than just a discrete choice
8 latent outcome approach, but actually bringing revenues
9 in. And that's going to be useful or in fact key for
10 breaking up the net density economy and business
11 stealing effect into the two different pieces that make
12 that up.

13 Obviously it provides some additional moments to
14 watch and puts things in a dollar metric which is cool,
15 and it might in some ways aid in identification as well.

16 So I had a few questions and suggestions. The
17 first one is just an expositional one, which is that one
18 of the big deliverables of this paper is relaxing the
19 only one store per opinion assumption. Right now
20 there's no intuition provided for why that's okay, other
21 than some math that's actually buried in the appendix,
22 and it's actually a fairly big and surprising result and
23 one that Pam didn't foresee. In fact she directly said
24 in the paper, "You can't have more than one firm per
25 opinion," so it will be nice to put a little bit more

1 intuition in terms of why that's happening. We talked a
2 little bit by Email, and I think I'm giving it a little
3 bit more.

4 Now, the second thing I would like to push on
5 for Nishida to think about is how much and how exactly
6 is the revenue data helping in this particular
7 application? Because one thing that's unfortunate is
8 that he doesn't actually have data on individual stores
9 or individual firms in terms of revenue.

10 He has more aggregate stuff like what is the
11 total revenue in a particular zip code, the kind of
12 stuff you can actually get from the Census of Retail
13 Trade. So there's some aggregation and censoring stuff
14 that's going on that he's having to put a parametric
15 structure on, and there's sort of a question of labeling
16 on whether additional parametric assumptions are helping
17 or hurting in terms of the things that he's interested
18 in identifying.

19 I might say that even if you had store level
20 revenue data, it's hard to know exactly what you should
21 put into the reduced form through working with reduced
22 forms or reduced form revenue equation. And it's not
23 clear what should go in there that shouldn't go in to
24 the sort of "reduced form cost" or C times Q function.
25 They probably have a lot of the same things in there,

1 and so a way of sort of summing this up would be saying
2 it would be nice to have a little bit more discussion of
3 identification, what exactly is the variation that's
4 identifying things.

5 One just concrete and easy suggestion here would
6 be to report the merger counterfactual both with and
7 without the revenue data and sort of give us an idea of
8 how the results change in both cases.

9 So the last thing is not really about this paper
10 but it's sort of more just a thought that was troubling
11 me as I was thinking about this sort of stuff. We know
12 that simultaneous games or simultaneous static mod games
13 generally exhibit multi-equilibrium, and right now in
14 terms of estimation, there's basically three solutions
15 that are on the table.

16 One is to focus on something that's unique
17 across equilibria, like how many firms there are in some
18 cases, although it turns out that's not going to be very
19 useful in a lot of interesting problems. You can
20 arbitrarily change the timing to be sequential in some
21 way and get a unique equilibrium.

22 You could also impose or maybe even estimate a
23 selection rule, and that's what's being done here. Or
24 you can estimate like I said in the running off of these
25 preferences in qualities or first order conditions, but

1 the problem is you might end up getting set
2 identifications instead of point identification.

3 So what's used here is a selection rule, and
4 that's fine. That's going to give you point
5 predictions, and you may risk being misspecified, but
6 you will get point predictions whereas if you did
7 quality stuff, you will have less risk of being
8 misspecified, but you get bound. But putting aside even
9 the estimation stuff, it sort of struck me that as we
10 start estimating more and more complicated structural
11 either static or dynamic equilibrium models, we're going
12 to have to start thinking about what is the appropriate
13 or at least honest way to perform counterfactuals in
14 these models.

15 Because most people just report one equilibrium
16 that they either decided to focus on by the explicit
17 selection rule or they just let the computer find the
18 first one that it tried to find, and that's pretty
19 arbitrary. And we sort of know that in general, for
20 pretty interesting games they're going to be lots of
21 equilibria interest, in fact there's no known mechanisms
22 for necessarily finding all of them.

23 And so it's not that clear if we're trying to be
24 useful to policymakers what we should be reporting to
25 them because if we can't even enumerate the set of

1 possible outcomes, we can't really make probabilistic
2 statements about what is going to happen when we change
3 the parameter values.

4 So that was just sort of something that I
5 thought would be interesting to think about in this
6 particular venue given that there are policy interested
7 people.

8 So overall I thought it was a really nice paper.

9 DR. NEVO: Thank you. Any questions? I want to
10 thank all the authors and discussants.

11 (Applause.)

12 DR. ROTHSTEIN: Now you'll see Dave.

13 We've had a lot today. As Chris said, we've see
14 how the academic community is thinking about some of the
15 problems that the FTC faces. Dave Balan is on the front
16 line of those problems, and so he'll talk for a bit
17 about how he and we actually tackle some of these
18 issues.

19 DR. BALAN: All right. As Chris said, there was
20 an idea that maybe a lot of people who are academics
21 might like to see something about what we actually do
22 here in the Bureau of Economics, and we wanted to choose
23 a topic that had an enforcement angle and maybe also a
24 research angle, something about how we integrated some
25 research from outside of the Commission, and also a

1 little bit of research that we did inside the Commission
2 into a real-world enforcement agenda.

3 On the program, this session has some extremely
4 grandiose title like "Economics Analysis at the FTC,"
5 which is much too broad, so we picked one specific issue
6 (hospital merger enforcement) to focus on. There are
7 many people who could have done something similar to
8 what I'm about to do about a different industry or a
9 different subject, which leads to the question of how it
10 got to be me up here and not somebody else.

11 And the answer is this: Chris Adams had the
12 misfortune of sitting next to me on a plane once, and he
13 was like crammed up against the window, and I was like
14 right next to him, and he no doubt thought that maybe if
15 he just agreed to whatever I said, I would shut up, so
16 he offered me this slot on the program. Of course it
17 didn't work, I kept talking anyway, but he tried and so
18 here I am.

19 So hospital mergers. The government used to win
20 hospital merger cases until it stopped winning hospital
21 merger cases and started losing them. In the '80s and
22 '90s it lost a whole bunch of hospital cases largely on
23 geographic market issues, judges finding markets that
24 were 90 miles wide and stuff, and partly on
25 not-for-profit type issues of whether not-for-profits

1 could or would do anything bad.

2 So the government got the hint after it lost
3 enough times, and it got out of the hospital merger
4 enforcement business, so there was no enforcement for a
5 long time. During that time there were a great many
6 hospital mergers, and there was a decent amount of
7 evidence that a lot of those mergers had caused
8 anticompetitive effects.

9 Mike Vita and Seth Sacher had the first paper in
10 this vein (they're both here at the FTC), and Bill Vogt
11 and Bob Town wrote a survey article where they looked at
12 a whole bunch of evidence, a lot of which suggested that
13 hospital mergers had significant price effects.

14 I should have said at the beginning that these
15 are my views, not those of the Commission or of any
16 individual Commissioner, which is the case.

17 In the early 2000s, then FTC Chairman Tim Muris
18 decided that he wanted to get back into the hospital
19 merger business. The way he thought we should start is
20 with retrospectives, looking at hospital mergers that
21 have actually happened, several of them just studies, no
22 enforcement stuff, just retrospective studies, and then
23 to litigate a case, a retrospective case.

24 That case was the Evanston Hospital case. Of
25 course many of you here are familiar with Evanston.

1 Evanston Hospital had previously acquired Highland Park
2 Hospital in Evanston, Illinois, and the FTC
3 retrospectively challenged that merger.

4 We have this internal court presided over by an
5 administrative law judge and we had a full trial before
6 the administrative law judge, and basically won at the
7 level of the ALJ. The ALJ accepted that the merger had
8 caused a substantial price increase. As you can
9 imagine, since it's a hospital case, the parties made a
10 lot of strong claims about clinical quality
11 improvements, that they claimed were brought about by
12 the merger. Parties in hospital cases often make such
13 claims because, well, first of all, it's sometimes true,
14 and secondly, that's the kind of thing you would say if
15 you wanted to have a sympathetic claim that your merger
16 was going to save people's lives. The ALJ mostly
17 rejected these claims.

18 The ALJ ordered that Highland Park Hospital be
19 divested. Then there was an appeal back to the
20 Commission itself, and the Commission upheld the ALJ's
21 findings, but did not uphold the divestiture remedy.
22 They had a different remedy, which is a story that's too
23 long to get into, but the important point for our
24 purposes is that both the ALJ and the Commission agreed
25 that our basic evidence was right.

1 The empirical analysis that we did in the
2 Evanston case was very straightforward. It was a
3 straightforward difference-in-differences kind of thing.
4 We did difference-in-difference analyses for both price
5 and for clinical quality. The advantage of doing things
6 this way, the advantage of starting with a retrospective
7 case, is it's a way of saying, look, in the past we
8 tried to convince courts that mergers were going to be
9 bad using prospective analyses, and we didn't succeed.
10 If we can show retrospectively that a merger was
11 actually bad, we at least get courts thinking that there
12 is such a thing as an anti-competitive hospital merger,
13 which you might have come to doubt if you looked at our
14 string of horrible losses in prospective cases.

15 You might think that because our case used this
16 direct retrospective evidence of an anti-competitive
17 price increase, that our analysis could afford to be
18 sort of the atheoretic. But theory is still necessary,
19 even in a retrospective case. Even when you do a
20 difference-in-differences analysis, and hopefully you do
21 it right and it's a pretty straightforward thing, you
22 can't be absolutely sure that the merger was the true
23 cause of the measured increase.

24 The parties on the other side might have an
25 alternative even if they concede that there was a price

1 increase as found by the difference-in-differences
2 exercise.

3 And the parties in the Evanston case did indeed
4 have such an alternative explanation, which I won't go
5 into. Chris Garmon, who might be here, and I have a
6 short talkie piece about it in the ABA Economics
7 Committee Newsletter. So theory is important because,
8 in proper Bayesian fashion, the stronger your theory for
9 how a merger could be anti-competitive, the stronger
10 your priors are that the merger in question is a
11 problem, and the more likely you are to believe any
12 given evidence suggesting that it's a problem.

13 Moreover, we definitely needed to sort of retool
14 our theory for future prospective cases because after
15 all, the whole purpose of this retrospective case was to
16 tool up to get back into the prospective hospital merger
17 business. We needed a reboot of the theory.

18 And we did that, and we now have a decent
19 theoretical framework. I have to make a disclaimer here
20 that I am not -- in any non-public case, I'm not saying
21 that the following is what we did say or what we will
22 see because I don't get to decide those things, but
23 here's what I say and what some other people around here
24 say.

25 It's really pretty straightforward. You need a

1 model that respects the institutional facts that
2 patients don't face prices because of insurance, and
3 that prices are set by bargaining between the hospitals
4 and the insurance companies. Patients choose which
5 insurance company to go with on the basis of which
6 service offerings they have, but for the most part
7 patients don't face prices directly; of the choices that
8 their insurer offers, patients can choose any hospital
9 they want with very little difference in their
10 out-of-pocket cost, regardless of the differences
11 between hospitals in the contracted prices at which they
12 contract with insurance companies.

13 So you need a model that respects that feature
14 of hospital markets, and it turns out that you can do
15 that pretty nicely in a pretty simple Nash bargaining
16 framework, which has some deficiencies, but which has
17 most of the intuitive properties that you would want.
18 Hospitals that have attributes that people like get
19 higher prices. Hospitals that face less competition get
20 higher prices.

21 There's one little digression here which I think
22 is worth doing because it's a lesson in how easily you
23 can lose sight of something pretty simple when you're
24 deep in the muck of a case or of a complicated research
25 project. A number of relatively recent papers that

1 develops new methodologies for simulating hospital
2 mergers model hospital merger effects as coming from
3 "all-or-nothing" bargaining, meaning that after the
4 merger, the merged entity is going to say take all our
5 hospitals or take none.

6 It turns out that if "all-or-nothing" bargaining
7 is indeed how bargaining works, you can get a merger
8 effect if and only if the hospitals are substitutes,
9 which is exactly what you want. If "all-or-nothing"
10 bargaining is how the bargaining works, then you can get
11 a merger effect, and how big the merger effect is will
12 depend on how close substitutes the merging parties,
13 which again is exactly what you want.

14 This started to make people think, including
15 some very smart people, that if the negotiations weren't
16 on an "all-or-nothing" basis, then there couldn't be a
17 merger effect. This, of course, is wrong. Absent
18 "all-or-nothing" bargaining, a close relative to the
19 very, very most basic merger intuition still applies.

20 When two potato chip brands merge and there's a
21 price effect, it's not because the firms say buy both
22 kinds of potato chips or buy none, it's because of the
23 simple standard post-merger internalization of lost
24 sales. In hospital mergers, it's almost exactly the
25 same thing. Here the internalization comes from the

1 merging hospitals. It's just saying, hey, if I don't
2 get a contract with this insurer, some of the patients
3 that would have gone to me will go to my merger partner
4 and I'll recapture some of those lost profits.

5 It took a surprisingly long time for a lot of
6 smart people to realize this, to realize that just
7 because "all-or-nothing" bargaining is common in the
8 hospital industry and so our standard is necessary for
9 there to be a merger effect. And this caused some
10 confusion when we ran into a situation that required us
11 to think about merger effects in an environment where
12 "all-or-nothing" bargaining was absent. I think this is
13 a lesson in not losing the thread of what should be your
14 bedrock intuitions when you're sort of in the muck and
15 things are getting complicated.

16 Keith Brand, who is here somewhere back there,
17 and I have a paper which I'll talk about in a minute
18 because, of course, I have to take this opportunity to
19 flog our paper, but we have a model along the lines
20 described above.

21 Before we get to our paper, I want to talk about
22 these new methodologies that others have developed for
23 simulating hospital mergers. These new methodologies
24 are variations on the theme of a price-concentration
25 study but not the sort of price-concentration studies

1 that people used in the bad old days.

2 In the old days you would define a market, and
3 then you would calculate an HHI in each market, and then
4 you would regress prices on HHI. The unit of
5 observation would be a market, and you would regress
6 prices on the HHIs.

7 These guys who developed these new methodologies
8 are a lot cleverer than that, and most of the cleverness
9 lies in coming up with very innovative concentration
10 measures that don't require a market definition
11 exercise, and which give you a measure for each
12 hospital, basically a measure of market power for each
13 hospital.

14 The measures are designed to capture the
15 substitution between hospitals, and have other
16 attractive properties that I won't discuss here. Prices
17 are regressed on the concentration measure, and again,
18 the unit of observation is a hospital.

19 So, that's what all these guys do, and they
20 generally tend to find that a lot of their simulations
21 produce predictions of pretty significant merger
22 effects. It would be natural to think that we might
23 want to find out how well these simulation methods
24 perform.

25 That's what our paper is about. One way to do

1 this would be to do an empirical exercise where you
2 gather data on a bunch of hospitals, measure the actual
3 effects and then do the stimulation methods on the
4 pre-merger data and then see how close they come to
5 predicting the actual effects. That's a worthwhile
6 thing to do, but is very time and data intensive and
7 that's not what we do.

8 What we do is generate artificial data on
9 hospitals and consumers, and then we have a bargaining
10 model of the sort described above. Right now there's
11 only one insurance company in the model, but we'll soon
12 add more. We solve our model for equilibrium prices and
13 for consumer choices where consumers choose whether to
14 buy insurance and which hospital to use conditional on
15 buying insurance. Then we merge a pair of hospitals
16 together and re-solve the model. The difference between
17 the original vector of prices (one price for each
18 hospital) and the new vector of prices is the "true"
19 merger effect and, of course, it's in quotes because
20 it's all made-up data. Then we take the pre-merger
21 data, apply the simulation methods discussed above and
22 compare the predicted effect to the "true" effect. We
23 perform this exercise for a large number of simulated
24 mergers.

25 To review: You take the pre-merger data, you

1 apply the simulation methods, you get the predicted
2 effects, you compare them to the "true" effects, and you
3 see how well they do. The basic answer is they do
4 pretty well, in the sense that the predicted merger
5 effects are generally pretty close to the "true"
6 effects.

7 In our results so far the simulation methods
8 have some tendency to slightly under-predict the "true"
9 effects, but we're not sure if that will go away or not
10 when we make some planned refinements to the model.
11 Now, of course, it's fair to ask, what the utility of
12 this exercise is. Does showing that the simulation
13 methods do a pretty good job predicting the "true"
14 merger effects from our model with our made-up data
15 constitute evidence that they will do a good job
16 predicting real-world merger effects? If they did a bad
17 job predicting merger the "true" effects, would that be
18 a mark against the simulation methods or a mark against
19 our model?

20 I would offer a limited defense along the
21 following lines. Our model is basically reasonable on
22 theoretical grounds. Reasonable enough that if the
23 simulation methods did a very bad job predicting the
24 "true" effects that come out of our model, it would
25 represent a mark against the methods. In Bayesian

1 terms, if a big divergence between the effects predicted
2 by the simulation methods and the "true" effects would
3 constitute evidence against the methods, then a close
4 correspondence between the two constitutes some evidence
5 for it.

6 Now on to clinical quality. Quality is a big
7 deal in hospital merger cases for the reasons we've
8 already talked about. Parties always claim that their
9 merger is going to improve quality. Sometimes it's even
10 true. It's often not true, but as you can imagine, it
11 would be pretty difficult for the FTC to bring or win a
12 case where there are going to be substantial quality
13 improvements. Even if you believed that there were
14 going to be price increases as a result of the merger,
15 it would be pretty hard to go into court and say, hey, a
16 bunch of people are going to die, but here's this big
17 price increase, so big that it's worth blocking the
18 merger anyway.

19 Now, of course, this doesn't mean there's
20 literally no trade-off between price and quality. You
21 might imagine that if the predicted quality improvement
22 is small enough and the predicted price effect is big
23 enough, the latter would overbalance the former. Also,
24 there is a direct quality effect caused by the price
25 increase, which is that price increases cause insurance

1 premiums to rise, which causes some people to lose their
2 insurance, and there is real evidence that uninsured
3 people have worse health outcomes than insured people.
4 So for a small enough predicted quality improvement, the
5 quality effects of the price increase might actually be
6 enough to condemn the merger on quality grounds alone.

7 Broadly speaking, parties make two kinds of
8 claims about clinical quality. The first one goes along
9 the following lines. Hospital A is a big, fancy
10 hospital system, and Hospital B is a little, local
11 hospital. A will buy a bunch of stuff for B, that B
12 wouldn't have bought for itself, and B will be better as
13 a result. This story has the obvious flaw that we
14 usually think that, at least to a first approximation,
15 any service that's worth making at B is worth making no
16 matter who owns it.

17 If the benefits exceed the costs, then we expect
18 the investment to be made, and if not, not. So to make
19 a story like this work, you need to invoke differences
20 between the hospitals in the cost of capital or
21 something like that, which leads to other problems, so
22 this is the less plausible of the two types of quality
23 stories. The more plausible of the two types of quality
24 story is that Hospital A has some kind of built-in
25 advantage and that after the merger, that advantage is

1 going to benefit Hospital B.

2 This story might involve some sort of
3 conventional economies of scale claim; perhaps A has
4 already made a high fixed cost, low marginal cost
5 investment that B can just join, and there are some
6 stories like this that are not totally laughable. It
7 might also involve a claim that is really not laughable
8 and in fact has, in some cases, caused us to close our
9 investigations, which is that A is just better, and that
10 if the merger goes through some of that will rub off on
11 B.

12 There really is such a thing as knowing what
13 you're doing in running a hospital, and so these kinds
14 of claims deserve to be taken extremely seriously and
15 were taken extremely seriously in the Evanston case and
16 in the prospective hospital merger cases which I'll now
17 get to talking about.

18 So Evanston happened. We sort of won. We
19 didn't get the remedy we wanted but we sort of won, and
20 then what happened? Well, remember that the main goal
21 was to get us back into the prospective hospital merger
22 business, and there have been two post-Evanston
23 prospective cases.

24 The first one was right nearby in Northern
25 Virginia. A five-hospital system called INOVA wanted to

1 acquire an independent hospital called Prince William
2 Hospital in Prince William County. The FTC investigated
3 and ended up filing for a preliminary injunction in
4 Federal District Court, and after we filed, the parties
5 abandoned the merger.

6 That case had a really happy ending because
7 Prince William Hospital ended up getting acquired by
8 another big system, so to the extent that you believe
9 that there really were some benefits to this independent
10 hospital affiliating itself with a big system, those
11 benefits were realized which is a good thing.

12 Then there's Carillion. Carillion is a big
13 hospital system in southwest Virginia. The Carillion
14 case had a new twist because it was the first one where
15 it wasn't hospitals buying a hospital. Rather, it was
16 the Carillion system buying two freestanding centers, a
17 freestanding imaging center and a free standing
18 outpatient surgery center. Carillion also gave up after
19 we filed a complaint (in this case in the FTC's internal
20 court). So we have not yet actually been able to put
21 our new approach to prospective hospital mergers to the
22 test in court because everybody gives up because they
23 don't want to fight with us.

24 Once again, I disclaim that none of this is
25 necessarily what we did do or will do in future cases

1 because of course I don't get to decide that, but
2 basically I think that the approach I've described is
3 out there in the world. I think the broader community
4 has seen the cases that we built and taken notice.

5 The INOVA case was public at least to the extent
6 that we filed a public document in court that had some
7 notion of what we were planning to do, although it did
8 not get to the point where there were briefs written, or
9 public court documents where people could really see
10 what we were doing in detail, but I think the broader
11 antitrust community has some idea of what we've been
12 doing here and is at least a little scared of it because
13 they have folded a couple of times so far.

14 So, conclusions. It's late and you guys want to
15 do other stuff than listen to me so I'll be quick.
16 We're back in the hospital merger business. We started
17 with the retrospective Evanston case. We've moved on to
18 prospective cases. The FTC's hospital merger
19 enforcement activity has, I think, satisfied the
20 criteria that the topic of this talk was supposed to
21 have, which is that it is a real world thing of some
22 importance, and it's also closely connected to
23 innovations in the research community, and to some
24 extent also to research within the Bureau of Economics.

25 There have been some innovations on the clinical

1 quality side as well, which I haven't talked about. We
2 had a separate clinical quality expert in these cases,
3 and that was actually its own education for all of us,
4 and some very, very interesting work has been done there
5 as well.

6 So I think the area remains active. I think
7 people are still doing research on it and certainly the
8 enforcement agenda is still alive so I think it's
9 interesting.

10 That's it.

11 DR. ROTHSTEIN: Why don't we take a couple
12 questions for the day? Thanks.

13 DR. VAN BIESEBROECK: I didn't quite understand
14 when you simulate your own data and you re-resolve the
15 model so we know it's going to happen, but when you do
16 this merger simulation, why you didn't get it exactly
17 right.

18 DR. BALAN: If you were using one of these
19 merger simulations methods on real data, the results
20 would be driven by where the hospitals are, where the
21 patients are, some attributes of the patients, some
22 attributes of the hospitals and so on. These would be
23 used to generate concentration measures that are at the
24 heart of the simulation methods.

25 You would then do this price concentration study

1 type thing where you regress price on the concentration
2 measure. You estimate that coefficient. You calculate
3 the change in the concentration measure that will come
4 about as a result of the merger. You multiply that by
5 the coefficient, and then you're done.

6 It works the same way when it's done within the
7 context of our model, except that you perform the
8 simulation method on our made-up pre-merger data.
9 There's certainly no law that says that that's going to
10 produce the exact same answer as actually resolving our
11 model and getting the "true" prices. That's precisely
12 what we're trying to test, how close does it come?
13 There's certainly nothing that says it's going to be
14 identical.

15 DR. VAN BIESEBROECK: So basically when you do
16 these merger simulations, you don't use all the
17 information, you just get summary statistics, and you do
18 it like that?

19 DR. BALAN: It's not the summary statistics. We
20 solved the model once in the pre-merger world. That
21 generates a bunch of patients and their hospital choices
22 that make up the pre -- merger data. Each patient in
23 that data is going to one hospital or the other. You
24 take that whole set of pre-merger data. It's not a
25 sample of it or anything. You take the whole set of pre

1 merger data. You apply the simulation methodologies to
2 the whole thing, and you run that, and you see what it
3 predicts the "true" merger effects.

4 So I may be missing something in the question.
5 It sounds like my answer was nonresponsive.

6 DR. VAN BIESEBROECK: I'm still thinking that
7 when you don't know the demands, you have to make a
8 functional form for demands, assumptions in one of the
9 stimulations, and if that's a different one from the
10 one --

11 DR. BALAN: There is no functional form
12 assumption on demand. The merger simulation methods
13 that we are setting out to test take a bunch of data on
14 prices and who went where and apply these merger
15 simulation methodologies which really are as simple as
16 what I've said.

17 They are these price on concentration measures
18 and get a predicted merger effect. There is no demand
19 estimation here at all. Of course the reason why this
20 is different from more familiar merger simulations is
21 because people don't face prices. In the other merger
22 simulation exercise, there would be a step where you're
23 estimating demand. Keith?

24 DR. BRAND: So we specified demand because we
25 have to model patient choices on insurance and hospital

1 choice given the fact that they have insurance, so it's
2 basically a ride down the straightforward discrete
3 choice model, whether or not to buy insurance, which
4 will be a function of the value of all the hospitals in
5 the network, and then we model the choice of hospital,
6 if that particular patient has actually purchased the
7 insurance or specifically has access to the network.

8 So the object here is instead of testing these
9 measures against the real world data, we're just going
10 to generate data by actually specifying a Nash
11 bargaining problem between one MCO, and in our case it's
12 ten hospitals. And we actually solved the explicit Nash
13 bargaining problem for the pre merger world and then for
14 all the parameterized mergers in those -- among those
15 ten hospitals.

16 You directly solve on those Nash bargaining
17 problems without using these competition measures to
18 generate the prices.

19 So what we're doing is we're taking the "data"
20 that we generate through this Nash bargaining model and
21 our unrated data, and then we'll pretend, okay, suppose
22 I'm looking at a merger in this market and I'm going to
23 get the observed prices which I would see, and I would
24 observe where patients are going. And I'm going to
25 directly apply these competition measures that the

1 authors have discussed earlier, which is not exactly the
2 same as a Nash bargaining model.

3 They are, at best crude, first order
4 approximations to the effect that you would see in a
5 Nash bargaining model, and we're testing how well these
6 crude first order approximations do against the truth
7 when you actually see the truth.

8 DR. BALAN: A much better answer, and this seems
9 like an opportune time to point out that the paper is in
10 the lobby, so anybody who wants to know what it says can
11 have it.

12 DR. ADAMS: Why don't we leave it there and give
13 David a round of applause, and also thanks to everybody
14 today, and thank you, and we'll see you tomorrow.

15 (Applause.)

16 (Whereupon, at 5:25 p.m. the conference was
17 adjourned.)

18

19

20

21

22

23

24

25

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25

CERTIFICATE OF REPORTER

DOCKET/FILE NUMBER: PO85800
CASE TITLE: MICROECONOMICS CONFERENCE
CONFERENCE DATE: November 19, 2009

I HEREBY CERTIFY that the transcript contained herein is a full and accurate transcript of the steno notes transcribed by me on the above cause before the FEDERAL TRADE COMMISSION to the best of my knowledge and belief.

DATED: 12/4/09

DEBRA L. MAHEUX

CERTIFICATION OF PROOFREADER

I HEREBY CERTIFY that I proofread the transcript for accuracy in spelling, hyphenation, punctuation and format.

DIANE QUADE